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ABSTRACT 
 
Human articular cartilage is an avascular tissue, and therefore functions in a hypoxic 
environment. Cartilage cells, the chondrocytes, have adapted to this and actually use hypoxia 
to drive tissue-specific functions. Previous work in our laboratory has shown that human 
chondrocytes enhance cartilage matrix synthesis in response to hypoxia specifically through 
Hypoxia Inducible Factor 2alpha (HIF-2α) mediated upregulation of master regulator 
transcription factor SOX9, which in turn drives expression of the main cartilage-specific 
extracellular matrix genes.  
 
HIF-α isoforms are themselves regulated by specific prolyl hydroxylases (PHDs) 
which target them for proteosomal degradation. In fact, the PHDs are the true direct oxygen 
sensors since they require molecular oxygen as a co-substrate. Here we show that PHD2 is 
the dominant isoenzyme regulating HIF-2α (and HIF-1α) stability in human chondrocytes. 
Moreover, specific inhibition of PHD2 using RNAi-mediated depletion caused an 
upregulation of SOX9 and enhanced extracellular matrix protein production. Depletion of 
PHD2 resulted in greater HIF-2α levels, and therefore enhanced SOX9-induced matrix 
cartilage matrix production, even when performed in hypoxia (1% oxygen) implying that 
PHD2 inhibition offers a novel means to enhance cartilage repair.  The need for HIF-specific 
hydroxylase inhibitors was highlighted as treatment with the oxoglutarate analogue 
dimethyloxalylglycine (which also inhibits the collagen prolyl hydroxylases) resulted in 
reduced secretion of type II collagen, a critical matrix component. 
 
Complimentary to these anabolic effects, hypoxia was found to mediate anti-catabolic 
effects, suppressing aggrecan degradation in human cartilage explants. In isolated 
chondrocytes hypoxia downregulates key matrix metalloproteinases (ADAMTS5 and 
MMP13) and upregulates metalloproteinase inhibitor (TIMP3). Unlike the anabolic effects 
(HIF-2α-dependent), these hypoxia induced anti-catabolic chondrocyte responses were 
predominantly HIF-1α dependent.   
 
Both anabolic and anti-catabolic hypoxia-induced responses were further enhanced by 
depletion of PHD2, whose inhibition thus offers a novel means to induce cartilage repair.  
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1.1  Background 
  
Oxygen is essential for metabolism - being necessary for the generation of adenosine 
5’-triphosphate (ATP) via oxidative phosphorylation, and used as a substrate in many 
enzymatic reactions in the body (Mitchell, 1961).  As organisms evolved from single cellular 
to multi-cellular it became necessary to develop delivery vessels in order to maintain oxygen 
homeostasis and facilitate oxygen supply to cells at the core of tissues.  In humans, the 
dissolved levels of oxygen in arterial blood range between 10-14% (pO2 75-100 mmHg), 
however, in the event of reduced partial pressure of atmospheric oxygen (e.g.:  high 
altitudes), occlusion of blood vessels supplying oxygen to a tissue (e.g.:  myocardial 
infarction), rapid cell growth (e.g., solid tumor) or cells being located sufficiently far away 
from vessels that they are beyond the diffusion distance of oxygen (~100-300µm) the tissue 
will be exposed to significantly reduced oxygen tensions or hypoxia (Torres Filho et al., 
1994).  Here we define hypoxia as a level of molecular oxygen low enough to stabilise HIF-α 
isoforms (≤5% O2) (Schofield and Ratcliffe, 2004).  Conversely, we define normoxia as level 
of oxygen under normal atmospheric conditions (20% O2).  We acknowledge that these are 
not levels of oxygen normally experienced in vivo (10-14% O2) and may be considered 
artificially high or supra-physiological.  We will elaborate on this issue in our further work 
(Chapter 6).      
  
A sudden decrease in oxygen tension is associated with many conditions including  
stroke, myocardial infarction, angina, and peripheral arterial disease and can lead to massive 
cell death  (Fraisl et al., 2009).  Cells can alter gene expression and adapt cellular processes in 
order to survive hypoxic environments.  For example, ATP generation shifts from an aerobic 
to anaerobic state increasing glucose intake, increasing expression of enzymes involved in the 
glycolysis pathway and decreasing the enzymes leading to the TCA cycle enabling ATP 
generation to continue in the absence of molecular oxygen.  The key mediators of cellular 
responses to hypoxia are the Hypoxia-inducible factors (HIF-1α and HIF-2α).  In addition to 
regulating gene expression responsible for glucose metabolism, HIF-1α and HIF-2α control 
genes responsible for ventilation, angiogensis, pH regulation, erythropoiesis, cell 
proliferation, differentiation and apoptosis (Gaber et al., 2005; Gendron et al., 2004; 
Semenza, 2001).   
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Interestingly, cartilage is a tissue which has had to adapt to a chronic condition of 
hypoxia. Indeed, it appears that it can utilise the chronic hypoxic signal of its environment to 
promote its phenotype or tissue-specific function.  For example, hypoxia regulates the 
production of SRY (sex determining region Y)-box 9 (SOX9), a tissue-specific transcription 
factor essential for cartilage development and responsible for regulating key extracellular 
matrix genes including Type II Collagen, Type IX Collagen, Type XI Collagen and Aggrecan 
(Bi et al., 1999; Domm et al., 2002; Lafont et al., 2008; Lafont et al., 2007; Murphy and 
Polak, 2004; Murphy and Sambanis, 2001; Tew et al., 2007).  Work in our laboratory has 
further demonstrated that hypoxia inducible factor 2α (HIF-2α), not hypoxia inducible-factor 
1α (HIF-1α), is integral for hypoxic induction of SOX9 and the subsequently enhanced 
cartilage matrix production (Lafont et al., 2007).  Prolyl- and asparaginyl- hydroxylases are 
members of an oxoglutarate-dependant dioxygenase family responsible for inhibiting HIF in 
the presence of sufficient oxygen.  We hypothesised that antagonising specific hydroxylases 
may (selectively) stabilise HIF-2α, promote the human articular chondrocyte phenotype and 
enhance cartilage deposition without inhibiting essential collagen prolyl- and lysyl- 
hydroxylases which could interfere with collagen fibre processing. 
 
 To introduce the work, I will describe the anatomy, physiology and function of 
articular cartilage and summarise the knowledge of its extracellular matrix and its turnover.  I 
will review the hypoxia signalling pathway and how it is regulated by HIF-targeting 
hydroxylases and discuss current views of the effect of hypoxia on the chondrocytes 
phenotype.  Finally I will discuss the pathogenesis of osteoarthritis (OA) and how the 
inhibition of HIF-targeting hydroxylases may provide a novel therapeutic approach to treat 
this chronic and disabling disease. 
 
1.2  Cartilage Structure and Function 
 
A diarthrodial or synovial joint is comprised of two bone ends with a smooth layer of 
hyaline (articular) cartilage coating each epiphysis; these articular surfaces are encased within 
a capsule which is lined by the synovial membrane.  The synovial membrane or synovium 
lines the inside of the joint capsule and is responsible for producing synovial fluid and 
providing immunologic protection.  The membrane acts like a molecular sieve allowing 
Chapter 2                                  Materials and Methods  
 
 
21 
 
water, small molecules and nutrients to pass from the vascular system into the joint cavity but 
restricts the movement of larger molecules.  Type B synoviocytes are resident cells within the 
synovial membrane and help to control the protein concentration of the synovial fluid.  They 
actively secrete proteins such as collagen, fibronectin and hyaluronan (which confers 
viscosity and elasticity) into the joint cavity.  During movement the synovial fluid is 
propelled across the articular surface serving as both lubrication and a source of nutrients for 
the articular cartilage.  
 
Articular cartilage is a dense, avascular, aneural and hydrated tissue.  In addition to 
providing a near frictionless surface for articulation articular cartilage has two main 
biomechanical properties essential to its function; tensile strength and ability to withstand 
compressive forces (Buckwalter and Mankin, 1998a; Poole et al., 2002).   
 
Articular cartilage is a specialized connective tissue with an extensive extracellular 
matrix.  Its two primary mechanical properties are mediated by collagen fibrils (predominatly 
type II) present in the matrix which confer tensile strength to articular cartilage and 
proteoclycans (mainly aggrecan), these molecules are water-saturated and the resulting 
swelling pressure creates a gel-like stiffness allowing the tissue to resist deformation and 
giving cartilage its ability to absorb shocks (Buckwalter and Mankin, 1998a; Muir, 1995; 
Poole et al., 2002).  Articular cartilage is a hydrated tissue with approximately 75-80% of the 
matrix comprised of water.  Of its dry weight, 70% is collagen, 20% is proteoglycan and 10% 
is composed of other matrix proteins (Eyre, 2002). 
1.2.1  The Chondrocyte 
 
Articular cartilage consists of a single cell type, the chondrocyte which is solely 
responsible for the synthesis, secretion and maintenance of the extracellular matrix (Goldring 
and Goldring, 2006).  Consistent with its function and hypoxic microenvironment, the 
chondrocyte cytoplasm has a large number of Golgi apparatus and rough endoplasmic 
reticulum with few mitrochondria.  Stockwell reported that the number of mitochondria per 
chondrocyte was significantly reduced in the deeper zones of articular cartilage relative to the 
upper zones (Stockwell, 1991).  As will be discussed (Chapter 1.5), chondrocytes exist under 
chronic hypoxic conditions and have adapted to this condition, with a strong dependance on 
anaerobic metabolism for ATP generation (Gibson et al., 2008).  Molecular oxygen 
Chapter 2                                  Materials and Methods  
 
 
22 
 
consumption in the tissue is very low, approximately 2-5% compared with that of a liver or 
kidney cell (Archer and Francis-West, 2003; Gibson et al., 2008; Stockwell et al., 1983). 
 
Chondrocytes are characterised by the expression of specific genes such as collagen 
type II and the SRY (sex determining region Y)-box 9 (SOX9) (Tew et al., 2007).  SOX9 is a 
master transcription factor responsible for the regulation (in concert with L-Sox5 and Sox6) 
of a number of cartilage extracellular matrix genes including COL2A1, COL9A1, COL11A2 
and AGGRECAN (Bridgewater et al., 1998; Kou and Ikegawa, 2004; Sekiya et al., 2002; Tew 
et al., 2007; Zhang et al., 2003; Zhao et al., 1997).  Sox9 has been demonstrated to be 
essential for the development and maintenance of cartilage in mice (Bi et al., 1999).  
Mutations to the SOX9 gene result in haploinsufficency of SOX9 resulting in a severe skeletal 
disease called compomelic dysplasia, characterized by short limbs, bowed legs, narrow gests 
and dwarfism (Meyer et al., 1997; Wagner et al., 1994).  Finally, Sox9 is downregulated in 
chondrocytes as they enter hypertrophy during endochondral ossification (Zhao et al., 1997). 
  
1.3  The extracellular matrix of cartilage 
 
Human chondrocytes are embedded in articular cartilage at a very low density 
(14.1x103/mm3), with the bulk of the tissue (dry weight) (~90-95%) comprising extracellular 
matrix (Stockwell, 1971).  Articular cartilage can be divided into four zones:  the superficial 
zone, the transitional zone, the radial zone and the calcified cartilage zone (cartilage interacts 
with subchondral bone).  These zones are each characterised by different amounts and 
organisation of matrix macromolecules (Fig. 1.1). 
 
The articular surface is comprised of a thin layer of densely packed, fine collagen 
fibres running parallel to the surface.  The fibrils have a periodic banding pattern and many 
form bundles.  Chondrocytes in the superficial zone are flattened and elliptical in shape, 
displaying cell-surface polarity (aligning parallel to the surface of the tissue).  The superficial 
layer contains high levels of collagen and low levels of proteoglycan (relative to other 
layers).  The layer has a high mechanical strength against the shear and tensile stress of the 
articular surface.  The chondrocytes within the transitional and radial zones are more 
spherical in shape and are arranged vertically into columnar clusters.  Similarly, collagen 
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fibres are arranged perpendicular to the articular surface and have a larger diameter (Hwang 
et al., 1992).  There are abundant levels of proteoglycans in these layers compared with the 
superficial layer.  Finally, the calcified cartilage zone separates hyaline cartilage from 
subchondral bone.  It contains a tidemark layer (basophilic boundary between calcified and 
uncalcified cartilage) and large amounts of type X collagen (Broom and Poole, 1982; 
Havelka et al., 1984; Redler et al., 1975). 
 
Components of articular cartilage are: 
1.3.1  Collagen: 
 
Collagen fibrils are present in all layers of articular cartilage and provide structural 
strength to the tissue (Eyre, 2002).  Collagen contains a tripeptide -X-Proline-Glycine motif 
(where X represents any amino acid).  Translated as procollagen, the non-helical N- and C-
terminal ends of the molecule are cleaved allowing 3 polypeptide α-helices to interact, 
polymerise and form the collagen fibril.  These fibrils are secreted into the extracellular 
matrix where they polymerise to form the primary component of the large cross banded 
fibrils (van der Rest and Garrone, 1991).     
 
Type II collagen (COL2A1) is the most predominant macromolecule in articular cartilage 
(~90% of the cartilage collagen) and is a homotrimer of three α(II) chains.  Type II collagen 
acts as a structural scaffold conferring tensile strength and creating a meshwork within which 
other components can be organised.  Type II collagen has a half life of approximately 100 
years and therefore it is believed that the synthesis of type II collagen in articular cartilage is 
down-regulated after skeletal maturity with little synthesized during adulthood, making 
articular cartilage vulnerable to catabolic effects of matrix metalloproteinases (although type 
II collagen synthesis is increased in osteoarthitic cartilage) (DeGroot et al., 2001; 
Hermansson et al., 2004; Maroudas et al., 1998; Maroudas et al., 1992).  However, we have 
previously demonstrated type II collagen expression in isolated healthy human articular 
chondrocytes and that levels of expression can be further enhanced by hypoxia (Lafont et al., 
2007; Thoms and Murphy, 2010). 
 
Cartilage also contains other distinct collagen types (Type VI, IX, X and XI collagen).  
Together, they consist ~10% of total collagen.  Type IX and XI collagen are shorter, 
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heterotrimeric, minor fibrillar collagens (Buckwalter and Mankin, 1998a; Muir, 1995; Poole 
et al., 2002).  Type XI collagen is thought to reside in the central portion of the collagen 
fibril, acting as a filamentous core template which regulates fibril diameter through its 
retained N-propeptide domains (Mendler et al., 1989).  Type IX collagen localizes to the 
superficial layer of the fibrils and projects out into the matrix (Poole et al., 1988) (Fig. 1.2).  
Type VI collagen has been identified in the pericellular matrix (the matrix surrounding the 
chondrocyte) of articular cartilage, its role is unknown (Soder et al., 2002).  Type X collagen 
is a homotrimer that is highly expressed by chondrocytes within the hypertrophic zone of the 
epihyseal growth plate.  In mature articular cartilage the expression of type X collagen is 
restricted to the calcified cartilage (Gannon et al., 1991). 
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  FIGURE 1.1.  Structure of articular cartilage.  A, schematic diagram of the cellular 
organisation in the four zones of articular cartilage:  the superficial, transitional, radial and 
calcified zone.  B, diagram of the collagen fibre architecture through the depth of articular 
cartilage.  (Newman, 1998) 
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1.3.2  Proteoglycan: 
 
Proteoglycans consist of a core protein covalently attached to one or more 
glycosaminoglycan (GAG) side chains.  These GAG side chains are long unbranched 
polysaccharides consisting of a repeating disaccharide that contains an amino sugar.  
Glycosaminoglycans are negatively charged and strongly hydrophilic, this is essential for 
their function.  Water-saturated aggrecan molecules are held within scaffold of collagen 
fibres creating a swelling pressure and stiffness allowing articular cartilage to resist 
deformation. 
  
Aggrecan is the main proteoglycan in cartilage and contributes 90% of the total 
proteoglycan content.  In the cartilage extracellular matrix aggrecan is bound to a backbone 
of hyaluronan (hyaluonic acid) and forms huge aggregates filling the interfibrillar space of 
the cartilage matrix (Hardingham, 1979; Roughley, 2006).  Up to 200 aggrecan molecules 
bind to each hyaluronan backbone.  The hyaluronan backbone is itself anchored to 
chondrocytes via CD44, a cell associated heperin sulphate proteoglycan.   
 
Each aggrecan molecule consists of a protein core, with three globular domains (G1, 
G2 and G3) and two interglobular domains.  Covalently attached to the core protein are 
numerous sulphated glycosaminoglycan chains of keratan sulphate (KS) and chondroitin 
sulphate (CS).  The negatively charged and hydrophilic nature of these GAG side chains 
repel each other and attract water molecules (75% of cartilage, by weight is water).  The 
hydrated swelling pressure of water-saturated aggrecan molecules enables cartilage to resist 
compression during joint loading (Roughley, 2006).  Unlike type II collagen, aggrecan has a 
significantly shorter half life (~3.4 years) and is therefore synthesised and turned over in 
adult cartilage (DeGroot et al., 2001; Maroudas et al., 1998; Maroudas et al., 1992).         
 
Other less abundant small proteoglycans found in the matrix include decorin, 
biglycan, lumican and fibromodulin which are thought to be involved in fibril assembly, 
organisation and stabilisation of collagen matrix structure within the cartilage extracellular 
matrix (Hedbom and Heinegard, 1993; Roughley, 2006). 
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FIGURE 1.2.  Interactions between type II collagen, type IX collagen and type XI 
collagen molecules.  Type II collagen is the most abundant collagen in articular cartilage and 
confers tensile strength to the tissue.  Type XI (blue) and type IX (yellow) collagen are cross-
linked to the type II collagen fibre.  Type XI collagen is thought to reside in the central 
portion of the collagen fibril, acting as a filamentous core template which regulates fibril 
diameter through its retained N-propeptide domains.  Type IX (red) collagen localises to the 
superficial layer of the fibrils and projects out into the matrix (Kadler et al., 2008). 
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FIGURE 1.3.  Domain structure of Aggrecan.  Aggrecan is the main proteoglycan in 
cartilage and contributes 90% of the total proteoglycan content.   It has a molecular mass 
>2,500 kDa. The core protein has 100-150 glycosaminoglycan (GAG) chains attached to it. 
Each aggrecan molecule consists of a protein core, with three globular domains (G1, G2 and 
G3), two interglobular domains, all bound to a backbone of hyaluronan (hyaluonic acid).  
Covalently attached to the core protein are numerous sulphated glycosaminoglycan chains of 
keratan sulphate (KS) and chondroitin sulphate (CS).  Both MMPs and ADAMTSs have been 
shown to cleave aggrecan at multiple sites, however the two major cleavage sites are within 
the first interglobular domain (between G1 and G2).  Proteolysis occurs predominantly at 
Glu373 – Ala374 and at Asn341 – Phe342 bonds.  The Glu373 – Ala374 bond is susceptible to 
ADAMTS cleavage resulting in the N-terminal neoepitope ARGSV.  The Asn341 – Phe342 
bond is cleaved by all known MMPs resulting in the N-terminal neoeptitope FFGV (Image 
provided by Terhi Raukko). 
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1.3.3  Other matrix molecules 
 
Other proteins in the cartilage matrix include the cartilage oligomeric matrix protein 
(COMP), fibronectin and chondromodulin-1.  COMP is an acidic glycoprotein with 5 
identical subunits and is thought to be involved in collagen cross linking and is therefore 
important for the assembly and stabilisation of the extracellular matrix (Posey and Hecht, 
2008; Shen et al., 1995).  Fibronectin is encoded by a single gene, but alternative splicing of 
its pre-mRNA leads to up to 20 different isoforms.  Firbronectin forms a dimer, consisting of 
two monomers linked by a pair of disulphide bonds and regulates a number of cellular 
processes including cell migration, adhesion and cell cycle progression (Pankov and Yamada, 
2002).  Chondromodulin-1 is a glycoprotein which strongly inhibits angiogenesis (vascular 
invasion of cartilage) and has recently been shown to induce the chondrocyte phenotype 
(Hiraki et al., 1997; Hiraki et al., 1991; Klinger et al., 2011). 
 
1.4  Cartilage extracellular matrix metabolism  
 
Chondrocytes slowly turn over cartilage matrix molecules.  Ideally there is an 
equilibrium between anabolism (matrix synthesis) and catabolism (matrix degradation), and 
cartilage matrix integrity is maintained.  The exact mechanism of cartilage matrix turnover is 
poorly understood and it is well established that once damaged, cartilage has a limited 
intrinsic matrix remodelling and repair capacity. 
 
Chondrocytes produce two important classes of enzymes involved in cartilage matrix 
degradation:  ADAMTSs (A Disintegrin And Metalloproteinase with ThomboSpondin type 1 
Motif) or aggrecanases and MMPs (Matrix-Metalloproteinases). 
1.4.1 Aggrecanases (ADAMTSs): 
 
The ADAMTSs are a family of 19 secreted metalloproteinases which contain a zinc 
atom at their catabolic site and have sequence homology to ADAM proteases (Kuno et al., 
1997).  ADAMTSs are all initially translated as inactive pre-proenzymes and unlike ADAMs, 
which are transmembrane proteins (with the exception of ADAM12 and ADAM28), the 
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ADAMTSs are secreted proteins with at least one thrombospondin type 1 sequence motif 
(TSR) capable of binding the extracellular matrix (Kuno and Matsushima, 1998; Tang, 2001).  
All ADAMTS enzymes have a reprolysin-type zinc-binding motif, HEXXHXXG/N/SXXHD 
(where X represents any amino acid) at their catalytic site (Porter et al., 2005). 
 
 Both MMPs and ADAMTSs have been shown to cleave aggrecan at multiple sites, 
however the two major cleavage sites are within the first interglobular domain (between G1 
and G2).  Proteolysis occurs predominantly at Glu373 – Ala374 and at Asn341 – Phe342 bonds.  
The Glu373 – Ala374 bond is susceptible to ADAMTS activity resulting in the C-terminal 
neoepitope NITEGE (bound to the hyaluronan backbone) and the N-terminal neoepitope 
ARGSV (released) (Nagase and Kashiwagi, 2003; Sandy et al., 1992).  ADAMTSs are not 
active to the Asn341 – Phe342 bond, this is cleaved by all known MMPs resulting in C-terminal 
neoeptitope DIPEN and N-terminal neoeptitope FFGV (Fig. 1.3).  MMP and ADAMTS 
generated neoepitope aggrecan fragments have been identified in culture media of cartilage 
explants in vitro as well as human synovial fluid in vivo (Sandy et al., 1992) (Fosang et al., 
1996; Lark et al., 1997; Little et al., 2002; Lohmander et al., 1993; Sandy and Verscharen, 
2001). 
 
ADAMTS1,4,5,8,9,15,16 and 18 can all cause aggrecan cleavage at the Glu373 – 
Ala374 bond however, ADAMTS4 and ADAMTS5 are the most active aggrecanases under 
physiological conditions (Abbaszade et al., 1999; Fushimi et al., 2008).  Furthermore, 
although MMPs can cleave aggrecan at the Asn341 – Phe342 bond it is believed that 
aggrecanases are predominantly responsible for aggrecan degradation in vivo and have been 
shown to contribute 80% of the aggrecan fragments detected is osteoarthritic synovial fluid 
(Struglics et al., 2006). 
1.4.2  Matrix Metalloproteinases (MMPs) 
 
MMPs are a family of over 28 multi-domain endopeptiases (Nagase et al., 2006).  The 
MMPs are responsible for matrix turnover and can collectively degrade all cartilage matrix 
macromolecules.  Like ADAMTSs, the MMP family are initially translated as inactive 
zymogens (proMMPs) and activated by proteolytic cleavage.  Similarly, MMPs are all zinc-
dependent enzymes, containing a zinc atom at the catalytic site.  MMPs can be further 
subdivided according to substrate and structure. There are five main groups: collagenases 
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(MMP1, -8, -13 and -18), gelatinases (MMP2 and 9), stromelysins (MMP3 and 10), 
matrilysins (MMP7 and 26) and the membrane-type MT-MMPs (MMP14, -15, -16, -17 and -
24) (Egeblad and Werb, 2002; Murphy et al., 2002). 
 
 Type II collagen is cleaved by collagenases (MMP1, -8, -13 and -18) and MMP13 has 
been identified as having the highest activity against type II collagen (Minond et al., 2006; 
Tetlow et al., 2001).  Collagenases unwind the collagen triple helix and cleave at a single 
point three quarters along the length away from the N-terminal (Knauper et al., 1996).  The 
neoepitopes formed by this cleavage can be detected by antibodies (Billinghurst et al., 1997; 
Hollander et al., 1994).  This cleavage generates characteristic one-quarter and three-quarter 
fragments, which are further degraded by gelatinases (MMP2 and MMP9). 
 
 Matrix metalloproteinase-3 (MMP-3) or Stromelysin-1 is a key member of the MMP 
family and has a broad substrate specificity including proteoglycans, gelatin, laminin, 
vitronectin, fibronectin, type IV collagen.  Furthermore, it is believed to control the activation 
of proMMP zymogens.  For example, MMP3 activates proMMP1 and proMMP13 (Knauper 
et al., 1996; Visse and Nagase, 2003). 
1.4.3  Tissue inhibitors of the matrix metalloproteinases (TIMPs) 
 
TIMPs play an important role as the main regulators of matrix metalloproteinases 
(MMPs) and aggrecanases (ADAMTSs) and are important for extracellular matrix 
homeostasis.  Cartilage homeostasis is a delicate balance between proteases and TIMP 
activity and a net imbalance has been implicated in cartilage loss.   
 
Four TIMPs have been identified (TIMP1, 2, 3, 4) - they are synthesised by 
chondrocytes and are endogenous inhibitors of MMP and to a lesser extent ADAMTS 
activity.  TIMP1, -2, -3 and -4 broadly inhibit all MMPs, with different effectiveness (Baker 
et al., 2002).  TIMP3 has been reported to inhibit all MMPs, in addition to ADAM-17, 
ADAMTS4 and ADAMTS5.  The Ki of TIMP3 for ADAMTS4 and ADAMTS5 is in the 
subnanomolar range (Hashimoto et al., 2001; Kashiwagi et al., 2001).  In addition TIMP3 is 
able to bind to polyanionic matrix components allowing for localisation in the cartilage 
extracellular matrix.  It has been reported that TIMP3 inhibits aggrecanase activity in vitro 
when added exogenously to interleukin-1α (IL-1α) or retinoic acid stimulated bovine and 
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porcine cartilage explants suppressing aggrecan neoepitope release (Gendron et al., 2003).  
Finally, Timp3-/- mice have increased proteinase activity and spontaneously development 
cartilage degradation illustrating the important role of TIMP3 in regulating extracellular 
matrix homeostatis (Sahebjam et al., 2007).  
 
1.5  Cartilage and hypoxia 
 
Chondrocytes encounter two forms of permanent stress, hypoxia and mechanical 
loading. Articular chondrocytes within synovial joints survive in a challenging 
microenvironment and are dependent upon the diffusion of oxygen from the underlying 
subchondral bone and the synovial fluid which bathes the articular surface and is propelled by 
joint movement (Lund-Olesen, 1970; Ogata et al., 1978).  For human articular chondrocytes 
within the core of the larger joints such as the knee, the cells may be 2-3mm distance from an 
arterial vessel (Haselgrove et al., 1993). 
 
Brighton and Heppenstall investigated the oxygen tension of epiphyseal cartilage in 
rats and rabbits using a platinum-iridum microelectrode (10µm in diameter).  Costochondral 
cartilage explants from 21 day old Sprague-Dawley male rats were excised and cultured.  The 
oxygen tension was found to gradually decrease from 97.3 mmHg (12.8% O2) at the 
subchondral bone to 12.1mmHg (1.5% O2) in the hyaline cartilage (Brighton and 
Heppenstall, 1971).  Subsequent work was carried out in vivo using a platinum-iridum 
microelectrode to measure oxygen tensions of the proximal tibial epipyseal plates in six-
week-old male New Zealand white rabbits.   Similarly in vitro oxygen tensions were reported 
to decrease from the subchondral bone to the hyaline cartilage (108.7 mmHg / 14.3% O2 to 
20.5 mmHg / 2.7% O2 respectively) (Brighton and Heppenstall, 1971).  Lund-Oleson studied 
the oxygen tension in 103 synovial fluids from knee joints.  The mean oxygen tension in 
synovial fluid from patients with osteoarthritis was 42.92 mmHg, and 63 mmHg in joints 
injured by trauma (Lund-Olesen, 1970).  Therefore, we can assume that chondrocytes near 
the surface of the tissue are exposed to an oxygen tension approximately 5.72 O2 – 8.35% O2  
(Lund-Olesen, 1970).  Finally, work by Silver in rabbit elastic cartilage supports previous 
work.  Oxygen tension in cartilage 0.5mm cubes was measured using microelectrodes and a 
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steep oxygen gradient was detected the surface of the tissue (80-90 mmHg / 11-11.6% O2) to 
the centre of the cubes (5-8 mmHg / 0.6-1% O2) (Silver, 1975). 
 
 Under normoxic conditions HIF-α isoforms are continuously hydroxylated, 
ubiquitinated and degraded by the 26S proteasome (Cockman et al., 2000).  HIF-α isoforms 
become stabilised and detectable in nuclear extracts < 3-5% O2 (Distler et al., 2004).  Our 
group has previously reported the presence of HIF-1α and HIF-2α in passaged human 
articular chondrocytes (Lafont et al., 2007).  Furthermore, immunohistochemisry of healthy 
human articular cartilage confirms the presence of HIF-1α and HIF-2α protein (Bohensky et 
al., 2009; Coimbra et al., 2004; Yudoh et al., 2005).  Stewart and colleagues demonstrated 
that HIF-2α is expressed in hypertrophic chondrocytes of the mouse growth plate, murine 
chondrocyte cell line ATDC5 cells and that chick chondrocytes up-regulate HIF-2α 
expression during chondrocyte differentiation (Stewart et al., 2006).  Immunohistochemical 
detection of HIF-1α has been reported in mouse knee cartilage BALB/C mice (Gelse et al., 
2008).   
 
In summary, human articular cartilage appears to function in a chronically hypoxic 
environment throughout life.  Depending on their position in the tissue, chondrocytes are 
exposed to approximately between 1-6% O2 – oxygen tensions at which HIFs become 
stabilised.  Thus reduced levels of molecular oxygen inhibit HIF-targeting hydroxylases and 
result in the stabilsation of HIF-1α and HIF-2α protein in human articular cartilage.  The 
effects of this on the chondrocyte phenotype and function will be discussed below (Chapter 
1.10).  
1.5.1  Mechanical Loading 
 
 Articular cartilage is subjected to chronic, cyclical stress of various magnitudes.  
Moderate mechanical loading is an important stimulus for articular cartilage and essential for 
maintaining extracellular matrix integrity (Urban, 1994).  Cyclical mechanical loading has 
been shown to stimulate proteoglycan synthesis in cartilage explants and monolayer 
chondrocytes (Korver et al., 1992; Larsson et al., 1991; Veldhuijzen et al., 1979) (Steinmeyer 
and Knue, 1997; Zhou et al., 2007).  Aggrecan, Fibronectin and COMP levels have all been 
shown to increase transiently at the mRNA level in response to cyclical loading in cartilage 
explants (Valhmu et al., 1998; Wong et al., 1999).  Conversely, immobilisation of normal, 
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healthy joints in paralysed patients following spinal cord injury results in a decrease in 
cartilage volume (Vanwanseele et al., 2003; Vanwanseele et al., 2002a; Vanwanseele et al., 
2002b).   
 
However, high frequency loading or a single impact loading can lead to cartilage 
matrix degradation.  It has been previously reported that exposure of chondrocytes to high 
frequency cyclic tension force (CTF) (>15kPa) inhibits proteoglycan and collagen synthesis 
and induced the expression of proinflammatory interleukin-1 (IL-1) and catabolic matrix 
degrading proteases MMP2 and MMP9 mRNA.  High-velocity loading of canine cartilage 
explants (5 MPa, 0.3Hz) induces cell death by apoptosis (Chen et al., 2001).  Further work by 
Jeffrey and colleagues demonstrated that in bovine cartilage subjected to a single impact load, 
cell death and was associated with suppression in proteoglycan and protein synthesis (Jeffrey 
et al., 1997). 
 
1.6  Osteoarthritis 
 
 Osteoarthritis (OA) is the most common joint disease (arthropathy) and is 
characterised by loss of articular cartilage, subchondral bone thickening and new bone 
formation in a synovial joint (typically knee, hip, hand, shoulder, spine or foot).  
Osteoarthritis affects approximately 15% of the total population and greater than 50% of the 
population over 60 years of age (Poole et al., 2002).  In the United Kingdom an estimated 36 
million working days are lost each year to osteoarthritis-related disability and in the United 
States an estimated $3 billion is spent annually on osteoarthritis (March and Bachmeier, 
1997; Woolf, 2003). 
1.6.1  Clinical Aspects of Osteoarthritis 
 
Osteoarthritis is a chronic disease causing the progressive loss of articular cartilage 
and resulting in joint pain, loss of function over time and reduced quality of life.  
Osteoarthritis may be defined by symptoms (pain, stiffness, crepitus, decreased mobility and 
deformity) or radiographic criteria (joint space narrowing) or both.  Because cartilage is 
aneural structural changes such as joint space narrowing can often occur without painful 
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symptoms and symptoms often do not present until late stage disease.  Population surveys 
illustrate that 50% of subjects with radiographic knee osteoarthritis have no pain and 50% of 
subjects who identified knee pain have no radiographic knee osteoarthritis (McAlindon et al., 
1992). 
 
Osteoarthritis can be subdivided into mono- or poly-articular and be further 
categorised as either idiopathic (of an unknown cause) or secondary (caused by another 
disease or condition) (Kellgren, 1952; Kellgren and Lawrence, 1957; Kellgren et al., 1963).  
Physical symptoms upon examination of osteoarthritic joints include: pain, decreased range 
of motion, crepitus, effusions and tenderness on palpation with the joint line.  Patients may 
describe localised pain on exercise (which is relieved by rest) and stiffness during periods of 
inactivity.  Osteoarthritis is also associated with elevated incidence of depression and a 
reduced quality of life (Axford et al., 2008; Penninx et al., 1996).  Plain radiographs are the 
gold standard for diagnosis and assessment of progression.  Radiographic criteria include:  
joint space narrowing, osteophyte formation, subchondral sclerosis and bone cysts.  
Biomarkers such as elevated C-reactive protein (CRP) and COMP may also be indicative of 
disease progression (Posey and Hecht, 2008; Punzi et al., 2005). 
 
Pharmacological therapy for osteoarthritis is far behind other skeletal diseases such as 
rheumatoid arthritis and osteoporosis (Conaghan et al., 2008).  In the United Kingdom, 
national institute for clinical excellence (NICE) guidelines layout a core treatment of local 
muscle strengthening supplemented by pain relief using paracetamol, topical/oral non-
steroidal anti-inflammatory drugs (NSAIDs), cyclo-oxygenase 2 (COX-2) inhibitors and 
opioids.  Surgical intervention using arthrospoic lavage and tissue debridement is used in the 
event of mechanical locking, giving way or X-ray evidence of loose bodies.  Finally, 
osteotomy or joint replacement is used in advanced stages of OA (Conaghan et al., 2008).  
There are no currently available disease-modifying osteoarthritis drugs.  Trials to regulate 
endogenous catabolic factors by administering protease inhibitors against MMP13 and 
ADAMTS5 targets have been unsuccessful because of insufficient efficiency and adverse 
events (Burrage and Brinckerhoff, 2007; Chuma et al., 2004; Flannery, 2010; Fosang and 
Little, 2008; Little et al., 2007; Nagase et al., 2006; Troeberg et al., 2008). 
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1.6.2  Aetiology of Osteoarthritis 
 
 There are multiple risk factors pertaining to the development and progression of 
osteoarthritis including; age, gender, heredity and mechanical damage (Buckwalter and 
Mankin, 1998b; Felson, 2004, 2005; Felson and Chaisson, 1997; Felson et al., 2004; Felson 
et al., 2000). 
 
 Age is consistently identified as a risk factor for osteoarthritis.  OA is rare in adults 
under 40 and prevalence rates of radiographic OA rise steeply after the age of 50 in men and 
age 40 in women (Felson et al., 1995; van Saase et al., 1989).  In addition, gender is a well-
recognised risk factor in osteoarthritis.  OA is more common in women (especially, 
especially after enter menopause) than men.  Hand and knee OA, in particular has been 
reported to be more prevalent among women (Hochberg, 1991; Oliveria et al., 1995).  
Oestrogen is believed to have a chondroprotective role against OA, a study of cartilage 
volume in postmenopausal women reported use of long term oestrogen replacement therapy 
(ERT) had significantly greater cartilage volume than controls and  ERT may prevent knee 
articular cartilage degradation (Wluka et al., 2001). 
 
 A family history of the disease is often present in patients presenting with OA.  Twin-
pair and sibling-risk and segregation studies highlighted that there may be a genetic 
component to osteoarthritis.  Studies suggested that OA might be transmitted as a complex, 
multifactorial trait rather than a single-gene disorder (Loughlin, 2001, 2003, 2005; Loughlin 
et al., 2002; Spector and MacGregor, 2004).  Genome wide linkage scans were performed 
and several genomic candidates identified linked to OA susceptibility.  These genes include:  
interleukin 1 gene cluster 2q11.2-q13 (IL-1), the matrilin 3 gene (MATN3) 2p24.1, the IL-4 
receptor α-chain gene (IL4R) 16p12.1, the secreted frizzled-related protein 3 gene (FRZB) 
2q32.1, the metalloproteinase gene ADAM12 10q26.2 and the asporin gene (ASPN) in hip 
OA 9q22.31 (Kizawa et al., 2005; Loughlin et al., 2004; Loughlin et al., 2002; Smith et al., 
2004; Stefansson et al., 2003; Valdes et al., 2006).    
 
The most important risk factor for the development and progression of osteoarthritis is 
mechanical damage.  This includes; occupation-related repetitive injury, obesity, joint 
deformity, joint misalignment and physical trauma.   
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It has been previously reported that occupations requiring repetitive bending and 
physical exertion have a higher prevalence of osteoarthritis (43.4% vs. 26.8%) (Felson et al., 
1991).  These occupations include: ballet dancers (feet and ankles), farmers (hips), coal 
miners (knees) and cotton mill workers (hands).  Work by Felson and colleagues using the 
Framingham database in elderly adults found an association between high levels of physical 
activity and incident of knee OA (Felson et al., 1997).  However, a link between low-impact 
recreational exercise and OA is controversial.  45 long distance runners and 53 controls were 
studied by Chakravarty and colleagues from 1987 to 2002 and monitored with serial knee 
radiographs.  Although OA was initially more prevalent in runners compared with the control 
group (6.7% vs. 0%) by the end of the study there was no greater prevalence (20% vs. 32%) 
or severity (2.2% vs. 9.4% severe OA) of OA in runners versus the control group.  It was 
concluded that long distance running in healthy older individuals was not associated with 
accelerated radiographic OA (Chakravarty et al., 2008).  
 
 Population based studies have shown that obesity increases susceptibility to 
developing OA (Creamer and Hochberg, 1997).  The first National Health and Nutrition 
Examination Survey (HANES I) reported in a study of 5193 participants (aged 35-74) that 
there were significant associations of knee osteoarthritis with obesity (Anderson and Felson, 
1988).  Obese (body mass index between 30-35) women had ~4 fold greater risk of knee OA 
as compared with non-obese control group and obese men had ~5 fold increased risk of knee 
OA compared with non-obese control group.  The mechanisms for how obesity influences 
OA is unclear (Anderson and Felson, 1988).  Logically, increased body mass increases 
mechanical stress placed on joints.  It is estimated that stresses of between 3-6 times one’s 
body weight are applied across the knee joint during movement (Felson et al., 1995).  
However, obesity is also associated with an increased risk of hand OA suggesting a possible 
link between increased adipose tissue and a circulating factor (Carman et al., 1994).  Two 
adipokines (leptin and apelin) have been reported in synovial fluid of OA patients and Bao 
and colleagues recently reported that recombinant rat leptin (100 μg) is a catabolic factor 
when injected into knee joints of rats compared to saline controls (Bao et al., 2010; Dumond 
et al., 2003; Hu et al., 2010a; Hu et al., 2010b).  Addition of leptin significantly upregulated 
catabolic factors MMP2, MMP9, ADAMTS4, ADAMTS5 and cathespin D mRNA and was 
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associated with histological depeletion of proteoglycan in rat cartilage whilst downregulating 
anabolic factor bFGF at the mRNA level (Bao et al., 2010). 
 
 Finally, physical trauma to the cartilage or indirect damage (to ligaments) leading to 
joint misalignment is a strong risk factor for OA and may cause as many at 10% cases of OA 
(Furman et al., 2006; Gelber et al., 2000).  Partial thickness cartilage defects in asymptomatic 
individuals are also likely to result in OA (Cicuttini et al., 2005).  Anterior cruciate ligament 
(ACL) tears and either damage or tears to meniscal tissue result in increased risk of 
developing OA (Englund and Lohmander, 2004; Lohmander and Felson, 2004; Roos et al., 
1995; Roos and Karlsson, 1998; Segawa et al., 2001; Sharma et al., 2008).  
 
 In summary, excessive wear and tear through joint overuse, obesity, joint instability 
and finally gross damage to the articular cartilage surface are all strongly associated with the 
development of osteoarthritis (OA).   
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FIGURE 1.4.  Articular structures affected in osteoarthritis.   A Healthy joint 
is shown: normal cartilage with a smooth articulating surface, normal underlying 
bone structure, no signs of synovial inflammation or of meniscal changes.  B 
Osteoarthritic joint: degenerate lesions and 'fibrillated' cartilage, bone 
remodelling (subchondral sclerosis and osteophytes), episodically inflamed 
synovium and frayed meniscus (Wieland et al., 2005). 
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1.6.3  Histological changes in osteoarthritis 
 
 Histological changes of osteoarthritis are well characterised and have a number of 
stages (Buckwalter and Mankin, 1998b; Collins and Mc, 1960; Meachim et al., 1965).  
Initially there is an progressive loss of proteoglycan, the articular cartilage surface loses its 
smooth appearence with early roughening and fibrillations becoming visible (Meachim et al., 
1965).  Microtracks deepen, fibrillations start as horizontal splits following the orientations of 
collagen fibres and then extend to form deep vertical fissures and clefts (McElligott and 
Collins, 1960).  Clusters of chondrocytes form at these fissures and at the surface of the tissue 
suggesting chondrocyte activation, proliferation and an attempted repair mechanism 
(Meachim et al., 1965; Meachim and Sheffield, 1969).  Later there are clear/empty lacunae 
suggesting cell death.  Fissures eventually become full thickness cartilage defects. 
 
In addition there are changes to the subchondral bone including; bone sclerosis, bone 
cysts and osteophyte formation.  There may also be episodic inflammation of the synovial 
membrane although it is unclear if these changes initiate OA or are secondary events (Fig. 
1.4). 
 
1.7  Molecular changes in osteoarthritis 
 
Osteoarthritis is traditionally thought of as a mechanical process, a consequence of 
“wear and tear” on a synovial joint.  However, a more accurate description would be to 
describe an imbalance between net anabolic (matrix synthesis) and net catabolic (protease 
activity) activity.  Articular cartilage destruction can be initiated by cartilage injury, 
overloading or problems in joint biomechanics.  Numerous factors including age, obesity, 
metabolism and response to growth factors may lead to an imbalance between anabolism and 
catabolism and hence to a disruption in cartilage homeostasis. 
1.7.1  Proteases and Osteoarthritis 
 
In osteoarthritis it is believed that there is an increase in matrix degradation through 
increased production of proteases (ADAMTSs, MMPs), increased protease activity 
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(increased cleavage of pro-enzymes) or decreased activity of catabolic regulators (TIMPs).  It 
has been previously suggested that one of the earliest events associated with OA is the loss of 
aggrecan core protein from the cartilage extracellular matrix and that this is a prerequisite for 
the subsequent proteolysis of collagen fibres.  Because chondrocytes continuously 
resynthesise aggrecan, this first step is potentially reversible.  The second step is considered 
permanent because, despite repair attempts, the original fibrous collagen network cannot be 
restored (Mankin and Lippiello, 1970; Mort and Billington, 2001).   
 
Work by two groups monitored mRNA levels in human cartilage samples from early 
degenerative and late-stage OA donors (Aigner and Stove, 2003; Aigner et al., 2003; Bau et 
al., 2002).  They reported a strong upregulation of MMP3 in early degenerative cartilage and 
a decrease in late-stage OA cartilage and an increased expression of MMP1, MMP2, MMP, 
MMP13, ADAMTS4 and ADAMTS5 in late stage OA cartilage (Aigner et al., 2003; Bau et 
al., 2002).   
 
MMP and ADAMTS generated neoepitope aggrecan fragments have been identified 
in culture media of cartilage explants in vitro as well as human synovial fluid in vivo 
suggesting elevated aggrecanase/MMP levels or activity (Fosang et al., 1996; Lark et al., 
1997; Little et al., 2002; Lohmander et al., 1993; Sandy et al., 1992; Sandy and Verscharen, 
2001).  Little and colleagues generated a line of aggrecan knockin mice with a mutation 
between the G1 and G2 domains which rendered aggrecan resistant to aggrecanase activity.  
It was reported that this knockin mutation significantly inhibited proteoglycan loss, 
diminished cartilage degradation and promoted cartilage repair (Little et al., 2007).  Adamts5 
knockout mice are significantly resistant to IL-1α and retinoic acid induced aggrecan 
cleavage as well as surgically induced cartilage destruction, compared with wild-type mice 
(Glasson et al., 2005).  No resistance to the progression of osteoarthritis was reported in 
Adamts4 knockout mice after surgical induction of joint instability and therefore Adamts5 is 
believed to be the more important aggrecanase in mouse cartilage (Glasson et al., 2004).  
However Song and colleagues demonstrated that the depletion of either ADAMTS5 or 
ADAMTS4 using siRNA in human cartilage explants inhibits proteoglycan release when 
explants were stimulated with tumor necrosis factor α (TNFα) and oncostatin M (OSM).  
This suggests that despite the dominant role of Adamts5 in mouse both ADAMTS4 and 
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ADAMTS5 may contribute towards cartilage destruction in human osteoarthritis (Song et al., 
2007).  
     
MMP13 is a matrix metalloproteinase thought to play a critical role in cartilage 
destruction.  MMP13 is more active against type II collagen than other collagenases and 
chondrocyte expression of MMP13 mRNA is increased in late-stage human OA cartilage in 
association with cartilage erosion (Aigner et al., 2001; Minond et al., 2006).  Neuhold and 
colleagues used a tetracycline-induced cartilage specific promoter to constitutively 
overexpress active human MMP13 in hyaline cartilage of transgenic mice.  Overexpression 
resulted in focal OA cartilage pathology at load bearing sites similar to human OA including 
proteoglycan and type II collagen degradation (Neuhold et al., 2001).  Little and colleagues 
demonstrated that the cartilage of Mmp13-/- mice is protected from structural cartilage 
damage in a surgically induced model of OA, however there was no significant reduction in 
aggrecanolysis, osteophyte development or chondrocyte hypertrophy (Little et al., 2009).  
MMP13-/- mice were able to inhibit cartilage degradation in the presence of aggrecan loss; 
this may suggest that aggrecan depletion on its own does not drive cartilage degradation.  
Proteases are clearly involved in the subsequent degradation of articular cartilage but the 
mechanism of initiation remains unclear.  
 
Destruction of articular cartilage and joint space narrowing is a clinical presentation 
of radiographic osteoarthritis, however it is important to note osteoarthritis is not limited to 
the articular cartilage and that other components of the joint may be involved.  Osteoarthritis 
is associated with subchondral bone remodeling, osteophyte formation, weakness in joint 
ligaments, loss of synovial fluid volume and episodically inflammation of the synovial 
membrane.  Increased MMP13 and TIMP1 expression was detected in hyperplastic synovial 
tissue and subchondral bone of osteoarthritic mice suggesting that other tissues may 
significantly participate in joint destruction and subsequent remodeling (Salminen et al., 
2002). 
1.7.2  Chondrocyte Phenotype 
 
 In response to cartilage matrix degradation OA chondrocytes may revert to a more 
active/juvenile phenotype and attempt to initiate extracellular matrix repair by proliferating 
and upregulating collagens, glycoproteins, and small proteoglycans (Lippiello et al., 1977; 
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Nelson et al., 1998; Pfander et al., 2004a; Rizkalla et al., 1992; Swoboda et al., 1998).  Type 
II collagen was found to be upregulated between 4-7 fold in OA chondrocytes, with 
particularly high expression in the radial zone (Aigner et al., 1999; Aigner et al., 2001; 
Nelson et al., 1998; von der Mark et al., 1992).  However these molecules are often damaged, 
have inferior mechanical properties, cannot overcome their catabolic environment and 
therefore cannot regenerate the normal cartilage matrix architecture (Rizkalla et al., 1992).   
 
Other data suggests that in addition to increased degradation of extracellular matrix 
proteins, chondrocytes undergo a phenotypic change, downregulating collagen type II, 
upregulating collagen X expression and becoming hypertrophic (Aigner et al., 2007; Aigner 
et al., 1999).  These hypertrophic cells eventually undergo apoptosis, and the reasons for this 
are unknown (Hashimoto et al., 1998; Poole et al., 2001).   
1.7.3  Osteoarthritis and Hypoxia 
 
It is logical to assume the progressive loss of articular cartilage in osteoarthritis 
reduces the diffusion distance for oxygen and increases the oxygen tension in oestoarthritic 
cartilage compared with healthy tissue.  However, experimental evidence suggests that the 
low partial pressure of molecular oxygen in synovial fluid is further decreased in 
osteoarthritic joints, and this is associated with increased HIF-1α activity (Grimmer et al., 
2006; Lund-Olesen, 1970; Schneider et al., 1996).  It has been suggested that chondrocyte 
metabolic activity increased in an attempt to repair damaged extracellular matrix.  This would 
consume molecular oxygen, decreasing the partial pressure of molecular oxygen in synovial 
fluid leading to increased HIF-1α activity.  It has also been suggested that HIF-1α isoforms 
are stabilised in HACs in response to cell stress (mechanical or inflammatory), this 
stabilisation promotes cell survival and is indepdent of oxygen tension (Coimbra et al., 2004). 
1.7.4  Regulation of matrix turnover, cytokines and other inflammatory 
genes 
 
 The role of inflammatory cytokines in osteoarthritis in vivo is unclear, however they 
are useful tools to study cartilage degradation in vitro. 
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Interleukin 1 (IL-1) and Tumor necrosis factor α (TNF-α).  Proinflammatory cytokine 
interleukin 1 (IL-1) is a cytokine mainly secreted by macrophages.  IL-1 has two forms, α and 
β, both have similar effects on cartilage.  IL-1 has been shown to upregulate catabolic factors 
(MMPs and ADAMTSs), increase inducible nitric oxide synthase (iNOS) expression and 
suppress the synthesis of aggrecan and type II collagen in chondrocytes (Bocquet et al., 1986; 
Kobayashi et al., 2005; Pasternak et al., 1986).  The stimulation of cartilage explants with IL-
1 induces the rapid depletion of proteoglycans in explants cultures (Flannery et al., 1999; 
Gebauer et al., 2005; Saklatvala, 1987; Vincenti and Brinckerhoff, 2002).  The induction of 
human IL-1β in temporomandibular joints of transgenic mice led to degeneration, 
dysfunction, and related pain in the joint (Lai et al., 2006).  However, IL-1β-knockout mice 
also develop OA lessions in cartilage of unoperated limbs (Clements et al., 2003).  IL-1 is 
mainly produced by macrophages and although it has been reported that chondrocytes have 
the capacity to synthesis IL-1 it remains controversial whether it can be produced in amounts 
necessary for pathogenesis (Gruber et al., 2004).  Similarly to IL-1, tumor necrosis factor α 
(TNF-α) induces the rapid depletion of proteoglycans in explants cultures (Saklatvala, 1987).  
 
Transforming growth factor-beta (TGF-β).  The TGF-β superfamily consists of 35 members, 
including the bone morphogenetic proteins (BMPs) and activins (de Caestecker, 2004).  TGF-
β has been shown to be an anabolic factor in bovine chondrocytes increasing synthesis of 
glycosaminoglycan and collagen type II (Davies et al., 2008).  In addition it inhibits the 
cytokine induced cartilage matrix degradation by upregulating matrix components, 
downregulating MMPs and upregulating TIMPs (Andrews et al., 1989; Hui et al., 2000; Su et 
al., 1999). 
 
Insulin-like growth factor-1 (IGF-1). Insulin-like growth factor-1 promotes proteoglycan 
synthesis, even in the presence of IL-1 and TNF-α (Loeser et al., 2005).  Treatment of 
cartilage explants with IGF-1 is chondroprotective, inhibiting cartilage degradation in 
response to cytokine stimulation (Tyler, 1989).  This chondroprotective effect may be 
mediated by inhibiting MMP activity (Hui et al., 2001).  
 
In summary, articular cartilage is a tissue whose function is dependent upon the 
integrity and composition of a specialised extracellular matrix which enables the tissue to 
absorb and resist compression and allow articulation.  Although the mechanisms of initiation 
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are unknown it is believed that during osteoarthtiris, an imbalance between net anabolic 
(matrix synthesis) and net catabolic (protease activity) activity leading to a disruption of 
cartilage homeostatis and an increase in the degradation of extracelluar matrix components.  
Increased protease (ADAMTSs and MMPs) activity results in loss of the water binding 
proteoglycans and the collagen network.  These changes in cartilage matrix structure are 
responsible for a net reduction in cartilage tensile strength and a loss of cartilage’s shock 
absorbing properties.   
 
1.8  Hypoxia Inducible Factors (HIFs) 
 
In 1991 Semenza and colleagues analysed the hypoxia induced upregulation of 
erythropoietin (EPO) in liver cells and using DNase analysis identified the binding of 
transcription factors to the EPO gene enhancer (Semenza et al., 1991; Semenza and Wang, 
1992).  Later work illustrated that the upregulation of EPO by hypoxia was present in all 
mammalian cell lines and therefore this oxygen-sensing transcription factor was not restricted 
to EPO producing cells (kidney or liver cells) (Maxwell et al., 1993).  In 1993 this oxygen 
sensing transcription factor was identified and named “Hypoxia-Inducible Factor 1” or “HIF-
1” (Wang and Semenza, 1993).  The protein was eventually purified by ion-exchange DNA-
affinity chromatography and its structure deduced (Wang et al., 1995; Wang and Semenza, 
1995). 
 
 HIF-1 is a hetero-dimer, consisting of an α and β subunit and belongs to the family of 
basic helix-loop-helix and PER-ARNT-SIM domain containing transcription factors (Distler 
et al., 2004).  These subunits are 120kDa (826aa) and 91-94kDa (789aa) in size respectively 
(Wang et al., 1995).  Both subunits of HIF are constitutively expressed at the mRNA level; 
however, the α subunit is regulated post-translationally by oxygen levels.   
1.8.1  HIF signalling pathway 
 
In well-oxygenated cells HIF-1α is regulated via two mechanisms.  Firstly, the α-
subunit is hydroxylated on specific proline residues within two oxygen-dependent-  
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 FIGURE 1.5.  The domain structure of HIF-1α and HIF-1β.  Both HIF-1α and HIF-β have 
N-terminal basic helix-loop-helix (bHLH) domains and an intermediate PAS domain or PER-
ARNT-SIM domain.  HIF-1α has the following domains; the N-terminal oxygen dependent 
degradation domain (NODDD); the C-terminal oxygen dependent degradation domain 
(CODDD); the N-terminal activation domain (NAD) and C-terminal activation domain (CAD).  
The CODDD and NAD overlap.  The hypoxic regulation of HIF-1α is conveyed by residues 
within the NODDD (-Pro), CODDD (-Pro) and CAD (-Asn) domains.  (Schofield and Ratcliffe, 
2004). 
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FIGURE 1.6.  Regulation of HIF-α isoforms by the direct oxygen sensors, PHDs / FIH-1 enzymes.  
Decreases in molecular oxygen (≤5% O2) inhibits two independent hydroxylation pathways involved 
in the regulation of HIF-α isoform activity:  Proyl-hydroxylase domain (PHD) enzymes and Factor 
Inhibiting HIF-1α (FIH-1) enzymes.  The absence of molecular oxygen inhibits HIF-α isoform 
hydroxylation allows heterodimerisation with HIF-1β and the binding of CBP/p300 co-activator.  
Active heterodimer migrates to the nucleus and there the transcription factor binds to specific hypoxia 
response elements or HREs (-5’RCGTG-3’) in responsive target genes.  HIF-α subunits have the 
following domains:  bHLH-PAS - basic helix-loop-helix domain and PER-ARNT-SIM domain, 
NODD- N-terminal oxygen dependent degradation domain, CODD - the C-terminal oxygen dependent 
degradation domain.  The hypoxic regulation of HIF-α subunits by PHD enzymes is conveyed by 
residues within the NODD (-Pro) and CODD (-Pro) domains (Fraisl et al., 2009).  
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degradation domains (NODDD and CODDD) by HIF-targeting proyl-hydroxylase enzymes 
(PHD1, PHD2, PHD3 and PHD4) (Fig. 1.5) (Ivan et al., 2001).  The PHD enzymes are a 
subfamily of dioxygenases that use molecular oxygen and 2-oxoglutarate (2-OG) as co-
substrates to add hydroxyl groups to specific proline residues on the α subunit (Schofield and 
Ratcliffe, 2004).  The hydroxylated proline residues are recognised by von Hippel–Lindau 
(VHL) protein of the E3 ubiquitin ligase complex, ubiquitinated and subsequently degraded 
by the 26S proteasome (Cockman et al., 2000).  Therefore, under normoxic conditions HIF-α 
protein has a very short half life (~5 minutes) (Thoms and Murphy, 2010). 
 
Secondly, another hydroxylase enzyme “factor inhibiting HIF-1” or “FIH-1” can also 
regulate the activity of HIF-α isoforms (Lando et al., 2002; Mahon et al., 2001).  Similarly to 
the PHD enzymes FIH-1 uses molecular oxygen and 2-oxoglutarate (2-OG) as co-substrates 
to add hydroxyl groups to a specific asparaginyl residue (Asn803 on HIF-1α and Asn851 on 
HIF-2α) present within the C-terminal transactivation domain of the α subunit (Freedman et 
al., 2002).  The hydroxylation of this residue is believed to disrupt the hydrophobic 
interactions between the C-TAD alpha helix and CH-1 domain of the CBP/p300 co-activator 
and so inhibits HIF transcriptional activity (Freedman et al., 2002). 
 
Conversely, at low oxygen tensions (less than 5% O2) limiting levels of molecular 
oxygen in the cell inhibits the PHD and FIH enzymes and they are unable to add hydroxyl 
groups to proline or asparaginyl residues of the α-subunit.  As a result, the α-subunit is not 
targeted by pVHL and not degraded by the 26S proteasome.  The α-subunit dimerises with 
the β subunit, migrates to the nucleus and there the transcription factor binds to specific 
hypoxia response elements or HREs (-5’RCGTG-3’), which are located in the major groove 
of DNA typically within the promoter region (Kinoshita et al., 2004; Wang and Semenza, 
1993, 1995).  In addition, the CBP/p300 co-activator is allowed to bind the C-TAD via its 
CH-1 domain.  The binding to HREs activates gene expression; HIF is known to regulate 
more than 100 genes via these HRE’s (Fig. 1.6) (Schofield and Ratcliffe, 2004).   
 
Because PHD enzymes and FIH-1 use molecular oxygen as substrates, they are, in 
fact, the direct oxygen sensors. 
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1.8.2  HIF-1α, HIF-2α and HIF-3α 
 
HIF-2α (EPAS1) is another HIF-α isoform closely related to HIF-1α with similar 
protein organisation and structure (Ema et al., 1997; O'Rourke et al., 1999; Tian et al., 1997).  
Both have an N-terminal basic helix-loop-helix (bHLH) domain, an intermediate PAS 
domain or PER-ARNT-SIM domain and an N- and C-terminal transactivation domain (N-
TAD / C-TAD).  The bHLH domain is found in many transcription factors and mediates 
DNA binding (Massari and Murre, 2000).  The PAS domain is necessary for dimerisation 
with HIF-β (Moglich et al., 2009).  The N-TAD and C-TAD are necessary for the regulation 
of HIF-α isoform stability and activity.  The N-TAD overlaps with the CODDD and is 
therefore involved in the regulation of α subunit stability.  The C-TAD is not directly 
involved in proteolytic regulation but regulates HIF transcriptional activity via FIH-1.   
 
HIF-2α shares a 48% amino acid homology to HIF-1α, with particularly high 
similarity in key functional domains:  there is 83% sequence identity between bHLH domains 
and 70% sequence identity between PAS domains (Ema et al., 1997).  There are also high 
levels of conservation (70% sequence identify) surrounding the N- and C-terminal oxygen 
dependent degradation domains (Ema et al., 1997).   
 
HIF-2α is regulated via the same mechanism as HIF-1α and has the ability to activate 
HRE-containing target genes.  It has been previously shown that HIF-1α and HIF-2α are able 
to regulate common and also unique targets in hypoxia.  Genes such as vascular endothelial 
growth factor (VEGF), adrenomedullin (ADM) and adipose differentiation-related protein 
(ADRP) are regulated by both HIF-1α and HIF-2α (Hu et al., 2006; Hu et al., 2003).  
Conversely, Raval and colleagues demonstrated that in VHL-defective renal carcinoma 
(RCC) cells HIF-1α specifically regulates pro-apoptotic gene BNIP3 (Raval et al., 2005).  
Work by Sowter and colleagues demonstrated, using siRNA, that the knockdown of either 
HIF-1α or HIF-2α resulted in markedly different effects on gene expression and cell 
migration depending on the cell types (Sowter et al., 2003).  Similarly, work by Rankin and 
colleagues in mouse hepatocytes also demonstrated that HIF-1α and HIF-2α have different 
transcriptional targets (phosphoglycerate kinase 1 and erythropoietin respectively) and 
therefore distinct roles in regulation of hypoxia-inducible genes (Rankin et al., 2007).  
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Finally, we have previously demonstrated that the hypoxic induction of SOX9 in human 
articular chondrocytes is HIF-2α and not HIF-1α dependent (Lafont et al., 2007). 
 
Hu and colleagues carried out domain swapping experiments on HIF-1α and HIF-2α 
and found that the replacement of HIF-2α N-terminal transactivation domain (but not the 
DNA binding bHLH domain, dimerization PAS domain or C-terminal transactivation 
domain) was sufficient to convert HIF-2α into a protein with HIF-1α functional specificity 
suggesting that target gene specificity is conferred by the N-terminal transactivation domain 
(Hu et al., 2007). 
 
In 1998, Gu and colleagues identified a third HIF-α isoform, HIF-3α.  HIF-3α is 
similar in structure and organisation to HIF-1α and HIF-2α however, HIF-3α lacks a C-
terminal transactivation domain (Gu et al., 1998).   HIF-3α may act as a dominant negative of 
other HIF-α isoforms, binding to HIF-1α or HIF-2α and forming transcriptionally inactive 
heterodimers.  Six different splice variants exist and variant HIF-3α4 has been demonstrated 
to bind to HIF-2α and attenuate its ability to bind to the HRE of hypoxia inducible genes in 
CC-RCC (clear-cell renal cell carincoma) cells (Maynard et al., 2007; Maynard et al., 2003).   
 
In addition to proline and asparaginyl hydroxylation HIF-1α has been reported to be 
phosphorylated and acetylated.  Richard and colleagues report strong phosphorylation of 
HIF-1α by p42/p44 mitogen-activated protein kinases (MAPKs) but not by p38 MAPKs or c-
Jun N-terminal kinase (c-JNK).  This phosphorylation increases HIF-1α transcriptional 
activity and is abrogated in the presence of MEK inhibitor PD98059 (Richard et al., 1999).  
In addition Jeong and colleagues have shown that the acetylation of HIF-1α (on Lys532) by 
ARD1 enhances ubiquitinated HIF-1α’s interaction with pVHL increasing its destabilisation 
(Jeong et al., 2002). 
 
1.9  Proyl-hydroxylase domain enzymes 
 
In 2001 the hydroxylation of two proline residues present on the HIF-α subunit was 
found to be essential for HIF-α to interact with pVHL and be subsequently degraded (Ivan et 
al., 2001; Jaakkola et al., 2001; Masson et al., 2001).  Subsequent genetic work in 
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Caenorhabditis elgans and Drosophila melanogaster identified a single HIF-proly-
hydroxylase enzyme which regulated the HIF-α subunit in each organism, named EGL-9 and 
dHPH respectively (Bruick and McKnight, 2001; Epstein et al., 2001).  EGL-9 and dHPH 
belong to a subfamily of dioxygenases which use oxygen and 2-oxoglutarate to hydroxylate 
proline residues within the HIF-α oxygen dependent degradation domain (ODDD).  Using the 
amino acid sequence of EGL-9 and dHPH four mammalian proyl-hydroxylase domain 
enzymes have been identified:  PHD1, PHD2, PHD3 and PHD4.  These enzymes are 407 
amino acids, 426 amino acids, 239 amino acids and 502 amino acids in size respectively 
(Bruick and McKnight, 2001; Epstein et al., 2001; Koivunen et al., 2007).      
 
The PHD enzymes are hydroxylases which use molecular oxygen as a substrate.  
Baculovirus produced PHD enzymes have Km vaules for oxygen between 230 - 250µM (23-
25% O2), which is slightly higher than the concentration of dissolved oxygen under 
atmospheric conditions (~200µM or 20% O2), therefore PHD enzymes can be thought of as 
direct oxygen sensors as small changes in oxygen tension will effect enzyme activity (Hirsila 
et al., 2003).  Under normoxic conditions one oxygen atom is added to a peptidyl-proline 
residue in the ODDD to form hydroxyproline and the other oxygen atom is used in an 
oxidative decarboxylation reaction to convert 2-oxyglutarate to succinate and CO2 (Berra et 
al., 2006).  The PHD enzymes do not hydroxylase free proline residues within the HIF-α 
subunit and recognise a specific conserved motif within the N-ODDD and C-ODDD:  
LXXLAP (where X represents any amino acid).   
   
PHDs use ascorbate and Fe2+ as cofactors, and this explains why PHD and FIH 
enzymes are suppressed in the presence of iron chelators such as desferrioxamine (DFO).  
Cobalt (Co2+) and nickel (Ni2+) salts act as iron antagonists, substituting Fe2+ in the PHD 
enzymes and suppressing oxygen binding activity (Semenza, 1999). 
 
The CLUSTALX multiple sequence alignment shown below illustrates that PHD1 
and PHD2 are well-conserved in their C-terminal end (55% identity) and possess less 
similarity at their N-terminal halves (Epstein et al., 2001).  PHD3 is the shortest of the PHD 
enzymes and aligns mostly with the C-terminal end of PHD1 and PHD2.  All PHD enzymes 
possess a conserved pair of histidine residues (H) and one carboxylate motif (D); together 
these form the facial triad which coordinates an Fe2+ ion at the catalytic site (HXD/E...H  
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FIGURE 1.7.  Proyl-hydroxylase domain (PHD) enzymes.  A PHD1/2/3/4 molecular 
weights, cellular localisation and enzymatic reactions are shown.  B  Multiple sequence 
alignment of PHD1/PHD2/PHD3 using CLUSTALX. 
A 
B 
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motif).  A positively charged Arginine (R) residue is used to bind the C-5 carboxyl group of 
2-oxoglutarate (Schofield and Ratcliffe, 2004).  These 4 residues are essential for the PHD 
enzymes’ function (marked with red arrows on the multiple sequence alignment (Fig. 1.7). 
PHD1, PHD2 and PHD3 are structurally similar; each has 8 antiparallel β-strands which are 
linked with short turns and folded into a “jelly-roll” motif (Schofield and Zhang, 1999)  
1999).  The pair of histidine residues (H) and one carboxylate motif (D) which together form 
the facial traid necessary to accommodate an Fe2+ ion at the catalytic site are found on or 
close to the 2nd and 7th β-strands (Aravind and Koonin, 2001; Myllyharju and Kivirikko, 
1997; Schofield and Zhang, 1999). 
 
PHD4 is a putative HIF-targeting hydroxylase, which has only been recently 
characterized and in contrast to PHD1, PHD2 and PHD3 it is structurally similar to collagen 
prolyl 4-hydroxylases (Koivunen et al., 2007).  PHD4 is an endoplasmic reticulum (ER) 
transmembrane protein with its catalytic domain within the lumen of the ER rather than the 
cytsol.  It aligns poorly with the other PHD enzymes but does have identical residues 
indicating the presence of a facial triad (two histidines and 1 one carboxylate motif).  In 
PHD4, the positively charged lysine is used to bind the C-5 carbosyl group of 2-oxoglutarate 
rather than arginine (Koivunen et al., 2007).  PHD4 has been shown to hydroxylate HIF-α-
ODDD reporter constructs and the knockdown of PHD4 using siRNA was shown to increase 
HIF-1α levels, albeit by a modest amount (~2 fold) (Koivunen et al., 2007).  
 
The PHD enzymes can be thought of as being cellular oxygen sensors.  They are 
detectable and functional under normoxic conditions.  However, PHD2 and PHD3 are 
themselves up-regulated by hypoxia.  Hypoxia response elements are present upstream of 
PHD2 and PHD3 transcription start sites and electrophoretic mobility-shift assays 
demonstrate that HIF-1α binds to these sites (Metzen et al., 2003; Pescador et al., 2005).  It is 
hypothesised that these PHD enzymes are up-regulated under hypoxia in order to rapidly 
degrade HIF-α isoforms and down-regulate hypoxia responsive genes once the cells are 
returned to normoxic conditions.  PHD1 has not been reported to be induced by hypoxia.  
Work by Koivunen and colleagues has demonstrated that PHD4 is up-regulated at the protein 
level in response to hypoxia in cultured human adult fibroblasts and embryonic kidney 
(HEK293), hepatoma (Hep3B) and fibrosarcoma (HT1080) cells (Koivunen et al., 2007). 
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Tissue distribution of the PHD enzymes has been investigated at the mRNA level in 
rats.  The mRNAs of PHD1/2/3 were detectable in the heart, liver, kidney, brain, testis and 
lung (Willam et al., 2006).  PHD2 was found to be ubiquitously expressed and has also been 
shown to be the most abundant PHD enzyme in several cell lines (Appelhoff et al., 2004; 
Berra et al., 2003; Willam et al., 2006).  PHD1 expression was highest in the testes and PHD3 
mRNA expression was highest in the heart suggesting particular roles for the proteins in these 
organs (Willam et al., 2006).  Koivunen and colleagues also investigated the distribution of 
PHD4 in adult human tissue.  Northern blotting revealed that PHD4 was highly expressed at 
the mRNA level in the heart, brain and pancreas.  Additional experiments using PCR 
identified low levels of PHD4 expression in epiphyeal cartilage (Koivunen et al., 2007). 
 
PHD1, PHD2, PHD3 have been detected at the protein level within the maturing zone 
of the human growth plate and in the mouse chondrocyte cell line N1511 (Terkhorn et al., 
2007).  PHD1/2/3/4 have been reported at the mRNA in human cartilage and at the PHD1/2/3 
have been reported at the protein level (Hirisila, et al, 2003; Koivunen et al., 2007; Terkhorn 
et al., 2007).   Recent microarray experiments in our laboratory on human articular 
chondrocytes found that while PHD2 mRNA is the most abundant PHD mRNA present under 
normoxic and hypoxic conditions, PHD3 message was the most highly induced by hypoxia 
(Murphy et al., 2009). 
1.9.1  Enzyme Specificity 
 
Under normoxic conditions two specific, conserved proline residues in the HIF-α 
subunit are hydroxylated by the PHD enzymes.  However, different PHD isoforms show a 
preference for HIF-1α’s N-ODDD (P402) or C-ODDD (P564) (Hirsila et al., 2003; Koivunen 
et al., 2006; Li et al., 2004).  All PHD enzymes are more active against C-ODDD than N-
ODDD substrates in vitro (Koivunen et al., 2006).  PHD3 is virtually inactive against N-
ODDD substrates (Hirsila et al., 2003; Koivunen et al., 2006; Li et al., 2004). 
 
In 2004, Appelhoff and colleagues used siRNA against the three HIF proyl-
hydroxylases (PHD1, PHD2, PHD3) in a range of cell lines.  It was found that all three PHD 
isoforms contribute towards the regulation of HIF-1α and HIF-2α.  However, some isoforms 
show selectivity between HIF-1α and HIF-2α (Appelhoff et al., 2004).  In MCF7 cells, the 
knockdown of PHD3 stabilised HIF-2α at higher levels than when control cells were exposed 
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to hypoxia and substantially delayed HIF-2α degradation following re-oxygenation 
(Appelhoff et al., 2004).  The knockdown of PHD3 had minimal effect on HIF-1α.  In 
contrast, the suppression of PHD2 led to the stabilisation of HIF-1α (Appelhoff et al., 2004).  
This work has been supported by other cell line studies suggesting that PHD enzymes have 
different selectivity against different HIF isoforms, with PHD1 and PHD3 being more active 
on HIF-2α and PHD2 preferentially hydroxylating HIF-1α (Berra et al., 2003; Ginouves et 
al., 2008). 
1.9.2  PHD knockout mice 
 
Work by Takeda and colleagues in 2006 investigated the roles of the PHD enzymes in 
mice.  Phd1-/- or Phd3-/- mice are apparently normal with no defects, however, Phd2-/- mice 
die mid-gestation between embryonic days 12.5 and 14.5 as a result of placental and heart 
defects (Takeda et al., 2006).  Phd2-/- knockouts led to a stabilisation and accumulation of 
both HIF-1α and HIF-2α in the placenta and embryo proper, however, most surprisingly, 
there was no specific HIF-α increase in the heart (Takeda et al., 2006).  The absence of HIF-α 
stabilisation in the heart is surprising as Phd2 was found to be the most highly expressed Phd 
enzyme at the mRNA level (Phd2>Phd1>Phd3), in both the placental and heart tissue.   Mice 
have severe heart defects including underdeveloped myocardium and trabaeculae, and there 
are two possible explanations for these reported heart defects in the absence of elevated HIF-
α isoforms levels - either Phd2 depletion in the embryo has a severe effect on circulatory 
system (e.g., raising blood pressure) and this indirectly damages the heart or, perhaps more 
likely, PHD2 regulates a HIF-independent target vital for heart development.  In addition, 
Phd2-/- increased HIF-1α and HIF-2α levels in the placenta of knockdown mice and was 
associated with severe defects including significantly reduced labyrinthine branching and 
widespread penetration of the labyrinth by spongiotrophoblasts and giant cells.  In summary 
it was demonstrated that Phd2 plays an essential role for mouse embroygenesis.   
 
Post-natal tamoxifen-induced, Cre-loxP-mediated Phd2 knockout in mice leads to 
increased angiogenesis (vascular density), angiectasia (increased blood vessel dilation) and 
recruitment of vascular smooth muscle cells in multiple organs in adult mice (Takeda et al., 
2007).  Six weeks after treatment with tamoxifen major vascular branches were significantly 
dilated and reddened, although there was no sign of oedema, inflammation or ulceration.  
Phd2 knockout led to increased vascular growth in the liver, heart, kidney, lungs and brain 
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although this effect did not necessarily correlate with local Phd2 depletion (there were very 
low levels of Phd2 depletion in the brain following tamoxifen treatment).  Consistent with 
work in cell lines, Phd2-/- led to the stabilisation and accumulation of HIF-1α but not HIF-2α 
in mouse liver and kidney tissue.  Angiogenic factors such as Vegf-a and Epo were found at 
increased levels in serum and EPO was overexpressed by 230-fold leading to severe 
polycythaemia (Takeda et al., 2007).  Overall this suggests that Phd2 is a major negative 
regulator of angiogenesis and erythropoietin (Takeda et al., 2007).    
 
Although Phd1-/- or Phd3-/- mice are apparently normal with no defects, adult Phd1-/- 
and Phd3-/- double knockouts develop moderate erythrocytosis although these levels were not 
as high as Phd2-/- deficient mice (Takeda et al., 2008).   Consistent with work in cell lines 
Phd1-/-/Phd3-/- double knockout led to preferential HIF-2α stabilisation and not HIF-1α in the 
liver (Takeda et al., 2008). 
 
Takeda and colleagues reported in 2006 that Phd1-/- mice are viable and apparently 
normal.  However, subsequent work by Aragones and colleagues suggests that PHD1 may 
play a role in muscle function and metabolism in mice.  Aragones reported that the loss of 
Phd1 reprograms myofiber glucose metabolism switching from oxidative, aerobic to more 
anaerobic ATP generation.  Phd1-/- mice have a decreased exercise tolerance and lower O2 
consumption in skeletal muscle.  Surprisingly the loss of Phd1 makes the skeletal muscle 
more resistant to ischaemic necrosis but the loss of Phd2 (Phd2+/-) or Phd3 (Phd3-/-) did not 
provide protection against ischemic cell death (Aragones et al., 2008).  This hypoxia 
tolerance was not due to HIF-dependent angiogenesis, erythropoiesis or vasodilation.  Phd1-/- 
had elevated levels of HIF-2α stabilisation in their myofibers compared to wild-type and by 
contrast HIF-1α levels were either low or undetectable in both genotypes.  The loss of HIF-2α 
in Phd1-/- deficient mice abrogated hypoxia tolerance.  This study suggests a role for Phd1 in 
hypoxia tolerance and glucose metabolism, and provides further evidence of PHD selectivity 
for HIF-α isoforms (Aragones et al., 2008). 
 
 In summary, the PHD enzymes possess species, tissue and cellular expression 
differences.  The current literature proposes that while all of the PHD enzymes can 
hydroxylase HIF-1α and HIF-2α, PHD2 is more active against HIF-1α and PHD1/PHD3 are 
more active against HIF-2α, although species and tissue differences are may occur. 
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1.10  Hypoxia and HIF stabilisation in human articular cartilage 
 
As mentioned above articular cartilage functions in a chronically hypoxic 
environment throughout life.  Depending of tissue depth, chondrocytes are exposed to 
approximately between 1-6% O2.  Reduced levels of molecular oxygen inhibit HIF-targeting 
hydroxylases and result in the stabilsation of HIF-1α and HIF-2α protein in human articular 
cartilage.  Immunohistochemistry of human articular cartilage confirms the presence of HIF-
1α and HIF-2α protein (Bohensky et al., 2009; Coimbra et al., 2004; Yudoh et al., 2005).  
Levels of HIF-1α stabilisation correspond with the logical pattern of oxygen gradient, 
increasing in intensity away from the surface of the tissue (Brucker et al., 2005).   
1.10.1  HIF stabilisation promotes differentiated chondrocyte  phenotype 
 
Experimental evidence suggests that the low partial pressure of molecular oxygen in 
synovial fluid is further decreased in osteoarthritic joints, and that this is associated with 
increased HIF-1α activity (Grimmer et al., 2006; Lund-Olesen, 1970; Schneider et al., 1996).  
Yudoh and colleagues investigated human articular cartilage of osteoarthritis (OA) patients 
and reported high expression of HIF-1α in degenerated regions compared with 
macroscopically intact regions.  The role of HIF-1α was further investigated by treating 
chondrocytes with interleukin-1β under normoxic and hypoxic conditions.  Treatment of 
chondrocytes with interleukin-1β stabilised HIF-1α and depletion of HIF-1α using small 
interfering RNA significantly increased the number of apoptotic chondrocytes.  Similarly, an 
inflammatory signal (TNF-α) in human chondrocytes and mechanical stress (overloading) in 
bovine cartilage discs have been shown to stabilise HIF-1α (Coimbra et al., 2004).  It has 
been suggested that HIF-1α is anti-apoptotic and protects articular chondrocytes from cell 
death induced by catabolic stress (Yudoh et al., 2005). 
 
Conversely, Bonhensky et al., reported decreased levels of HIF-2α in osteoarthritic 
human articular cartilage.  The decrease in HIF-2α was linked with increased cell death in 
chondrocytes and it was proposed that HIF-2α is a modulator of autophagy and protects the 
cells from apopotsis (Bohensky et al., 2009).  
 
Hif-1α-/- mice die in utero as early as E8.5 exhibiting multiple morphological defects 
demonstrating that HIF-1α is essential for embryonic development (Compernolle et al., 2003; 
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Iyer et al., 1998; Ryan et al., 1998).  Similarly, HIF-β-/- mice die in utero between 9.5 and 
10.5 days gestation from primarily from defects in placenta angiogenesis (Kozak et al., 1997; 
Maltepe et al., 1997).  Schipani and colleagues demonstrated that the mouse developmental 
growth plate is hypoxic and that HIF-1α is essential for proliferation and survival of murine 
growth plate chondrocytes in vivo.  Cartilage-specific HIF-1α depletion led to cell death 
within articular and growth plate chondrocytes resulting in long bone, rib and vertebral body 
defects coupled with decreased expression of the CDK inhibitor p57 (Schipani et al., 2001).  
It was concluded that HIF-1α is essential for growth plate development and chondrocyte 
survival in response to hypoxic conditions. 
 
Scortegagna and colleagues demonstrated that hif-2α-/- mice survive but have 
substantially shorter lifespan, lower body weight, overt cardiac hypertrophy, mitochondrial 
dysfunction, skeletal myopathy and hepatosteatosis providing evidence that while HIF-2α is 
not embryonic lethal, it plays a fundamentally important functional role and is not redundant 
(Scortegagna et al., 2003).  Similarly, homozygous knockout of HIF-2α in the limb bud 
mesenchyme caused a modest delay in endochondral bone development at E17.5 (Araldi et 
al., 2011).  Others have shown that homozygous deficient hif-2α-/- mice die at the early 
embryonic stage (Saito et al., 2010; Tian et al., 1998; Yang et al., 2010).  A recent publication 
in Nature Medicine reported that heterozygous deficient hif-2α+/- mice grew without 
abnormalities of major organs but showed mild dwarfism compared to wild-type littermates 
(Saito et al., 2010).  Heterozygous deficient hif-2α+/- mice have reduced limb length (8-16% 
shorter), increased hypertrophic and proliferation zones suggesting a role for hif-2α in 
endochondroal ossification and bone growth in mouse (Saito et al., 2010). 
 
Robins and colleagues identified putative Hypoxia Responsive Elements (HREs) 
within the promoter of tissue specific transcription factor Sox9, in mouse pluripotent 
mesenchymal stromal (ST2) cells.  Hypoxia increased expression of Sox9 and caused ST2 
cells to differentiate along a chondrocyte pathway (Robins et al., 2005).  However this 
hypoxic induction of Sox9 was not confirmed at the protein level.  The hypoxic upregulation 
of Sox9 was abolished when these putative HRE sites were mutated (Robins et al., 2005).    
This hypoxia induced chondrogenesis was further investigated by Kanichai and colleagues.  
Mouse MSCs were exposed to hypoxia and chondrogenesis observed by measuring collagen 
II, Sox9 expression and proteoglycan deposition (Kanichai et al., 2008).  When siRNA was 
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used to knockdown HIF-1α, the hypoxia-induced chondrogenesis was absent.  The authors 
concluded that HIF-1α provided a beneficial effect to cartilage and was a key mediator of 
chondrogenesis (Kanichai et al., 2008).  However, Kanichai and colleagues only focused on 
HIF-1α and failed to investigate HIF-2α function. 
1.10.2  HIF stabilisation  increases cartilage matrix synthesis 
 
Hypoxia not only promotes chondrocyte differentiation but also promotes 
chondrocyte function.  Hypoxia has been shown to increase cartilage matrix deposition in 
murine epiphyseal chondrocytes.  The deletion of the pVHL (which would stabilise both HIF-
1α and HIF-2α) results in significantly reduced chondrocyte proliferation rate, ~1.4 fold 
increase in Col2a1 mRNA expression and the presence of atypical large cells within the 
resting zone (Pfander et al., 2004b).  Pfander and colleagues also isolated and cultured 
epiphyseal chondrocytes from wild-type and Hif-1α-/- mice.  They reported that the exposure 
of wild-type cells to 0.5% oxygen increased Col2a1 protein levels ~2 fold and this hypoxic 
induction was lost in Hif-1α--/- cells (Pfander et al., 2003).  Aggrecan mRNA and protein 
levels were unchanged upon exposure to hypoxia (Pfander et al., 2003). 
 
Ren and colleagues isolated mouse chondrocytes from the hips and knees of 3- or 4- 
day old C56BL/6 mice.  All mice possessed homologous loxP sites flanking the HIF-1α 
locus.  Mouse chondrocytes were exposed to hypoxic conditions and the upregulation of 
Col2a1 (~1.5 fold) and Aggrecan (~1.4 fold) observed via real-time PCR (Ren et al., 2008).  
When the chondrocytes were infected with an adenovirus containing Cre recombinase 
(creating Hif-1α-/-cells) this hypoxia induced extracellular matrix synthesis was lost.  Ren and 
colleagues concluded that the hypoxia induced cartilage matrix synthesis was HIF-1α 
dependent (Ren et al., 2008). 
 
Work by Amarilio and colleagues examined the expression of Sox9 under hypoxic 
conditions in mouse mesenchymal cells derived from E11.5 Hif1α floxed mouse embryos 
infected with AdCre or AdGfp.  Low oxygen tensions increased Sox9 expression (~2 fold) in 
control cells and this hypoxic induction of Sox9 was lost in Hif-1α depleted cells.  This 
hypoxic induction of Sox9 was not confirmed at the protein level.  Conversely, the 
overexpression of Hif-1α induced an increase in Sox9 expression (Amarilio et al., 2007).  
Chromatin immunoprecipitation provided evidence for direct recruitment of HIF-1α to the 
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Sox9 promoter (Amarilio et al., 2007).  Hypoxia upregulated Col2a1 (~1.7 fold) and 
Aggrecan (~2.3 fold) at the mRNA level in mouse mesenchymal cells and this hypoxic 
induction is lost in Hif-1α depleted cells. 
 
Saito and colleagues recently overexpressed HIF-2α in a mouse chondrogenic cell line 
(ATDC5 cells) treated with normoxia and found overexpression of HIF-2α significantly 
increased mRNA levels of Col2a1 (~2 fold) and Aggrecan (~2 fold).  ATDC5 cells 
transfected with siRNA against Hif-2α did not show a significance decrease in Col2a1 or 
Aggrecan mRNA levels compared to control (Saito et al., 2010).  However this is expected as 
experiments were performed under normoxic conditions and HIF-2α would not be stabilised 
at 20% oxygen due to hydroxylation of its proline residues by the PHD enzymes, and 
subsequent ubiquitination and proteosomal degradation. 
 
There is significant evidence that hypoxia upregulates expression of cartilage matrix 
genes in bovine, porcine and human chondrocytes and has similar effects in human meniscal 
cells (Adesida et al., 2006; Domm et al., 2002; Lafont et al., 2007; Murphy and Polak, 2004; 
Murphy and Sambanis, 2001; Strobel et al., 2010; Zhang et al., 2011).  We have previously 
demonstrated in healthy human articular chondrocytes that key cartilage matrix genes 
COL2A1, COL9A1, COL11A2 and AGGRECAN, whilst upregulated by hypoxia, are not 
direct HIF-target genes and this hypoxic upregulation is mediated by key cartilage 
transcription factor SOX9.  Furthermore, the hypoxic upregulation of SOX9 was found to be 
HIF-2α, and not HIF-1α dependent. 
 
 Although hypoxia has been shown to increase cartilage matrix deposition in murine 
chondrocytes, this reported hypoxic induction is weaker than that reported in human (and 
other large animal) articular chondrocytes.  Isolated and cultured mouse chondrocytes 
exposed to hypoxia have typically been shown to upregulate Col2a1 mRNA 1.5 – 2 fold 
(Amarilio et al., 2007; Pfander et al., 2003; Pfander et al., 2004b; Ren et al., 2008; Saito et 
al., 2010).  Aggrecan mRNA levels have been reported unchanged upon exposure to hypoxia 
or have been upregulated very modestly (Amarilio et al., 2007; Pfander et al., 2003; Pfander 
et al., 2004b; Ren et al., 2008; Saito et al., 2010).  In contrast HACs treated with hypoxia 
upregulate Col2a1 4 - 12 fold and Aggrecan 2 – 5 fold at the mRNA level (Lafont et al., 
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2007; Murphy and Polak, 2004; Thoms and Murphy, 2010).  Possible reasons for this will be 
elaborated on in discussion sections of Chapter 4 and Chapter 5. 
 
Collagen proyl-4-hydroxylases (C-P4Hs) are tetramers (consisting of 2 α subunits and 
2 β units) responsible for catalysing the formation of 4-hydroxyproline by hydroxylation of –
X-Pro-Gly- triplicates within the pro-α collagen chains.  Like HIF-targeting hydroxylases 
collagen proyl-4-hydroxylases use 2-oxoglutarate and oxygen as substrates (iron and 
ascorbate as cofactors) to hydroxylate proline residues and this hydroxylation is essential for 
the formation of intramolecular hydrogen bonds and subsequent stable triple-helical 
formation (Jimenez et al., 1973; Kukkola et al., 2003; Myllyharju, 2003; Van Den 
Diepstraten et al., 2003).  Unlike the PHD1/2/3, however, C-P4H enzymes have a low Km for 
oxygen (40µM vs. 230-250µM) suggesting that C-P4H enzymes remain active even under 
low oxygen tensions (Hirsila et al., 2003).  This is logical given the roles of the HIF- and 
Collagen- Proyl hydroxylases.  PHD1/2/3 act as cellular oxygen sensors and therefore even a 
small change in oxygen tension can influence their activity.  In contrast, C-P4Hs must show 
high activity even in challenging hypoxic micro-environments (e.g., cartilage extracellular 
matrix synthesis or wound repair in a tissue with poor vascularisation).  Posttranslational 
modification of type II procollagens are essential steps for formation of the triple helices and 
their subsequent secretion.  It has been demonstrated that hypoxia increases expression of 
collagen proyl-4-hydroxylase α and β subunits in primary human articular chondrocytes and 
this upregulation was abolished by treatment with 2-Methoxestradiol (2ME2) (Grimmer et 
al., 2006; Hofbauer et al., 2003).  2ME2 has been shown to decrease levels of HIF-α isoforms 
in chondrocytes through an unknown mechanism of inhibition.  Therefore hypoxia has two 
mechanisms of promoting type II collagen secretion, upregulating COL2A1 gene expression 
and increasing expression of collagen proyl-4-hydroxylases (C-P4Hs) necessary for collagen 
post-translational processing.   
 
In summary, the stabilisation of HIF-α isoforms promotes the chondrocyte survival 
and phenotype.  In addition hypoxia has a strong net anabolic effect upregulating key matrix 
genes COL2A1, COL9A1, COL11A2, and AGGRECAN in human articular chondrocytes 
(HACs).  We have previously demonstrated that the hypoxic upregulation of SOX9 was 
found to be HIF-2α, and not HIF-1α dependent.  Finally, hypoxia has been reported to 
increase levels of collagen prolyl 4-hydroxylase levels suggesting that hypoxia upregulates 
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not only COL2A1 gene transcription but also regulates the post-translational processing of 
type II collagen fibres and hence their secretion.  This opens novel, exciting possibilities of 
manipulating the endogenous oxygen sensing pathways, for example, inhibiting PHD 
enzymes in order to selectively stabilise HIF-2α and hence promote articular chondrocyte 
function, promote cartilage synthesis and to stimulate repair.  We performed our research 
using healthy human articular cartilage and human articular chondrocytes.  This provides 
important clinically relevant information as the data generated can be extrapolated to what 
may be happening to human articular cartilage in vivo. 
 
Interestingly two recent publications in Nature Medicine have suggested that HIF-2α 
is a transactivator of many catabolic factors and is implicated in experimentally induced 
mouse models of osteoarthritis (Saito et al., 2010; Yang et al., 2010).  We will further discuss 
this topic in Chapter 4.   
 
1.11  Summary and aims of the project 
 
In summary, the stabilisation of HIF-α isoforms promotes chondrocyte survival and 
maintenance of the differentiated phenotype, the latter through upregulation of cartilage 
master regulator, transcription factor SOX9.  In addition hypoxia has a strong net anabolic 
effect upregulating key matrix genes COL2A1, COL9A1, COL11A2, and AGGRECAN in 
human articular chondrocytes (HACs) (Bi et al., 1999; Domm et al., 2002; Murphy and 
Polak, 2004; Murphy and Sambanis, 2001).  Previous work in our laboratory has 
demonstrated that hypoxia inducible factor 2α (HIF-2α), not HIF-1α, is integral for hypoxia-
induced SOX9 expression and the subsequently enhanced cartilage matrix production (Lafont 
et al., 2007).  Prolyl- and asparaginyl- hydroxylases are members of an oxoglutarate-
dependant dioxygenase family responsible for inhibiting HIF in the presence of oxygen.  We 
hypothesise that antagonising specific hydroxylases may (selectively) stabilise HIF-2α, 
promote the human articular chondrocyte phenotype and enhance cartilage deposition without 
inhibiting prolyl and lysyl hydroxylases essential for collagen processing (Fig. 1.8). 
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FIGURE 1.8.  Summary and hypothesis.  HIF-2α mediated  induction  of  cartilage  
matrix  synthesis  by  human  articular chondrocytes  (HACs)  may  be  possible  through  
the  inhibition  of  specific  HIF-2α targeting prolyl hydroxylase (PHD) enzymes.  Image 
from (Murphy et al., 2009). 
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1.11.1  Aims of the Project 
 
1. To firstly investigate the regulation of HIF-α isoforms in human articular 
chondrocytes by HIF-specific hydroxylases (PHD1, PHD2 and PHD3) and determine 
(using RNAi) which enzymes are critical (and potentially specific) for HIF-2α regulation.   
 
2. To discover if inhibition of such potentially HIF-2α-specific hydroxylases leads to 
enhanced SOX9 expression and extracellular matrix synthesis in human articular 
chondrocytes.  
 
3. To compare general hydroxylase inhibition (e.g., DMOG) to specific inhibition of 
HIF targeting enzymes, with regard to extracellular matrix deposition.   
 
4. To investigate the regulation of key catabolic factors responsible for extracellular 
matrix degradation by hypoxia in human articular chondrocytes.   
 
5. Finally, to investigate the observed hypoxic regulation of human articular 
chondrocyte function in other model species, namely pigs and mice.  This will provide 
preliminary results for future possible animal studies.   
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2.1  Reagents  
 
Unless otherwise stated, all chemicals were supplied by Sigma-Aldrich (Dorset, UK) 
or BDH Chemicals (Dorset, UK) and are of the highest quality.  Bovine serum albumin, 
electrophoresis grade (BSA) was from PAA Laboratories (Pasching, Austria).  Phosphate 
buffered saline (PBS) was obtained as a 10x sterile solution (VWR, Lutterworth, UK).  A 
1xPBS solution was generated by diluting the 10x stock with ultrapure ddH2O. 
2.1.1  General buffers and reagents 
 
10xPBS:  43mM Na2HPO4, 14mM KH2PO4, 14mM KCL and 1.37M NaCl at pH 7.3.   
 
Radio-immunoprecipitation assay (RIPA) lysis buffer:  100mM Trizma base pH7.4, 300mM 
NaCl, 20mM NaF, 2mM EDTA, 0.2mM βglycerophsphate, 2%(w/v) Na vanadate, 2% 
deoxycholate, 0.5% SDS and 1% NP-40.  
  
Urea/SDS lysis Buffer:  8 M urea, 10% glycerol, 1% SDS, 5 mM DTT, 10 mM Tris-HCl.  
 
Bradford reagent:  0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (v/v) ethanol and 
8.5% (v/v) H3PO4.   
 
SDS sample buffer:  2% SDS, 50 mM Tris, 10% glycerol, 0.1% bromophenol blue, 5% 2-β-
mercaptoethanol.   
 
Transfer buffer:  25mM Trizma Base, 190mM glycine, 20% methanol).   
 
PBST:  1XPBS, 0.1% Tween 20.   
 
Membrane Blocking Solution 1:  5% non-fat dried milk, 0.1% Tween 20 in 1xPBS.   
 
ECL Solution 1:  9ml ddH2O, 1 ml 1M Tris-HCl, 45 µl Coumaric acid stock, 100 µl Luminol 
stock [pH 8.5].  Add Tris-HCl first and mix.  Add Coumaric acid and mix.  Then add the 
Luminol and mix.  Store in the dark at 4oC.   
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ECL Solution 2:  9ml ddH2O, 1 ml 1M Tris-HCl, 6µl Hydrogen Peroxide, 30% stock 
[pH8.5].  Store in the dark at 4oC.   
 
Running buffer:  25mM Tris-HCL (pH 8.3), 200mM Glycine, 0.1% SDS).   
 
Deglycosylation Buffer:  50 mM Tris HCl (pH 7.5), 50 mM sodium acetate, and 10 mM 
EDTA. 
 
4xSDS sample buffer:  2% SDS, 50 mM Tris, 10% glycerol, 0.1% bromophenol blue, 5% 2-
β-mercaptoethanol. 
2.1.2  Cytokines  
 
Porcine and human cartilage explants, as well as passaged human articular chondrocytes 
(HACs) were stimulated with IL-1α.  Details are described below. 
2.1.3  Inhibitors 
 
Mouse and human cartilage explants, as well as human passaged articular chondrocytes 
(HACs) were treated with pharmacological inhibitors.  Details are described below. 
2.1.4  Antibodies 
 
Primary and secondary antibodies for western blotting used in experiments are listed in table 
2.3 below. 
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Table.  2.1  Cytokines 
 
Cytokine 
 
Species Source Vehicle 
Interleukin-1 α 
 
Human  Professor J. Saklatvala Serum Free DMEM 
 
 
 
 
 
Table.  2.2  Inhibitors  
 
Inhibitor 
 
Target Source Concentration Vehicle 
SB202190 
 
p38 MAP kinase 
inhibitor 
Calbiochem 
(559388) 
2µM DMSO 
Desferrioxamine (DFO) Iron chelator  10mM PBS 
Dimethyloxaloylglycine 
(DMOG) 
2-oxoglutarate 
dependent hydroxylase 
family. 
Biomol 
international, 
LP (E1-347) 
2mM PBS 
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Table.  2.3  Primary and Secondary antibodies. 
 
Antibody specificity 
 
Antibody Type Dilution Source 
SOX9 
(ab5535) 
 
Rabbit, polyclonal 1:1000 Chemicon, 
Southampton, UK 
PHD2 
(ab4561) 
 
Rabbit, polyclonal 1:1000 Abcam, 
Cambridge, UK 
PHD3 
(Clone 188e) 
 
Mouse, 
monoclonal 
1:20 Oxygen Sensing Group, Oxford, 
FIH-1 
(NB100-428SS) 
 
Rabbit, polyclonal 1:1000 Novus Biologicals, 
Littleton, CO. 
HIF-1α 
(Clone 54) 
 
Mouse, 
monoclonal 
1:250 BD Transduction Laboratories, 
Lexington, KY 
HIF-2α 
(Sc-13596) 
 
Mouse, 
monoclonal 
1:250 Santa Cruz Biotechnology, Santa 
Cruz, CA 
Col2α1 
(MAb8887) 
 
Mouse, 
monoclonal 
1:1000 Chemicon, Southampton, UK 
TIMP1 
 
Sheep, polyclonal 1:500 Antibody was provided by Hideaki 
Nagase (Kennedy Institute, 
London, UK) 
 
TIMP3 
(ab39184) 
 
Rabbit, polyclonal 1:1000 Abcam, Cambridge, UK 
Aggrecan 
ARGSV [BC-3] 
(ab3773) 
 
Mouse, 
monoclonal 
1:100 Abcam, Cambridge, UK 
α-Tubulin 
(ab7291) 
 
Mouse, 
monoclonal 
1:5000 Sigma Aldrich company ltd, 
dorset, UK 
Rabbit Ig HRP 
(P0217) 
 
Swine, Ig 1:2000 DAKO Cytomation, A/S, 
Denmark 
Mouse Ig HRP 
(P0218) 
 
Rabbit, Ig 1:2000 DAKO Cytomation, A/S, 
Denmark 
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2.2  Cell and tissue culture 
 
Dulbecco’s modified Eagle’s medium (DMEM) was obtained as a 1x sterile and 
endotoxin-free solution from PAA (Pasching, Austria).  Note: Unless otherwise stated this 
was always supplemented with 10% (v/v) foetal bovine serum (FBS) and 1% 
penicillin/streptomycin (Biosera, East Sussex, UK). 
2.2.1  Isolation of human cartilage explants  
 
Healthy human articular cartilage was obtained from patients after they provided 
informed consent, and following local ethics committee guidelines.  Samples of cartilage 
were obtained 37 patients (29 male, 8 female; age 8-55, mean age 24.8 years) who received 
amputations due to osteosarcomas or soft tissue sarcomas.  Samples were not taken from 
amputations were the sarcoma was present in the joint.  The cartilage was harvested from the 
femoral condyle and tibial plateau (on the day of surgery) using aspetic technique, diced into 
small pieces (3 mm²) and cultured in DMEM. 
 
For most cartilage explant experiments ~60mg cartilage (20 explants) was cultured in 
a 6cm dish in 5ml of DMEM media and incubated in either 20% oxygen tension or 1% 
oxygen tension at 37oC in a Galaxy Triple gas incubator (CRS Biotech, Ayrshire, Scotland, 
UK) supplemented with 5% CO2.   
2.2.2  Isolation of human articular chondrocytes   
 
The cartilage was harvested from the femoral condyle and tibial plateau using aspetic 
technique, diced into small pieces (3 mm²).  This diced cartilage was incubated overnight in 
DMEM containing 0.5mg/ml collagenase type 2 from Clostridium histolyticum 
(Worthington, Freehold, NH) and incubated at 37oC overnight with constant shaking (~50 
rpm). 
 
Following overnight digestion, cells were isolated by passing the digested suspension 
through a cell strainer (BD Falcon, BD Biosciences, Bedford, USA) to remove any larger 
undigested material.  The cell suspension was centrifuged for 5 minutes at 1500 r.p.m and the 
cell pellet washed twice with medium.  Cells were counted using a standard haemocytometer 
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and initially seeded at a density of 8x10³ cells/cm² in DMEM.  Cultures were incubated at 
37oC, 20% oxygen in a Galaxy triple gas incubator (CRS Biotech, Ayrshire, Scotland, UK).  
Chondrocytes were passaged at the time of confluency (typically after 7 to 14 days) and re-
seeded in 15cm dishes (in 25ml of medium) at a density of 5x10³ cells/cm². 
 
2.2.3  Isolation of mouse cartilage explants  
 
Mouse hip explants were prepared from the hips of 6-week-old male C57Bl/6 mice.  
The skin and soft tissue was removed from the hind legs.  The hip joints were dislocated and 
the proximal femoral heads isolated using aspetic technique under an anatomical microscope.  
Femoral heads were cultured using the same protocol as human explants (5 hips per 6cm dish 
in 5ml DMEM). 
2.2.4  Isolation of mouse chondrocytes 
 
Mouse femoral head explants were incubated overnight in DMEM containing 
0.5mg/ml collagenase type 2 from Clostridium histolyticum (Worthington, Freehold, NH) and 
incubated at 37oC overnight with constant shaking (~50 rpm). 
 
Following overnight digestion, cells were isolated by passing the digested suspension 
through a cell strainer (BD Falcon, BD Biosciences, Bedford, USA) to remove any larger 
undigested material.  The cell suspension was centrifuged for 5 minutes at 1500 r.p.m and the 
cell pellet washed twice with medium.  Cells were counted using a standard haemocytometer 
and initially seeded at a density of 8x10³ cells/cm² in DMEM.  Cultures were incubated at 
37oC, 20% oxygen in a Galaxy triple gas incubator (CRS Biotech, Ayrshire, Scotland, UK).  
Chondrocytes were passaged at the time of confluency (typically after 7 to 14 days) and re-
seeded in 15cm dishes (in 25ml of medium) at a density of 5x10³ cells/cm². 
2.2.5  Porcine cartilage explant isolation and culture: 
 
Porcine articular cartilage was taken from the 2nd-3rd metacarpophalangeal (MCP) 
joints of 3 to 6 month old (male and female) pigs obtained from a local slaughterhouse within 
16 hours of slaughter.  Before use porcine trotters were soaked in 1% virkon solution and 
then washed with 70% ethanol (Dupont Relyon Preventation Solutions, Sudbury, UK).   
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After skinning the trotter, the MCP joint was opened in a biological safety cabinet.  
Cartilage explants from 1 joint were dissected using aspetic technique from the articular 
surface directly into DMEM and cut into cubes (3 mm3).  10 explants of cartilage (~30 mg 
wet weight) per well were placed in a 48-well plate with 300µl of DMEM media.  Following 
dissection explants were rested in the incubator in 20% oxygen conditions for 24 hours. 
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2.4  Small interfering RNA (siRNA) transfection: 
 
Primary (P0) or 1st to 3rd passage (P1-P3) human articular chondrocytes (HACs) were 
seeded at 5x103 cells/cm2 in 6cm tissue culture dishes (in 5ml of medium).  Cultures were 
incubated at 37oC, 20% oxygen and 5% CO2 until 50% confluent (typically 1 day).  
Lipofectamine 2000 (Invitrogen, San Diego, CA) was used to transfect cells with small 
interfering RNA (siRNA) at a final concentration of 10 nM in serum-free OptiMEM I. The 
PHD1, PHD2 and PHD3 targeting siRNA (Applied Biosystems, Foster City, CA) which 
were used are listed on Table 2.4. siRNA oligos against HIF-1α and HIF-2α were used as 
previously described (Lafont et al., 2007).  As a non-targeting control, siRNA against 
luciferase (Dharmacon, Lafayette, CO) were transfected in parallel.  Four hours after 
transfection the OptiMEM was removed and replaced with DMEM (containing 10% FCS and 
1% penicillin/streptomycin) pre-equilibrated at the appropriate oxygen tension (20% or 1%).  
Cells were subsequently incubated in each oxygen tension for 3 days. 
 
 Passaged (P1-P3) mouse articular chondrocytes were transfected with siRNA against 
Phd2 using the same protocol.   
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Table.  2.4  Oligonucleotide sequence of siRNA* 
 
Species siRNA Sequence 
 
Homo sapiens siPHD1 #1 5’- CAUGCAGGGCACGAUAUAGUC  -3’ 
Homo sapiens siPHD1 #2 5’- GCAUCACCUGUAUCUAUUA  -3’ 
   
   
Homo sapiens siPHD2 #1 5’- GAAGCUGGGCAGCUACAAAAT -3’ 
Homo sapiens siPHD2 #2 5’- CAAAUGGAGAUGGAAGAUGUG -3’ 
   
   
Homo sapiens siPHD3 #1 5’- GGAGAGGUCUAAGGCAAUGTT -3’ 
Homo sapiens siPHD3 #2 5’- AGAGCUAGGUCUACUGAUATT -3’ 
   
   
Homo sapiens siFIH-1 #1 5’ - GGUUUUAACUGGAACUGGATT - 3’ 
   
   
Homo sapiens siHIF1α 5’- AGCAGUAGGAAUUGGAACATT -3’ 
   
   
Homo sapiens siHIF2α 5’- GCGACAGCUGGAGUAUGAATT -3’ 
   
   
Mus musculus siPhd2 5’- CAAGGUACGCAAUAACUGUTT -3’ 
   
 
*siRNA = small interfering RNA 
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2.5  Reverse Transcriptase-PCR from cartilage 
2.5.1  RNA extraction from cartilage explants  
 
RNA was isolated from ~60mg diced cartilage explants (approximately 20 pieces of 
3mm3 cartilage cubes).  Culture media was removed and human cartilage explants were 
transferred to an eppendorf containing 600µl TRIzol (Invitrogen, Paisly, UK).  Explants were 
shaken vigorously at 4oC for 4 hours, before centrifugation at 13000 rpm for 10 minutes at 
4oC.  The supernatant was taken and RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Crawley, UK) following manufacturer’s guidelines and finally from the QIAamp spin 
columns eluted in 30μl of RNAase free water.   RNA quality and quantity was analysed using 
a digital spectrophotometer (Cecil Instruments, Cambridge, UK), samples with UV 
absorbance A260/A280 ratio < 1.8 were rejected and RNA was stored at -80oC until use. 
2.5.2  RNA isolation from primary and passaged chondrocytes 
 
RNA from primary or passaged chondrocytes was extracted using 600µl RLT buffer 
supplemented with 1:100 (2-β-mercaptoethanol).  RNA was isolated using the RNeasy Mini 
Kit (Qiagen, Crawley, UK) following manufacturer’s guidelines and finally from the 
QIAamp spin columns eluted in 30μl of RNAase free water.   RNA presence, quality and 
quantity was confirmed using a digital spectrophotometer (Cecil Instruments, Cambridge, 
UK), samples with UV absorbance A260/A280 ratio < 1.8 were rejected and RNA was stored at 
-80oC until use. 
2.5.3  Reverse Transcription of RNA 
 
0.5µg of total RNA in a total volume of 10μl RNAase free water was incubated at 
70oC for 10 minutes.  Complementary DNA (cDNA) was generated using a reverse 
transcription kit (Promega, Southampton, England, UK) from 0.5µg of total RNA using 
manufacturers guidlines.  Volumes of reagents used were:  
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RT Mix per sample    µl 
 
10x Reverse Transcriptase buffer  2 
dNTP Mix     2 
MgCl2 25mM     4 
Random Primers    1 
AMV Reverse Transcriptase (25µ/µl) 0.5 
RNase Inhibitor (40u/µl)   0.5 
 
Total master mix volume   10 
 
2.5.4  Realtime polymerase chain reaction (PCR): 
 
Newly synthesised cDNA was diluted in 80µl DNase free water and stored in two 
50µl aliquots to reduce future freeze/thawing cycles.  Four percent (4µl) of this cDNA 
(reverse transcribed from 0.5µg of initial RNA) was then used for real-time PCR assays using 
TaqMan technology and a PCR Corbett Research thermocycler (Corbett Research, Australia).  
The delta delta threshold cycle (ΔΔCt) method of relative quantitation was used to calculate 
relative mRNA levels for each transcript examined. The ribosomal protein gene (RPLP0) was 
used to normalise the data as it was not regulated by hypoxia in our system.  Pre-developed 
primer/probe sets for the following genes were purchased from Applied Biosystems (Foster 
City, CA):  PHD1, PHD2, PHD3, FIH-1, COL2A1, COL9A1, COL11A2, AGGRECAN, 
SOX9, VEGF, PLOD2, LOXL3, HIF-1A, HIF-2A and RPLP0. 
 
RT-PCR primers (MWG Biotech, Ebersberg, Germany) for the following genes were 
also used: ADAMTS4, ADAMTS5, MMP1, MMP3, MMP13, TIMP1, TIMP2, TIMP3.  
Sequence details are listed on table 2.3 
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Table 2.5  RT-PCR Primers 
 
Species Name Sequence 
 
 
Homo sapiens 
 
Sense ADAMTS4 
 
5’- ATGGCTATGGGCACTGTCTCTT -3’ 
Homo sapiens Anti-sense ADAMTS4 5’- GGAAAGTCACAGGCAGATGCA -3’ 
Homo sapiens Sense ADAMTS5 5’- GGCCATGGTAACTGTTTGCT -3’ 
Homo sapiens Anti-sense ADAMTS5 5’- AATGTCAGGTTGCAGTG -3’ 
Homo sapiens Sense MMP1 5’- GGACCAACAATTTCAGAGAGTACAAC  -3’ 
Homo sapiens Anti-sense MMP1 5’- CCAAGAGAATGGCCGAGTTC -3’ 
Homo sapiens Sense MMP3 Primers provided by Yasu Sawaji 
Homo sapiens Anti-sense MMP3 (Kennedy Institute, London, UK) 
Homo sapiens Sense MMP13 5’- TTACCAGACTTCACGATGGCATT  -3’ 
Homo sapiens Anti-sense MMP13 5’- TCGCCATGCTCCTTAATTCC -3’ 
Homo sapiens Sense TIMP1 5’- ACCGCAGCGAGGAGTTTCT -3’ 
Homo sapiens Anti-sense TIMP1 5’- CTGCAGGTAGTGATGTGCAAGAG -3’ 
Homo sapiens Sense TIMP2 5’- ATGTAGTGATCAGGGCCAAAGC -3’ 
Homo sapiens Anti-sense TIMP2 5’- AGGGTTGCCATAAATGTCGTTT -3’ 
Homo sapiens Sense TIMP3 5’- CCTGCTACTACCTGCCTTGC -3’ 
Homo sapiens Anti-sense TIMP3 5’- GGCGTAGTGTTTGGACTGGT -3’ 
Homo sapiens Sense RPLP0 5’- CCATTGAAATCCTGAGTGATGTG -3’ 
Homo sapiens Anti-sense RPLP0 5’- CTTCGCTGGCTCCCACTTT -3’ 
   
   
Sus scrofa Sense ADAMTS5 5’- TGATGGTCATGGTAACTGTTTGCT -3’ 
Sus scrofa Anti-sense ADAMTS5 5’- GTAGGTCTGTCCCGGGAGTTC -3’ 
Sus scrofa Sense MMP13 5’- CATGAGTTTGGCCATTCCTT -3’ 
Sus scrofa Anti-sense MMP13 5’- GTTGGGGTCTTCATCTCCTG -3’ 
Sus scrofa Sense TIMP3 5’- CCTGCTACTACCTGCCTTGC  -3’ 
Sus scrofa Anti-sense TIMP3 5’- GGCGTAGTGTTTGGACTGGT  -3’ 
Sus scrofa Sense SOX9 5’- AGTACCCGCACCTGCACAAC  -3’ 
Sus scrofa Anti-sense SOX9 5’- TTCAGCAGTCTCCAGAGTTTGC  -3’ 
Sus scrofa Sense COL2A1 5’- GTCCTCTGCGACGACATAATCTG -3’ 
Sus scrofa Anti-sense COL2A1 5’- TCTGTCCCTTTGGTCCCAGTT -3’ 
Sus scrofa Sense AGGRECAN 5’- AGGCAGAGGTGGCTTCAGTC -3’ 
Sus scrofa Anti-sense AGGRECAN 5’- CCAGAATCTAGCAGGGAGTCATC -3’ 
Sus scrofa Sense RPLP0 5’- CCTCCTTCTTCCAGGCTTTAGG -3’ 
Sus scrofa Anti-sense RPLP0 5’- CACATCACTCAGGATTTCAATGG -3’ 
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2.6  Preparation of cell and tissue lysates 
2.6.1  Chondrocytes  
 
6cm wells containing primary (P0) and passaged HACs were washed twice with 
1xPBS and lysed with 150µl of either SDS/urea or RIPA lysis buffer supplemented with the 
P8340 protease inhibitor cocktail (1:100) (Sigma Aldrich company ltd, Dorset, UK).  This 
cocktail is a mixture of protease inhibitors (AEBSF, Aprotinin, Bestatin hydrochloride, E64, 
Leupeptin hemisulfate salt, Pepstatin A) with a broad specificity for serine, aminopeptidases, 
cysteine and aspartic proteases. 
 
 SDS/urea lysis buffer was used to lyse cultures for subsequent detection of HIF-α 
isoforms.  RIPA lysis buffer was used all other cellular proteins were being analysed.   
 
Wells were scraped with a cell scraper and cell lysates were transferred to an 
eppendorf, sonicated using a probe (Ultrasonic, sonicator frequency 4.5) for 5 seconds and 
centrifuged at 13,000 RPM for 20 minutes at 4oC in order to remove any cell debris.  150 µl 
supernatant was removed and assayed for protein concentration using the Bradford assay (see 
section 2.6.4). 
2.6.2  Secreted proteins 
 
HACs were cultured in a 5x103 cells/cm2 in 6cm tissue culture dishes.  HACs were 
transfected using protocol described above (2.4) and cultured for 24 hours in DMEM 
(containing 10% FCS and antibiotics) at the appropriate oxygen tension (20% or 1%).   After 
24 hours medium was removed and HACs were washed twice in serum free media.  HACs 
were then cultured in 2200µl serum free DMEM supplemented with 1% 
penicillin/streptomycin and 1% Insulin, transferrin, and selenium (ITS)  (Sigma Aldrich 
company ltd, dorset, UK).  HACs were serum starved for 2 days.  1ml of conditioned medium 
was treated with 100µl of deoxyclolic acid (0.15%), left at room temperature for 10 minutes 
and then precipitated by addition of 110µl trichloracetic acid (72%).  Samples were 
centrifuged at 12000RPM for 10 minutes.  The supernatant was aspirated and the protein 
pellet washed with 200µl ice cold acetone.  Samples were air dried and the pellet resuspended 
in 4x SDS sample buffer.  
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For the detection of secreted TIMP1 and TIMP3 HACs were cultured using the 
protocol above, except for the detection of TIMP3 cell culture medium was supplemented 
with 200ug/ml Heparin.  After 2 days of serum starvation 600µl of media was precipitated 
with 1ml of ice cold acetone, vortexed and left at -20oC for 20 minutes.  Samples were 
centrifuged at 13,000 RPM for 10 minutes at 4oC, air dried and resuspended in 4xSDS 
sample buffer. 
2.6.3  Cartilage explants 
 
 10 Human articular cartilage explants or 5 mouse hip explants were washed twice 
with 1xPBS and lysed in 150µl of RIPA lysis buffer supplemented with the P8340 protease 
inhibitor cocktail (1:100) (Sigma Aldrich company ltd, dorset, UK).  Samples were shaken 
vigorously at 4oC for 4 hours.  Finally, samples were centrifuged at 13000RPM for 20 
minutes and the supernatant was aspirated.   
2.6.4  Determination of protein concentration by Bradford Assay 
 
The protein concentration of each extract was determined using the Bradford assay.  
Cell lysates were diluted 1:100 in Bradford reagent and the A595nm was measured using a 
digital spectrophotometer (Cecil Instruments, Cambridge, UK).  A595nm was measured three 
times for each extract, an average value taken of the three readings and the protein 
concentration (µg/ml) was calculated using the digital spectrophotometer (Cecil Instruments, 
Cambridge, UK).   
 
The presence of the highly abundant and charged cartilage matrix components 
precluded use of this method to accurately determine protein concentrations from cartilage 
explant lysates.  Therefore an equal volume of lysis buffer (from an equal number of 
similarly sized explants) was loaded into each lane when performing SDS-PAGE and the 
protein loading confirmed by analysing the loading control (α-tubulin) levels. 
 
It was not possible to accurately determine cellular protein concentrations of passaged 
HACs lysed in SDS/urea lysis buffer.  Therefore in these experiments parallel dishes were 
lysed using RIPA in order to estimate concentration. 
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For the normalisation of secreted proteins the volume of media used was adjusted 
after standardisation according to total protein measurement using the Bradford assay from 
the cell layer.   
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2.7  SDS-PAGE: 
 
Resolving buffer  380mM Tris/HCl pH 8.8 
    6%, 8%, 10%, 12% or 15% (w/v) acrylamide 
    0.1% (w/v) SDS 
    0.07% (w/v) ammonium persulphate 
    0.07% (v/v) TEMED 
 
Stacking buffer  125mM Tris/HCl pH6.8 
    3.9% (w/v) acrylamide 
    0.1% SDS 
    0.1% (w/v) ammonium persulphate 
    0.1% (v/v) TEMED 
 
The electrophoretic separation of proteins was carried out using a Mighty Small II 
vertical electrophoresis system (Hoefer scientific instruments) and separated according to 
molecular weight using standard protocol (Laemmli, 1970; Schagger and von Jagow, 1987). 
 
Resolving and stacking gels were prepared by mixing 30% acrylamid:bis-acrylamide 
(37.5:1) with the associated resolving (350mM Tris-HCL pH 8.8), and 0.1% SDS) and 
stacking (125mM Tris-HCL (pH 6.8), and 0.1% SDS) gel buffers.  The acrylamide 
concentration ranged from 6% - 15% for resolving gels and was fixed at 3.9% for stacking 
gels.  Gels were polymerised by adding ammonium persulphate (APS) to 0.07% (w/v) and 
N,N,N’,N’-tetramethylethylenediamine (TEMED) to 0.07% (v/v). 
 
Protein samples were boiled for 5 minutes in 4x SDS-Sample buffer, loaded onto gels 
and electrophoresed in running buffer (National diagnostics) at a constant voltage (100V) for 
1 ½ hours.  SeeBlue molecular weight markers (Invitrogen) were loaded onto each gel in 
order to monitor electrophoresis and estimate the size of proteins.   
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2.8  Western blotting and immunodetection 
 
 Western blot was used to detect specific proteins in cellular lysates or secreted 
proteins which had been resolved by SDS-PAGE electrophoresis.  PVDF-transfer membranes 
(Millipore, Bedford, USA) were pre-hydrated using 100% methanol for 10 seconds.  The 
PVDF membrane and SDS-PAGE gel were then equilibrated in transfer buffer, placed on top 
of one another and sandwiched between four sheets of 3mm chromatography paper and two 
sponges in a gel holder cassette.  The cassette was then placed in a Trans-blot chamber 
(Biorad, Hercules, CA) filled with transfer buffer.  The transfer of proteins from SDS-PAGE 
gel to PVDF membrane was carried out a constant voltage (100V) for 1 ¼ hours.  The 
transfer buffer was kept at 4oC by a water-circulating cooling pump.   
 
Following transfer PVDF membranes were pre-hydrated using 100% methanol for 10 
seconds and placed protein side up on a clean non-porous surface for 10 minutes.  The 
membranes were gentle agitated in blocking solution for 1 hour (5% Tesco low fat dried milk 
powder in 1xPBST) and then incubated with the primary antibody overnight at 4oC.  A list of 
primary antibodies used for immunoblotting can be found in table 2.3. 
 
Following overnight incubation membranes were washed 3 times, for 10 minutes each 
wash with PBST.  Appropriate anti-mouse or anti-rabbit horseradish peroxidise-conjugated 
secondary antibodies were diluted in membrane blocking solution and applied to the 
membrane for 1 hour at room temperature with gentle agitation.  Following incubation 
membranes were washed four times, 10 minutes each wash, with PBST.      
 
Excess PBST was drained off the membrane and the membrane placed protein side up 
on a clean non-porous surface (eg:  a gel staining box).  Equal volumes of ECL Solution 1 
and ECL Solution 2 (GE healthcare) were mixed and pipetted onto the membrane.  After one 
minute the excess detection reagents were drained off and the PVDF placed protein side 
down on a saran wrap.  The saran wrapped membranes were placed in an X-ray cassette and 
the HRP-bound proteins visualized using blue-sensitive film (Fujifilm Super RX, Fujifilm, 
Bedford, UK).   
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In order to detect PHD3 and HIF-2α 40µg of protein was used.  Otherwise 20µg of 
protein was resolved by SDS-PAGE electrophoresis. 
 
 To re-probe membranes with further antibodies, membranes were incubated with 1x 
stripping buffer (Re-Blot Plus Strong Solution, Chemicon, Temecula, USA) for 20 minutes at 
room temperature with gentle agitation.  Membranes were washed twice with PBST for 10 
minutes, treated with blocking solution for 30 minutes and subsequently incubated with 
another antibody. 
 
2.9  Articular cartilage explant culture and ARGSV-Neoepitope 
detection 
 
Human or porcine articular cartilage was cut into cubes (3 mm3) and 10 explants (~30 
mg wet weight) per well were placed in a 48-well plate with 300µl of media.  Explants were 
rested in 20% oxygen for 24 hours, washed with serum-free DMEM and preincubated for 48 
hours at either 20% oxygen tension or 1% oxygen tension.  Explants were stimulated with IL-
1α or vehicle (serum free media) and then further cultured for 24 hours at either 20% oxygen 
tension or 1% oxygen tensions. 
 
 300µl of media was collected, deglycosylated overnight at 37oC with 1µl 
chondroitinase ABC and 1µl keratinase (Seikagaku Kogyo, Tokyo, Japan) in 98µl 
deglycosylation buffer.  Acetone precipitation was carried out as previously described (2.6.3).  
Samples were loaded onto a 6% PAGE gel and blotted with anti-ARGSV neoepitope 
antibody (ab3773, 1:100). 
 
2.10  Statistical analysis 
 
Data were compared using either a paired t-test or one-way analysis of variance with 
Bonferroni post-test.  The software GraphPad Prism 4 (GraphPad Software, San Diego, CA) 
was used to perform statistical analysis.  Results are expressed as a mean +/- the SEM from 
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independent experiments (i.e., tissue or cells obtained from individual donors).  A P value 
less than 0.05 was considered significant.                                            .
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3.1  Introduction 
 
Articular cartilage consists of a single cell type, the chondrocyte, which is solely 
responsible for the synthesis and maintenance of the extracellular matrix (Poole et al., 2002). 
The rigid nature of type II collagen fibrils present in the matrix confers tensile strength to the 
tissue and the swelling pressure caused by water-saturated aggrecan molecules creates a 
compressive gel-like stiffness allowing the tissue to resist deformation and giving cartilage its 
ability to absorb shocks (Buckwalter and Mankin, 1998a, b; Poole et al., 2002).  Due to its 
shock-absorbing and articulating functions, articular cartilage cannot afford a blood or nerve 
supply. The tissue is therefore dependent on diffusion of oxygen from the synovial fluid on 
one side and the vascularised underlying bone on the other.  As a result, articular cartilage (at 
least in larger animals and man) is maintained in a low oxygen environment (1-6% oxygen 
tension) throughout life (Brighton and Heppenstall, 1971; Milner et al., 2006; Silver, 1975). 
There is now significant evidence that hypoxia is a critical parameter in promoting the 
chondrocyte phenotype. It has been shown that hypoxia upregulates key cartilage 
transcription factor SOX9 and increases expression of the main extracellular matrix genes in 
bovine and human chondrocytes (Domm et al., 2002; Katopodi et al., 2009; Lafont et al., 
2007; Murphy and Polak, 2004; Murphy and Sambanis, 2001).  
 
The response of cells to hypoxia is mediated by HIFs, hetero-dimeric transcription 
factors consisting of an α and β subunit (Semenza, 2000).  Both subunits of HIF are 
constitutively expressed at the mRNA level, however, the α-subunit is regulated post-
translationally by oxygen levels.  In well-oxygenated cells, the α-subunit is hydroxylated on 
specific, conserved proline residues by HIF-targeting prolyl hydroxylase domain enzymes 
(PHD1, PHD2 and PHD3) (Ivan et al., 2001; Jaakkola et al., 2001; Yu et al., 2001).  The 
PHD enzymes are a subfamily of dioxygenases that use molecular oxygen and 2-oxoglutarate 
(2-OG) as co-substrates to add hydroxyl groups to specific proline residues on the α subunit 
(Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001).  The hydroxylated 
proline residues on HIF-α are recognised by von Hippel–Lindau (VHL) protein of the E3 
ubiquitin ligase complex, ubiquitinated and subsequently degraded by the 26S proteasome 
(Cockman et al., 2000). As intracellular oxygen concentrations are reduced, the activity of the 
proyl hydroxylase enzymes is suppressed, HIF-α isoforms are not hydroxylated and therefore 
escape proteosomal degradation and so can heterodimerize with HIF-1β, translocate to the 
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nucleus and bind to cis-regulatory hypoxia response elements (HRE’s) located in target 
genes. Previous work in our laboratory has demonstrated that hypoxic induction of the key 
cartilage matrix genes in human chondrocytes is mediated specifically by the HIF-2α isoform 
which upregulates SOX9, leading to enhanced expression of the matrix genes (Lafont et al., 
2007).   
 
Suppression of PHD enzymes leads to stabilisation of HIFs and offers a potential 
treatment option for many ischaemic disorders, such as peripheral artery occlusive disease, 
myocardial infarction and stroke (Fraisl et al., 2009). We hypothesise that antagonising 
specific PHDs could be a novel way of promoting cartilage matrix deposition from 
chondrocytes by enhancing HIF-2α levels, upregulating key transcription factor SOX9 and 
increasing extracellular matrix synthesis. 
 
In this chapter we report that PHD2 is the dominant isoenzyme regulating HIF-2α 
stability in human chondrocytes.  Moreover, specific inhibition of PHD2 using RNAi-
mediated depletion caused an upregulation of SOX9 and enhanced extracellular matrix 
protein production.  Most importantly, depletion of PHD2 resulted in greater HIF-2α levels, 
and subsequently enhanced SOX9-induced cartilage matrix production, compared to the 
levels normally found in hypoxia (1% oxygen).  This suggests the exciting possibility that 
PHD2 inhibition offers a novel means to enahanced cartilage matrix synthesis above normal 
levels in the joint.  In addition PHD2 inhibition upregulated key pro-Lysyl hydroxylases 
involved in collagen formation implying that PHD2 inhibition offers a novel means to 
enhance cartilage repair. The need for HIF-specific hydroxylase inhibitors was highlighted as 
treatment with the 2-oxoglutarate analogue dimethyloxalylglycine (which also inhibits the 
collagen prolyl hydroxylases) resulted in reduced secretion of type II collagen, a critical 
matrix component. 
 
3.2  Up-regulation of SOX9 and key extracellular proteins in human 
cartilage explants under hypoxic conditions  
 
Human cartilage explants from a range of patients (3 male and 2 female donors; age 
14-38 years; mean age 25 years) were incubated for 3 days under normoxic (20% oxygen) or 
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hypoxic (1% oxygen) conditions.  Messenger RNA (mRNA) levels of cartilage-specific 
transcription factor SOX9 as well as key cartilage matrix proteins were analysed after 
normalising the data using the housekeeping gene RPLP0.  As we have previously 
demonstrated ribosomal protein (RPLP0) is not regulated by hypoxia (Lafont et al., 2008; 
Lafont et al., 2007).  Consistent with our previous work in passaged human articular 
chondrocytes, hypoxia significantly upregulates cartilage specific transcription factor SOX9 
as well as of key cartilage extracellular matrix genes COL2A1, COL9A1, COL11α2, 
AGGRECAN at the mRNA level (Fig. 3.1) (Lafont et al., 2007).  Exposure to 1% oxygen 
tension increases SOX9 expression levels 5.8 fold, COL2A1 expression 29.9 fold, COL9A1 
18.7 fold, COL11α2 14.7 fold and AGGRECAN 16.9 fold (compared to control levels in 
normoxia). 
 
In order to confirm the hypoxic upregulation of SOX9 in human cartilage explants at 
the protein level cartilage explants from a range of patients (3 male and 1 female donors; age 
10-54 years [mean age 35.5 years]) were cultured at various oxygen tensions (20%, 3% and 
1%) or treated with hypoxia mimetics:  the 2-oxoglutarate analogue DMOG or an iron 
chelating agent, DFO for 3 days.  DFO and DMOG inhibit all members of the iron, 2-
oxoglutarate dependent hydroxylase family, which include the HIF-targeting hydroxylases.  
SOX9 protein levels appear to be upregulated in human cartilage explants in response to 
hypoxia and these levels of upregulation correspond with decreasing levels of molecular 
oxygen, i.e., 1%>3%>20% (Fig. 3.2 A).  SOX9 was also appeared to be upregulated at the 
protein level in response to proyl-hydroxylase domain enzyme inhibitors DMOG and DFO 
(Fig. 3.2 B, C, D).  Lack of protein quantification in these (and other western blots) mean that 
we cannot confirm the hypoxic upregulation of SOX9 at the protein level, we will discuss this 
Chapter 6.  We attempted to investigate the levels of HIF-α isoform stabilisation in human 
cartilage however we encountered difficulty lysing cartilage using urea lysis buffer and we 
were not successful.   
 
In summary, proyl-hydroxylase domain protein inhibition using either hypoxia, 
DMOG or DFO was found to induce SOX9 at the protein level in human cartilage explants 
and this is consistent with the hypoxic induction of SOX9 reported at the mRNA level (Figure 
3.1). 
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FIGURE 3.1.  Hypoxia upregulates cartilage specific transcription factor SOX9 and 
main cartilage matrix proteins in human cartilage explants.  Data are based on human 
cartilage explants.  TaqMan PCR data showing relative levels of mRNA for SOX9, COL2A1, 
COL9A1, COL11A2 and AGGRECAN (A – E, respectively) after culture for 3 days in 20% 
and 1% oxygen.  All values were normalised using the RPLP0 housekeeping gene and 
represent mean and SEM results of 4-5 independent experiments (i.e., cells from 4-5 different 
donors).  *P < 0.05; **P < 0.01 (versus 20% oxygen). 
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FIGURE 3.2.  Hypoxia appears to increase SOX9 protein levels in human cartilage 
explants.  Data are based on human cartilage explants from 4 different donors (A-D). The 
western blots show increasing SOX9 levels at decreasing oxygen tensions (20%, 3% and 1%) 
or after treatment with hypoxia mimics:  2-oxoglutarate analogue DMOG or iron chelating 
DFO for 3 days. 
 
Chapter 3            Promotion of the Articular Chondrocyte Phenotype by Inhibition of HIF-specific Hydroxylases 
 
 
 
91 
 
3.3  HIF-targeting hydroxylases - PHD2 is the Most Abundant, and 
PHD2 and -3 are Hypoxia Inducible in HACs  
 
 Our initial experiments in human articular chondrocytes were to assess relative 
abundance of the proyl-hydroxylase domain (PHD) enzymes in human articular chondrocytes 
(HACS) and determine the presence/absence of a hypoxic induction as their relative levels 
might suggest which PHD enzyme was dominant (although different specificities may also 
play a part). 
 
HACs from 7 patients (5 male and 2 female donors; age 11-44 years [mean age 16 
years]) were cultured for 3 days under normoxic (20% oxygen) or hypoxic conditions.  The 
mRNA levels of PHD1, PHD2 and PHD3 were analysed after normalising the data using the 
housekeeping gene RPLP0. The relative abundance of each gene was calculated after setting 
the expression of PHD3 at 20% oxygen to a value of 1.  This method of calculating the 
relative abundance of the three PHD isoenzymes at the mRNA level makes the assumption 
that the efficiency of amplification between the different PCR primers is equal (in practice, 
all amplification efficiencies were similar, being over 90%).  
 
PHD2 was the most abundant transcript of the three isoenzymes in both 20% and 1% 
oxygen.  Interestingly, although PHD3 had the most pronounced hypoxic induction (average 
19.2 fold induction) it was the least abundant PHD enzyme at the mRNA level in both 20% 
and 1% oxygen (Fig. 3.3 A). This is consistent with data at the protein level.  PHD2 and 
PHD3 proteins were found to be induced by hypoxia (Fig. 3.3 B & C).  In addition 20µg of 
PHD2 was visualised using enhanced chemiluminescence after 3 minutes exposure to X-ray 
film whereas 40µg PHD3 required 45 minutes exposure to detect any protein. 
 
Our previous microarray study found that PHD2 was the most abundant enzyme in 
both normoxia and hypoxia (Murphy et al., 2009).  PHD3 mRNA levels were the lowest in 
normoxia but under hypoxia PHD3 mRNA levels were greater than PHD1 (20% - 
PHD2>PHD1>PHD3.  1% - PHD2>PHD3>PHD1).  This slight discrepancy between the 
work shown in Figure 3.3 and our previous microarray study could be due to the use of 
passaged HACs in this study while primary HACs were used by Murphy and colleagues
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FIGURE 3.3. PHD2 is the most abundant HIF-targeting hydroxylase in HACs, while 
PHD2 and PHD3 are both hypoxia inducible. Data are from passaged (P1-P3) HACs after 
culture for 3 days at 20% oxygen, 1% oxygen or treated with 10mM of the hypoxia mimetic 
desferrioxamine (DFO). A, TaqMan-based data showing the relative mRNA abundance in 
cultured HACs of the PHD enzymes at the mRNA level in normoxic or hypoxic conditions 
(PHD3 mRNA levels in 20% oxygen were assigned a value of 1). Values are the mean and 
S.E.M. of 7 independent experiments (i.e., HACs from 7 different donors);  ns = not 
significant;  *P < 0.05; ***P < 0.001.  B, Western blots showing increased PHD2 levels in 
hypoxia (1% oxygen), and after treatment with 10mM DFO. C, PHD3 levels, like PHD2 were 
increased by hypoxia and DFO, but were undetectable in 20% oxygen.    
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Thus PHD2 and PHD3 are induced by hypoxia.  PHD2 is the most abundant PHD 
enzyme in human articular chondrocytes.  PHD3, although expressed at relatively low levels, 
is the most highly induced by hypoxia. 
 
3.4  Knockdown of PHD1/2/3 in passaged human articular 
chondrocytes using siRNA 
 
In order to determine the role of the different PHD enzymes in the regulation of HIF-
1α / HIF-2α in HACs we generated a range of siRNA oligonucleotides against each PHD 
isoform.  PHD1, PHD2 and PHD3 were specifically depleted in HACs using small interfering 
RNA (siRNA) and lysed 3 days after transfection (Fig. 3.4 A, B, C).  10nM of a single siRNA 
oligonucleotide was used in each transfection and two different oligonucleotides were used 
for each gene (for sequences see Table 2.4). SiRNA against luciferase (siLuc) was used as a 
non-targeting control.  Messenger RNA analysis by real-time PCR revealed that PHD1 was 
depleted 72% (siPHD1 #1) and 95% (siPHD1 #2), on average, compared to siLuc levels.  
PHD2 was depleted 82% (siPHD #1) and 86% (siPHD2 #2), on average, while PHD3 was 
depleted by 87% (siPHD3 #1) and 84% (siPHD3 #2).   
 
Western blotting confirmed the depletion of PHD2 (Fig. 3.4 D) and PHD3 (Fig. 3.4 E) 
at the protein level.  PHD1 was not assessed as no specific antibody was available.  
Knockdown of PHD3 was performed in the presence of the iron chelator DFO as PHD3 
levels were more easily detectable in DFO.  The oligonucleotides which produced the 
greatest knockdown at the mRNA level were used in subsequent experiments.   
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FIGURE 3.4. RNAi-mediated depletion of PHD1/2/3 in HACs.  TaqMan real-time PCR data 
showing mRNA depletion of PHD1 (A), PHD2 (B) and PHD3 (C) in passaged HACs (P2-P3) 
after 3 days in culture. Cells were transfected with 10nM siRNA directed against each PHD 
and an siRNA targeting luciferase (siLuc) was used as a control.  Values represent the mean 
and S.E.M. from 3-5 independent experiments (i.e., HACs from 3-5 different donors).  Note: 
ns - not significant.  *P < 0.05; ***P < 0.001 versus 20% oxygen siLuc.  D, Western blot 
showing RNAi-mediated depletion of PHD2 protein in HACs (in 20% oxygen). E, RNAi-
mediated PHD3 protein depletion is shown in the presence of 10mM DFO, as PHD3 levels in 
normoxia were undetectable. In all cases, HACs were cultured for 3 days before termination of 
experiment. 
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3.5  Depletion of PHD2 in Normoxia Stabilises HIF-α Isoforms in HACs, 
and Upregulates SOX9 
 
In order to assess the functional effect of the knockdowns on HIF-α isoform 
stabilisation, HACs were transfected with a single oligonucleotide siRNA against PHD1, 
PHD2, PHD3 or luciferase (as a non-targeting control).  Following transfection HACs were 
cultured under normoxic conditions for 3 days before lysis.   
 
Under normoxic conditions HIF-1α / HIF-2α are hydroxylated by the PHD enzymes 
and are rapidly degraded.  The knockdown of PHD2 in HACs significantly stabilised both 
HIF-1α and HIF-2α in 20% oxygen (Fig. 3.5 A).  The knockdown of PHD1 also contributed 
to the stabilisation of both HIF-1α and HIF-2α in normoxia, but to a much lesser extent than 
PHD2 depletion.  Despite its pronounced hypoxic induction, depletion of lowly expressed 
PHD3 had no detectable effect on levels of either HIF-α isoform in normoxia. 
 
Since depletion of PHD2 had the dominant effect with regard to HIF-α stabilisation in 
normoxia, we performed reoxygenation experiments to further assess its role in HIF-α 
regulation. In these reoxygenation experiments, HACs were transfected with siRNA against 
PHD2 and cultured for 3 days in hypoxia before being suddenly switched to 20% oxygen.  
Cells were lysed 0-, 5-, 10-, 20-, 40- and 60- minutes after exposure to normoxia (20% 
oxygen). In parallel cultures, siRNA against luciferase (siLuc) was used as a control in order 
to provide the optimal control for accurate comparison with PHD2 depletion. We found that, 
in agreement to previous reports (Appelhoff et al., 2004), upon exposure to normoxia HIF-α 
subunits have a very short half-life (approximately 5 minutes).  If the knockdown of 
individual PHD enzymes significantly reduces the rate of HIF-α isoform decline upon 
reoxygenation this would provide further evidence of the PHD enzyme’s contribution to HIF-
α protein regulation.  Here we demonstrate that the knockdown of PHD2 greatly slows the 
degradation of HIF-1α and HIF-2α (Fig. 3.5 B, C) thus confirming its key role in regulation 
of the protein stability of both HIF-α isoforms.   
 
In summary, PHD2 (the most abundant PHD enzyme) was found to be the dominant 
proyl-hydroxylase domain (PHD) enzyme responsible for the regulation of both HIF-1α and 
HIF-2α.  To further investigate how specific PHD enzyme depletion may affect the  
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FIGURE 3.5. PHD2 depletion in normoxia stabilises HIFs and upregulates SOX9 in 
HACs.  A, Unlike PHD1 or PHD3, depletion of PHD2 resulted in significant stabilisation of 
both HIF-1α and HIF-2α protein in HACs following 3 days culture in 20% oxygen. Control 
(siLuc) shows that neither HIF-α isoform is normally detectable in the presence of 20% 
oxygen.  Depletion of PHD2 significantly slows the rate of HIF-1α (B) and HIF-2α (C) 
degradation upon reoxygenation, i.e., switching the cells from 1% to 20% oxygen. Following 
siRNA transfection HACs were incubated for 3 days in 1% oxygen  before being exposed to 
20% oxygen for the indicated time (in minutes) prior to lysing.  Control siRNA (siLuc) 
transfections were carried out in parallel as a control. Note: for simplicity α-tubulin loading 
controls from a representative experiment are shown in each case.  D, Depletion of PHD2, 
but not PHD1 or PHD3, resulted in increased SOX9 protein levels in HACs after 3 days in 
culture in 20% oxygen. 
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chondrocyte phenotype PHD1, PHD2 and PHD3 were depleted in HACs under normoxic 
conditions and levels of key cartilage specific transcription factor SOX9 assessed at the 
protein level.   Our previous work has demonstrated that hypoxic induction of SOX9 is HIF-
2α dependent (Lafont et al., 2007).  Only depletion of PHD2 resulted in enhanced SOX9 
protein levels compared to luciferase controls (Fig. 3.5 D) in agreement with our previous 
work that SOX9 is upregulated in response to HIF-α isoform stabilisation. 
 
3.6  PHD2 Depletion Enhances Expression of Cartilage Matrix by HACs 
in Both Normoxia and Hypoxia 
 
In order to examine the effect of PHD2 knockdown on the main markers of the 
chondrocyte phenotype, primary and passaged HACs were cultured for 3 days at 20% and 
1% oxygen and transfected with either siRNA against PHD2 or luciferase as a non-targeting 
control.  The knockdown of PHD2 was confirmed at the mRNA level (Fig. 3.8 A) and protein 
level (Fig. 3.6 A).  The effect of PHD2 depletion on HIF-α isoforms was investigated (Fig. 
3.6 B and C).  Markers of the chondrocyte phenotype (SOX9) and essential matrix 
components of the cartilage extracellular matrix (COL2A1, COL9A1, AGGRECAN) were 
examined at the mRNA level (Fig 3.8 B – F) and protein level (Fig 3.7 D and E).  Finally two 
enzymes involved in the first steps of collagen cross linking: Lysyl oxidase homolog 3 
(LOXL3) and procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) were examined 
(Fig 3.9 A and B) as well as the message levels of mRNA levels of HIF1α and HIF2α (Fig. 
3.10 A and B)  
 
There was no detectable difference in HIF-1α levels between PHD2 depleted cultures 
in 20% and 1% oxygen, both being greater than that achieved by hypoxia alone (siLuc) (Fig. 
3.6 B). In contrast the knockdown of PHD2 at 20% oxygen stabilises HIF-2α to levels 
approximately equal to that in hypoxia alone (siLuc).  However, depletion of PHD2 in 1% 
oxygen further enhanced HIF-2α levels (Fig. 3.6 C) suggesting that PHD2 is not the only 
factor regulating HIF-2α levels in hypoxia. 
 
Levels of SOX9 and key cartilage matrix protein COL2A1 were analysed in PHD2-
depleted HAC cultures from a range of patients.  Both SOX9 and secreted type II collagen 
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levels were upregulated by PHD2 depletion in normoxia to levels roughly equal with (or 
slightly greater than) hypoxia.  PHD2 depletion under hypoxic conditions, however, 
increased protein levels above hypoxia alone.  The enhancement of SOX9 and COL2A1 
expression in response to PHD2 depletion correlates with HIF-2α stabilisation, i.e., with 
greatest levels achieved by PHD2 depletion in 1% oxygen (Fig. 3.7A, B).  SOX9 mRNA was 
also significantly upregulated in response to PHD2 depletion in a manner similar to the 
response at the protein level (Fig. 3.8 A). In fact, all the key cartilage extracellular matrix 
genes were upregulated in response to PHD2 inhibition.  The knockdown of PHD2 under 1% 
oxygen tension (approximate physiological oxygen tension at the core of cartilage) 
significantly increases SOX9 expression 6 fold, COL2A1 expression 38.5 fold, COL9A1 34.5 
fold, COL11α2 58.9 fold and AGGRECAN 6.5 fold (compared to control levels in normoxia) 
(Fig. 3.8 C to F respectively).  This is important as it demonstrates that PHD2 depletion can 
increase the matrix production levels over than occurring in physiological conditions (1% 
oxygen). 
   
Our group has previously demonstrated that two enzymes involved in the first steps of 
collagen cross linking Lysyl oxidase homolog 3 (LOXL3) and procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 2 (PLOD2) are upregulated by hypoxia (Lafont et al., 2008). 
Here we confirm this hypoxic upregulation in HACs (Fig 3.9 A and B).  Depletion of PHD2 
in 1% oxygen tension upregulates PLOD2 mRNA expression 16.1 fold and LOXL3 mRNA 
expression 5.35 fold (compared to control levels in normoxia) exceeding levels in hypoxic 
alone.  It is a further benefit that PHD2 inhibition not only upregulates chondrocyte gene 
expression of extracellular matrix collagens but also key enzymes necessary post-
translationally for collagen formation and stabilisation.  As expected, expression of a non-
hypoxia regulated genes proyl-hydroxylases 1 (PHD1) and Factor Inhibiting HIF (FIH-1) 
were unaltered in response to PHD2 depletion (FIG. 3.9 C, D).   
 
Interestingly hypoxia significantly downregulated the mRNA levels of HIF2α and in 
particular, HIF1α at the mRNA level.  Depletion of PHD2 significantly decreases HIF1α 
mRNA levels in normoxia (Fig. 3.10 A).  Suppression of PHD2 had no effect on HIF2α 
mRNA expression in hypoxia or normoxia (Fig. 3.10 B).  This data is consistent with work 
previously described by Kim and colleagues and will be discussed further in the subsequent 
discussion section (Chapter 4).  
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FIGURE 3.6. PHD2 depletion in HACs stabilises HIF-1α and HIF-2α in normoxic conditions 
and further enhances HIF-2α stabilisation in hypoxia. A, PHD2 was depleted in HACs in both 
20% and 1% oxygen cultures. B, HIF-1α levels were enhanced in PHD2 depleted HACs; while no 
difference was detectable between PHD2 depleted cultures in 1% or 20% oxygen. C, HIF-2α levels 
were enhanced following PHD2 depletion in both normoxia and in hypoxia. Note: All data in the 
figure were obtained from primary and passaged HACs after 3 days in culture. Cells were 
transfected with 10nM siRNA against PHD2 (siPHD2), or, as a control against luciferase (siLuc). 
For simplicity only α-tubulin loading controls from representative experiments are shown. 
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FIGURE 3.7. PHD2 depletion in HACs upregulates SOX9 and secreted type-II collagen 
protein levels both in normoxia and in hypoxia.  PHD2 was depleted in HACs in both 20% and 
1% oxygen cultures.  A, SOX9 protein levels were enhanced following PHD2 depletion in both 
normoxia and in hypoxia with greatest levels occurring in hypoxia. E, Secreted type-II collagen was 
detected following TCA precipitation of culture medium. Data were normalised based on Bradford 
measurements of protein content in the cell layers. Secreted type-II collagen protein levels followed 
a similar pattern to SOX9, being highest in PHD2 depleted HACs cultured in hypoxia. Note: All 
data in the figure were obtained from primary and passaged HACs after 3 days in culture. Cells 
were transfected with 10nM siRNA against PHD2 (siPHD2), or, as a control against luciferase 
(siLuc). For simplicity only α-tubulin loading controls from representative experiments are shown. 
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  FIGURE 3.8. PHD2 depletion in HACs enhances expression of the key differentiated 
chondrocyte markers.  All data in the figure were obtained from passaged HACs after 3 days in 
culture at either 20% or 1% oxygen. Cells were transfected with 10nM siRNA against PHD2 
(siPHD2), or, as a control against luciferase (siLuc).  TaqMan real-time PCR data showing 
mRNA expression PHD2 (A) and of key chondrocyte markers SOX9, COL2A1, COL9A1, 
COL11A2, AGGRECAN (B – F, respectively) are upregulated by hypoxia and further enhanced by 
PHD2 depletion.  Note: ns – not significant; *P < 0.05; **P <0.01; ***P < 0.001. 
 
Chapter 3            Promotion of the Articular Chondrocyte Phenotype by Inhibition of HIF-specific Hydroxylases 
 
 
102 
 
 
 
 
 
  
FIGURE 3.9. PHD2 depletion in HACs enhances expression of the key collagen processing 
enzymes.  All data in the figure were obtained from passaged HACs after 3 days in culture at 
either 20% or 1% oxygen. Cells were transfected with 10nM siRNA against PHD2 (siPHD2), or, 
as a control against luciferase (siLuc).  TaqMan real-time PCR data showing mRNA expression 
key collagen processing genes PLOD2 and LOXL3.  PLOD2 and LOXL3 upregulated by hypoxia 
and further enhanced by PHD2 depletion.  (A and B respectively).  PHD1 and FIH1, are two 
known non-hypoxia inducible genes (C and D respectively).  These show no change in response 
to PHD2 depletion. Note: ns – not significant; *P < 0.05; **P <0.01; ***P < 0.001. 
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FIGURE 3.10.  Hypoxia downregulates expression of HIF-1α and HIF-2α at the 
mRNA level.  All data in the figure were obtained from passaged HACs after 3 days in 
culture at either 20% or 1% oxygen. Cells were transfected with 10nM siRNA against 
PHD2 (siPHD2), or, as a control against luciferase (siLuc).  TaqMan real-time PCR data 
showing mRNA expression hypoxia significantly downregulated the mRNA levels of 
HIF1α and HIF2α at the mRNA level (A and B respectively).  Note: ns – not significant; 
*P < 0.05; **P <0.01; ***P < 0.001.  
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3.7  Factor inhibiting HIF (FIH-1) knockdown does not increase SOX9 
levels when combined with PHD2 depletion 
 
 The asparaginyl hydroxylase Factor Inhibiting HIF or FIH-1 regulates the 
transcriptional activity of HIF-α.  FIH-1 hydroxylates a specific asparginyl residue within the 
c-terminal transactivation domain of the α-subunit.  This hydroxylation disrupts the binding 
of the CBP/p300 coactivator and inhibits HIF transcriptional activity.  
 
 In order to investigate the regulation of FIH-1 by hypoxia, HACs were cultured for 3 
days under normoxic conditions, hypoxic conditions or in the presence of hypoxia mimetic, 
iron chelator DFO.  Consistent with our previous work FIH-1 was found not to be regulated 
by hypoxia (Fig. 3.11 A).   
 
In order to investigate the role of FIH-1 in regulating HIF-α in HACs, FIH-1 was 
depleted using small interfering RNA (siRNA).  Passaged chondrocytes were transfected with 
10nM of a single siRNA and lysed 3 days after transfection.  siRNA against luciferase was 
used as a non-targeting control.  Messenger RNA analysis by real-time PCR revealed the 
effectiveness of the knockdown to be 97% knockdown (compared with siLuc 20% oxygen) 
(Fig. 3.11 B).  This knockdown was confirmed at the protein level (Fig. 3.11 C). 
 
In order to determine if we could create an additive effect by increasing both HIF-2α 
stabilisation and activity HACs were transfected with siRNA against both PHD2 and FIH-1.  
Passaged human articular chondrocytes were transfected with siRNA against PHD2 plus 
FIH-1, PHD2 alone or luciferase alone as a non-targeting control and cultured for 3 days at 
20% or 1% oxygen.  Protein levels of key cartilage-specific transcription factor SOX9 were 
used as a functional readout.  PHD2 + FIH-1 knockdown did not have an additive effect and 
did not result in levels of SOX9 greater than PHD2 depletion alone. Possible reasons for this 
will be examined in our discussion. 
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  FIGURE 3.11.  RNAi-mediated depletion of FIH-1 in HACs has no significant effect on SOX9 
expression when combined with PHD2 knockdown.   Passaged HACs (P2) cultured for 3 days at 
20% oxygen, 1% oxygen or treated with 10mM of the hypoxia mimetic desferrioxamine (DFO). A, 
western blot showing no significant increase in FIH-1 levels in hypoxia (1% oxygen), and after 
treatment with 10mM DFO.  Passaged (P2) HACs were then transfected with 10nM siRNA directed 
against FIH-1 and an siRNA targeting luciferase (siLuc) was used as a control.  B, Western blot 
showing RNAi-mediated depletion of PHD2 protein in HACs (in 20% oxygen).  Confirmed using 
Taqman real-tiome PCR, C.  Note: ns - not significant.  ***P < 0.001 versus 20% oxygen siLuc.  
Finally, passaged HACs (P3) were cultured for 3 days at either 20% or 1% oxygen.  Cells were 
transfected with 10nM siRNA against PHD2 (siPHD2), both PHD2/FIH-1 (siPHD2+siFIH-1) or 
against luciferase as a control (siLuc).  D, western blot shows FIH-1 depletion has no significant 
increase  in SOX9 expression when combined with PHD2 knockdown. 
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3.8  General Hydroxylase Inhibition Upregulates SOX9 but Inhibits 
Expression and Secretion of the Cartilage Collagens 
 
Finally we investigated the possible therapeutic role of broad (i.e., non-specific) 2-
oxoglutarate-dependent hydroxylase inhibition.  The 2-oxoglutarate analogue DMOG inhibits 
all members of the 2-oxoglutarate dependent hydroxylase family, which includes not only the 
HIF-targeting hydroxylases (PHD1, PHD2, PHD3, FIH-1), but also the collagen prolyl-4-
hydroxylases. 2mM DMOG treatment increased expression of SOX9 at the mRNA (Fig. 3.12 
C) and protein level (Fig. 3.12 A, D).  Mitogen inducible gene-6 (MIG-6), a previously 
identified HIF-2α target gene was also shown to be upregulated by DMOG at the protein 
level (Fig. 3.12 B).  Similarly vascular endothelial growth factor (VEGF), a classic HIF-target 
gene was likewise upregulated by DMOG (Fig. 3.12 E).   
 
However, DMOG-induced upregulation of SOX9 didn’t result in upregulation of the 
cartilage-specific collagens COL9A2, COL11α2, and COL2A1 (Fig. 3.13 A, B, C and D).  
Western blot analysis demonstrates that, in fact, the addition of 2mM DMOG inhibits 
secretion of type II collagen protein into the culture medium (Fig. 3.13. D). Therefore, 
DMOG, like hypoxia and PHD2 depletion, upregulates SOX9. However, it has completely 
the opposite effect of hypoxia and PHD2 depletion with regard to expression of the cartilage 
collagens – decreasing their levels. 
 
The significance of this for a collagen-rich like cartilage will be detailed in our 
discussion. 
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FIGURE 3.12.  General hydroxylase inhibition upregulates hypoxia dependent genes 
SOX9, MIG6 and VEGF.  Passaged HACs were cultured for 3 days under normoxic 
(20%) or hypoxic (1%) conditions, in the presence/absence of 2mM 
dimethyloxaloylglycine (DMOG) - a general hydroxylase inhibitor.  Addition of DMOG 
enhanced SOX9 protein (A and D) and mRNA levels (C).  MIG6, a previously identified 
HIF-2α target gene was upregulated in response to DMOG at the protein level (B).  E, 
Expression of classic HIF target gene VEGF was significantly enhanced by DMOG.   
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FIGURE 3.13.  General hydroxylase inhibition inhibits expression and secretion of 
the cartilage collagens. Passaged HACs were cultured for 3 days under normoxic (20%) 
or hypoxic (1%) conditions, in the presence/absence of 2mM dimethyloxaloylglycine 
(DMOG) - a general hydroxylase inhibitor. DMOG was found to decrease the expression 
of the cartilage-specific collagens COL9A1 (A), COL11A2 (B) and COL2A1 (C) mRNA 
levels.  D, DMOG treatment inhibited secretion of type-II collagen in HACs. Note: ns – 
not significant, *P < 0.05; **P <0.01. 
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3.9  Discussion 
 
We have previously shown that HIF-2α (not HIF-1α) is essential for hypoxic 
induction of cartilage matrix gene expression in HACs (Lafont et al., 2007).  Furthermore, it 
achieves this predominantly through upregulation of transcription factor SOX9, which drives 
matrix gene expression (Lafont et al., 2008).  Since HIFs themselves are regulated by specific 
prolyl hydroxylases (PHDs), we investigated which of these enzymes targets HIF-2α.  With 
the aim of promoting the chondrocyte phenotype and enhancing cartilage deposition without 
inhibiting the prolyl- and lysyl- hydroxylases essential for collagen processing.  Using an 
RNAi approach we identified PHD2 as the key hydroxylase in HACs responsible for 
regulating HIF-2α.  Crucially, we provide clear evidence that such specific inhibition of 
PHD2 promotes the differentiated phenotype and enhances cartilage matrix production by 
HACs both in normoxia and hypoxia.  This opens up the exciting possibility of PHD2-
specific inhibition as a means to stimulate cartilage repair. 
3.9.1  Hypoxia upregulates SOX9 and key extracellular matrix proteins in 
human cartilage explants  
 
Cartilage functions in a chronically hypoxic environment throughout life.  Depending 
of depth chondrocytes are exposed to varying oxygen tensions; 6% O2 near the surface and 
approximately 1% O2 at the core of the tissue.   
 
Here we report that SOX9 and cartilage extracellular matrix proteins (COL2A1, 
COL9A1, COL11A2 and AGGRECAN) are upregulated in response to hypoxia in healthy 
human cartilage explants.  There is a clear upregulation of SOX9 at the protein level in 
human articular cartilage explants this hypoxic upregulation correlates with decreasing levels 
of molecular oxygen (1%>3%>20%).   
 
Assuming that chondrocytes experience physiological oxygen tensions ~6-1% O2 it 
might be more appropriate to report that the exposure of human cartilage explants to supra-
physiological oxygen tension (20% O2) reduces the expression of SOX9 and key cartilage 
matrix genes COL2A1, COL9A1, COL11A2 and AGGRECAN.  Chondrocytes near the 
surface of the tissue experience oxygen tension ~6% O2, here we demonstrate that these 
levels of SOX9 can this can be increased by inhibition of PHD enzymes (limiting molecular 
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oxygen) and opens opportunities to further enhance the endogenous chondrocytes phenotype 
by PHD enzyme inhibition. 
 
This work in human explants is consistent with our previous work in human articular 
chondrocytes and further evidence that hypoxia is a critical parameter in promoting the 
chondrocyte phenotype and increasing the synthesis of extracellular matrix proteins (Lafont 
et al., 2007; Murphy and Polak, 2004; Murphy and Sambanis, 2001).  Healthy human 
cartilage explants are a rare and clinically valuable tissue.  Unlike human osteoarthirtic 
cartilage (which has undergone advanced degenerative changes and has a altered phenotype), 
murine cartilage or a chondrocyte cell line we believe that our data may be directly 
extrapolated to adult human cartilage and provides important, clinically valuable information. 
3.9.2  PHD2 is the most abundant, but PHD3 the most hypoxia-inducible, 
HIF targeting hydroxylase in human articular chondrocytes 
 
The relative abundance of the various PHD enzymes was measured at the mRNA 
level under normoxic and hypoxic conditions.  PHD1/2/3 were all detectable in human 
articular chondrocytes, with PHD2 being the most abundant.  This is consistent with existing 
literature.  These hydroxylases have been previously reported in human cartilage at the 
mRNA (PHD1/2/3/4) and protein (PHD1/2/3) level (Hirsila et al., 2003; Koivunen et al., 
2007; Terkhorn et al., 2007).   In addition, mRNA studies in rats report that in all organs 
examined (heart, liver, kidney, brain, testis and lung) PHD2 was reported to be the most 
ubiquitously expressed (Koivunen et al., 2007; Terkhorn et al., 2007; Willam et al., 2006).   
 
Our results also showed that PHD2 and PHD3 are up-regulated at the mRNA level in 
response to hypoxia in human articular chondrocytes.  This hypoxic induction was confirmed 
at the protein level by western blot for PHD2 and PHD3.  The hypoxic induction of PHD2 
and PHD3 at the protein level has been reported elsewhere in cell lines (Appelhoff et al., 
2004).  Electrophoretic mobility-shift assays have demonstrated the binding of HIF-1α to 
HREs upstream of PHD2 and HREs have been identified (using bioinformatics) 40kb 
upstream of PHD3 (Metzen et al., 2003; Pescador et al., 2005).   
 
However, it is not clear why PHD2 and PHD3 are up-regulated in response to 
hypoxia.  It has been hypothesised that this occurs in a negative feedback mechanism 
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ensuring the rapid degradation of HIF-α isoforms and downregulation of hypoxia responsive 
genes once the cells encounter increased oxygen levels (D'Angelo et al., 2003).  Although we 
observed PHD3 to be the most highly hypoxia-inducible hydroxylase (17.8 fold), the levels 
of PHD3 were relatively low and it did not appear to significantly contribute towards HIF-α 
stabilisation in HACs.   
 
It is illogical that PHD3 is so strongly regulated by hypoxia but has no function in 
chondrocytes therefore our data implies that either PHD3 does regulate HIF-α but upon 
depletion levels of stabilised HIF-1α / HIF-2α protein levels are too low to detect or PHD3 
may have a role outside of targeting HIF-α isoforms in HAC.  Interestingly, Köditz and 
colleagues recently demonstrated that PHD3 interacts with activating transcription factor-4 
(ATF-4).  ATF-4 is induced by hypoxia/DMOG in a pVHL independent manner and siRNA-
mediated down-regulation of PHD3, but not of PHD2, was sufficient to stabilise ATF-4 under 
normoxic conditions (Koditz et al., 2007).   
3.9.3  The regulation of HIF-α in human articular chondrocytes by PHD1, 
PHD2 and PHD3 
 
Previous work has demonstrated that PHD1, PHD2 and PHD3 have the ability to 
hydroxylate both HIF-1α and HIF-2α.   Work in a range of cell lines has suggested 
differential function of the PHD enzymes in regulation of HIF-α isoforms (Appelhoff et al., 
2004).  For example, in MCF7 cells knockdown of PHD3 stabilised HIF-2α to higher levels 
compared with hypoxic control, and substantially delayed HIF-2α degradation following re-
oxygenation (Appelhoff et al., 2004).   
 
Further work using knockout mice (see Chapter 1) suggests that PHD2 is more active 
against HIF-1α and PHD1/PHD3 are more active against HIF-2α.  Although these studies 
indicate that PHDs may show differential regulation of HIF-α isoforms, at least some of the 
observed differences are most likely due to the relative abundance of each hydroxylase 
(which is dependent on cell and tissue type).  In fact, the Km values of all three PHD 
isoenzymes for recombinant HIF-1α and HIF-2α oxygen degradation domains (ODDDs) are 
quite similar, with PHD1 having the lowest Km value for both recombinant HIF-α ODDDs 
(Koivunen et al., 2006). All three PHD isoenzymes also have virtually identical Km values for 
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oxygen (Hirsila et al., 2003) implying that changes in oxygen tension will not affect the 
relative contribution of the three enzymes to HIF-α stabilisation.    
 
In our experiments with HACs, only depletion of the most abundant hydroxylase 
(PHD2) significantly stabilised both HIF-1α and HIF-2α in 20% oxygen and slowed 
degradation of each HIF-α isoform in reoxygenation experiments.  PHD3 depletion had no 
detectable effect on either HIFα isoform stabilisation.  Our data also suggests that PHD1 
slightly contribute towards the regulation of HIF-1α and HIF-2α isoforms.   
 
Interestingly, however, there was a difference between HIF-1α and HIF-2α in regards 
to their stabilisation by PHD2 depletion.  No further increase in HIF-1α stabilisation was 
detectable in PHD2 depleted HACs when cultured in 1% oxygen compared to that seen in 
20% levels.  In contrast, HIF-2α levels were further increased when PHD2 depleted cells 
were cultured in hypoxia implying that other factors in addition to PHD2 regulate HIF-2α in 
hypoxia.  PHD1 may be one such factor since we observed some HIF-2α stabilisation 
following depletion of PHD1 in normoxia (although less that that caused by PHD2 
knockdown).   
 
Factor inhibiting HIF-1α (FIH-1), is an iron-dependent dioxygenase capable of 
regulating HIF-α isoform activity (Lando et al., 2002; Mahon et al., 2001), we found the 
knockdown of FIH-1 had no significant effect on SOX9 expression even when this 
knockdown was combined with a PHD2 knockdown.  This may be because the increase in 
HIF-2α activity has no effect on SOX9 expression or because use of two different siRNA 
oligonucleotides simultaneously decreases the knockdown efficiency and therefore does not 
stabilize HIF-2α to levels equal with PHD2 depletion alone. 
 
Surprisingly, we report that hypoxia and the stabilisation of HIF-α isoforms by 
inhibition of PHD2 appears to downregulate the expression HIF-1α and HIF-2α at the mRNA 
level.  This will be further discussed in Chapter 4 in the context of further data. 
 
It has been previously demonstrated in vitro using recombinant PHD enzymes 
expressed in insect cells that PHD1/2/3 have essentially identical Km values for oxygen, 
approximately 25% O2 (Hirsila et al., 2003).  This Km value is higher than the expected 
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oxygen tension encountered in vivo (6%-1% O2) and is consistent with PHD enzyme function 
(small change in oxygen tension can influence their activity).  More recently it has been 
shown in vitro using recombinant PHD2 and peptides containing HIF-1α and HIF-2α 
ODDD’s that PHD2 has a lower Km for oxygen, approximately 10% O2 and has some 
functional activity even at 1% O2 (~400 d.pm.).  Here we demonstrate that PHD2 still 
displays significant activity in 1% oxygen, since depletion of PHD2 under hypoxic conditions 
resulted in greatly increased levels of both HIF-α isoforms and further enhanced SOX9 
expression.  As described above chondrocytes experience physiological oxygen tensions ~6-
1% O2 in vivo therefore, 20% oxygen tension is artificially higher than in vivo and 1% 
oxygen tension represents the most extreme microenvironment (the core of the cartilage).  It 
might be more appropriate to report that the exposure of human articular chondrocytes to 
supra-physiological oxygen tension (20% O2) represses the chondrocytes phenotype, 
reducing the expression of SOX9 and key cartilage matrix genes COL2A1, COL9A1, 
COL11A2 and AGGRECAN.     
 
By inhibiting PHD2 we are able to upregulate HIF-1α / HIF-2α (and subsequently 
increase SOX9 and cartilage matrix gene expression) to levels in excess maximum 
physiological conditions.  We are able to exploit endogenous oxygen sensing pathways to 
promote articular chondrocyte function, fully “turning on” the HIF-signalling pathway and do 
better than nature.  To be able to enhance HIF-2α levels above those typically found in 
hypoxia is potentially of great importance since we have previously shown that HIF-2α 
upregulates cartilage-specific matrix expression through induction of SOX9 (Lafont et al., 
2008; Lafont et al., 2007).  Furthermore, our results were generated using freshly isolated 
(P0) and passaged (P1-P3) HACs.  Healthy human articular chondrocytes are rare and 
clinically valuable cells.  Unlike human osteoarthirtic chondrocytes, murine cartilage or a 
chondrocyte cell line our data can be directly extrapolated to adult human cartilage and 
provides important, clinically valuable information. 
3.9.4  Therapeutic applications of work 
 
Experiments with the general hydroxylase inhibitor dimethyloxalylglycine (DMOG) 
highlight the importance of development of HIF-specific hydroxylase inhibitors with regard 
to the collagen rich tissue cartilage.  Addition of 2mM DMOG enhanced SOX9 levels in 
HACs, and we have previously shown that this is dependent (like hypoxia) specifically on 
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HIF-2α (Murphy et al., 2009).  Addition of DMOG upregulated SOX9 however, unlike the 
case of hypoxia or PHD2 depletion, DMOG did not result in upregulation of the cartilage-
specific collagen genes: COL2A1, COL9A1 and COL11A2.  Most importantly, secretion of 
type II collagen was inhibited by DMOG.  This is most likely due to the fact that DMOG also 
inhibits the collagen prolyl 4-hydroxylases (C-P4Hs).   
 
Collagen proyl-4-hydroxylases (C-P4Hs) are tetramers (consisting of 2 α subunits and 
2 β subunits) responsible for catalysing the formation of 4-hydroxyproline by hydroxylation 
of –X-Pro-Gly- residues within the pro-α collagen chains.  Like HIF-targeting hydroxylases 
collagen proyl-4-hydroxylases use 2-oxoglutarate and oxygen as substrates (and iron and 
ascorbate as cofactors) to hydroxylate proline residues and this hydroxylation is essential for 
the formation of intramolecular hydrogen bonds and subsequent stable triple-helical 
formation (Jimenez et al., 1973; Kukkola et al., 2003; Myllyharju, 2003; Van Den 
Diepstraten et al., 2003).  Unlike the PHD1/2/3 C-P4H enzymes have a low Km for oxygen 
(40µM vs. 230-250µM) suggesting that C-P4H enzymes can remain active even under low 
oxygen tensions (Hirsila et al., 2003).  This makes sense given the roles of the HIF- and 
Collagen- Proyl hydroxylases.  PHD1/2/3 act as cellular oxygen sensors therefore even a 
small change in oxygen tension can influence their activity.  In contrast, C-P4Hs must be able 
to act in stressful micro-environments (eg:  cartilage extracellular matrix synthesis or wound 
repair in a tissue with poor vascularisation).  Posttranslational modification of type II 
procollagens are essential steps for formation of the triple helices and subsequent secretion.  
Inhibition of C-P4Hs by DMOG leads to misfolded, unhydroxylated procollagen chains, 
these are retained by the cell and targeted for intarcellular degradation (Berg et al., 1983).   
 
Similarly to our work Gelse and colleagues recently carried out a study injecting the 
joints of STR/ORT mice with the non-specific hydroxylase inhibitor dimethyloxalylglycine 
(DMOG).  STR/ORT mice spontaneously develop osteoarthritis and injection of DMOG was 
unable to prevent the formation of severe arthritis.  Although Sox9 was up-regulated in 
response to DMOG injection, immunohistochemistry and immunofluorecence revealed 
incomplete post-translational processing and intracellular accumulation of type II collagen in 
chondrocytes.  It was concluded that this impaired secretion of collagen was due to inhibition 
of collagen proyl-4-hydroxylases by the non-specific hydroxylase inhibitor DMOG (Gelse et 
al., 2008).    
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This stresses the importance of developing PHD2- specific inhibitors (or at least HIF-
specific prolyl-4 hydroxylases) which do not inhibit key collagen proyl-4-hydroxylases which 
are essential for correct collagen posttranslational modification.  Furthermore, Grimmer and 
colleagues have previously demonstrated that the collagen proyl-4-hydroxylases α and β 
subunits were significantly enhanced in response to hypoxia in HACs (Grimmer et al., 2006; 
Hofbauer et al., 2003).  We aim to investigate this in our further work and demonstrate that 
collagen prolyl 4-hydroxylase levels can be further enhanced by PHD2 depletion.  
Complementary with these findings here we report that two further enzymes involved in 
collagen fibril formation, LOXL3 and PLOD2 are unregulated in response to hypoxia and 
further enhanced by PHD2 inhibition (Lafont et al., 2008).  This suggests that hypoxia 
upregulates not only COL2A1 transcription but also accelerates the post-translational 
processing of type II collagen fibres and their secretion.  Furthermore, these two effects may 
be enhanced by PHD2 enzyme inhibition. 
 
  This adverse effect of general hydroxylase inhibition on collagen processing is 
particularly relevant to cartilage as it is a highly collagen rich tissue.   For this reason the use 
of DMOG clearly has no therapeutic application in the treatment of arthritis.   
 
In summary, here we demonstrate that consistent with our previous work in human 
articular chondrocytes hypoxia promotes chondrocyte function in human cartilage explants.  
Moreover, work in human articular chondrocytes demonstrated that the specific depletion of 
HIF-2α targeting hydroxylase PHD2 significantly upregulated the cartilage master regulator, 
transcription factor SOX9, and key matrix genes COL2A1, COL9A1, COL11A2, and 
AGGRECAN.  We believe that the use of healthy human articular cartilage and human 
articular chondrocytes provides important clinically relevant data that may be directly 
extended to human articular cartilage in vivo. 
 
Crucially, here we demonstrate that PHD2 displays significant activity even at 1% 
oxygen, since depletion of PHD2 under hypoxic conditions resulted in greatly increased 
levels of both HIF-α isoforms and further enhanced SOX9 expression.  1% oxygen tension 
represents the most extreme microenvironment (the core of the cartilage).  By inhibiting 
PHD2 we are able to upregulate HIF-1α / HIF-2α (and subsequently increase SOX9 and 
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cartilage matrix gene expression) to levels in excess of those achieved by physiological 
conditions.  This opens novel, exciting possibilities of manipulating the endogenous oxygen 
sensing pathways in order to promote articular chondrocyte function, promote cartilage 
synthesis and to stimulate repair.  In addition, PHD2 inhibition upregulated key pro-Lysyl 
hydroxylases involved in collagen formation implying that PHD2 inhibition offers a novel 
means to enhance cartilage repair upregulating SOX9 and key cartilage matrix proteins with 
inhibiting the enzymes involved in pro-collagen fibril formation.   
 
 
 
 
Chapter 4                          Hypoxia is an Anti-catabolic Regulator of Human Articular Cartilage 
 
 
 
117 
 
 
 
 
 
 
 
 Chapter 4 
 Hypoxia is an Anti-catabolic Regulator of Human Articular Cartilage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                          Hypoxia is an Anti-catabolic Regulator of Human Articular Cartilage 
 
 
 
118 
 
4.1  Introduction 
 
Osteoarthritis is traditionally thought of as a mechanical process, a consequence of 
“wear and tear” on a synovial joint.  However, a more accurate description would be to 
describe an imbalance between net anabolic (matrix synthesis) and net catabolic (protease) 
activity (Cawston et al., 1999; Grimmer et al., 2006; Nelson et al., 1998; Rizkalla et al., 
1992).   
 
In osteoarthritis it is believed that there is an increase in cartilage matrix degradation 
through an increased production of proteases (ADAMTSs, MMPs), an increase in protease 
activity (increased cleavage of pro-enzymes) or a decrease in catabolic regulators (TIMPs).  
Increased mRNA expression of catabolic matrix metalloproteinases and aggrecanases, e.g., 
MMPs-1,-3 and -13, and ADAMTS-4 and -5 has been found in human osteoarthritic cartilage 
and are associated with increased matrix loss (Bau et al., 2002; Song et al., 2007; Stanton et 
al., 2005; Vincenti and Brinckerhoff, 2002).  In addition chondrocytes appear to undergo 
phenotypic changes, upregulating collagen X expression and thus adopting somewhat of a 
hypertrophic phenotype (Aigner et al., 2007).  Increased net catabolism compromises the 
structural integrity of cartilage extracellular matrix, the tissue loses its ability to absorb and 
respond to mechanical stress (Grimmer et al., 2006).  Destruction of the cartilage 
extracellular matrix leads to joint pain, loss of function over time and reduced quality of life.   
 
Here we report the benefit of hypoxia, namely the stabilisation of HIF-α isoforms 
inhibits IL-1α induced aggrecan cleavage in human cartilage explants.  Furthermore, hypoxia 
suppresses the endogenous release of aggrecan fragments in unstimulated cartilage 
suggesting that hypoxia has an anti-catabolic effect in cartilage is able to reduce matrix 
degradation.  In order to investigate the anticatabolic effect we monitored expression of a 
number of genes and found that the stabilisation of HIF-α isoforms in human articular 
cartilage explants has an anti-catabolic effect downregulating mRNA expression of several 
catabolic proteases associated with cartilage matrix degradation and upregulating anti-
catabolic enzyme tissue inhibitor of metalloproteinases 3 (TIMP3).  This result in human 
tissue (cartilage explants) was replicated in HACs (monlayer cultures) and using an RNAi 
approach we provide clear evidence that hypoxia and specifically the stabilisation HIF-1α 
(not HIF-2α) has an anti-catabolic effect in human articular cartilage.  Furthermore, we show 
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that depletion of PHD2 enhances this anti-catabolic effect in both normoxia and hypoxia.  
Finally, stimulation with IL-1α stabilises HIF-1α but decreases HIF-2α in HACs.  Data 
suggests that this may be partly mediated at the transcriptional level and would seem to 
represent a different mechanism than hypoxia of HIF regulation. 
 
4.2  Hypoxia inhibits aggrecan degradation in human articular 
cartilage explants  
 
In order to study the effect of hypoxia on aggrecan degradation, we stimulated human 
articular cartilage explants with proinflammatory cytokine interleukin 1α (IL-1α).  
Stimulation with IL-1α causes the cleavage of the aggrecan core protein by aggrecanases 
within the first interglobular domain (between G1 and G2) (Flannery et al., 1999; Gebauer et 
al., 2005; Saklatvala, 1987; Vincenti and Brinckerhoff, 2002).  Proteolysis occurs at the 
Glu373 – Ala374 bond resulting in the C-terminal neoepitope NITEGE (bound to the 
hyaluronan backbone) and the N-terminal neoepitope ARGSV (Nagase and Kashiwagi, 2003; 
Sandy et al., 1992).  This C-terminal aggrecan fragment can be detected by western blotting 
cartilage explant culture medium with antibodies which recognise the ARGSV neoepitope.  
In human articular cartilage explants anti-ARGSV neoepitope antibodies recognise a 
dominant 150 kDa band and a fainter 250 kDa fragment.  Release of ARGSV neoepitope was 
detected 24 hours after stimulation with IL-1α and even present in unstimulated cartilage. 
 
Freshly dissected healthy human cartilage explants from 4 donors were pre-incubated 
in normoxic or hypoxic conditions for 48 hours before treatment, stimulated with either IL-1α 
or vehicle (serum free media) and returned to original oxygen tensions.  In human cartilage 
explants hypoxia inhibited the release of ARGSV neoepitope when explants were stimulated 
with IL-1α (Fig 4.1).  Generally, this inhibition of ARGSV neoepitope release was IL-1α 
dose dependent and long exposure of X-ray film revealed that hypoxia also inhibited ARGSV 
neoeptitope release in unstimulated cartilage explants suggesting that hypoxia may be able to 
inhibit endogenous matrix turnover (Fig 4.1).   
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  FIGURE 4.1. Hypoxia inhibits aggrecan degradation in human articular cartilage explants.  
Healthy human cartilage explants from 4 donors were pre-incubated in normoxic or hypoxic 
conditions for 48 hours before stimulation with either IL-1α (10ng/ml or 1ng/ml) or vehicle 
(serum free media) and returned to their original oxygen tensions.  Degraded aggrecan fragments 
released into the medium were detected by western blotting using an anti-ARGSV neoepitope 
antibody. Culture medium was precipitated using acetone. Note: longer exposure blots are also 
shown to highlight neoepitope release under control (non-IL-1α) conditions. 
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However, not all patients followed this trend:  Figure 4.1 A, there appears to be no 
dose dependent release of ARGSV when cartilage explants treated with 20% oxygen are 
stimulation with 10ng/ml or 1ng/ml of IL-1α.  Figure 4.1 C, there is a higher level of ARGSV 
release in unstimulated 20% oxygen control compared with 20% oxygen 1ng/ml IL1α 
stimulated explants.  Figure 4.1 E, the hypoxic inhibition of ARGSV release in unstimulated 
cartilage explants is very subtle.  These differences may be due to patient variability or due to 
gel loading error. 
 
In summary, treatment with hypoxia inhibits aggrecan degradation in both 
unstimulated and IL-1α stimulated in healthy human cartilage explants. 
 
4.3  Down-regulation of catabolic and upregulation of anti-catabolic 
enzymes in human cartilage explants under hypoxic conditions  
 
Human cartilage explants from a range of patients (3 male and 2 female donors; age 
14-46 years [mean age 26.6 years]) were incubated for 3 days under normoxic (20% oxygen) 
or hypoxic (1% oxygen) conditions.  The messenger RNA levels (mRNA) of catabolic 
enzymes ADAMTS4, ADAMTS5, MMP1, MMP3, MMP13 as well as anti-catabolic inhibitors 
TIMP1, TIMP2 and TIMP3 were analysed after normalising the data using the housekeeping 
gene RPLP0 (Fig. 4.2 A to H).  Aggrecanases ADAMTS4 and ADAMTS5 cleave aggrecan at 
a well-defined site.  Similarly, the matrix metalloproteinases MMP1, MMP3 and MMP13 
have the ability to cleave aggrecan but they are also implicated in the catabolism of collagen 
fibers and other matrix components following loss of aggrecan from cartilage.   
 
Here we report that hypoxia significantly downregulates key aggrecanase ADAMTS5 
expression (1.75 fold reduction) at the mRNA level (Fig. 4.2 B).   Hypoxia had also 
significantly downregulating collagenase MMP13 mRNA expression 3 fold (Fig. 4.2 E).  
TIMP3 was upregulated at the mRNA level (8.48 fold) in response to hypoxia (Fig. 4.2 H).  
This data shows a predominantly anticatabolic response to hypoxia, with downregulation of 
key catabolic enzymes and upregulation of essential catabolic inhibitor TIMP3 which inhibits 
a broad spectrum of MMPs, ADAM-17, ADAMTS4 and ADAMTS5. 
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4.4  Anti-catabolic effects of hypoxia are HIF-1α and not HIF-2α 
dependent  
 
FIGURE 4.2.  Hypoxia downregulates key cartilage catabolic enzymes ADAMTS5 and 
MMP13, upregulates matrix metalloproteinase MMP3 and anti-catabolic factor TIMP3 in 
human cartilage explants.  Data are based on human cartilage explants from 4-5 different 
donors.  TaqMan PCR data showing relative levels of mRNA for ADAMTS4, ADAMTS5, MMP1, 
MMP3, MMP13, TIMP1, TIMP2 and TIMP3 (A t  H, respectively) after culture for 3 days at 20% 
and 1% oxygen.  All values were normalised using the housekeeping gene RPLP0 and represent 
mean and SEM results of 3-5 independent experiments (i.e., cells from 4-5 different donors).  
Note: ns - not significant.  *P < 0.05; **P < 0.01 (versus 20% oxygen)   
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4.4  Anti-catabolic effects of hypoxia are HIF-1α and not HIF-2α 
dependent 
 
In order to determine whether the anti-catabolic effects were mediated by either HIF-
1α or HIF-2α, we depleted each isoform in human articular chondrocytes (HACs) using 
siRNA.  HACs were transfected with siRNA against HIF-1α, HIF-2α, HIF-1α + HIF-2α or 
luciferase (as a non-targeting control), cultured for 3 days at either 20% oxygen or 1% 
oxygen before lysis.    Real-time PCR revealed that HIF-1α mRNA was depleted by 89%, on 
average and HIF-2α message was depleted 96% compared to 1% oxygen siLuc levels (Fig. 
4.3 A and B).  Western blotting confirmed depletion of HIF-α isoforms at the protein level 
(Fig. 4.3 C).  Faintly detectable levels of HIF-1α protein were present in the normoxic control 
(siLuc 20%) and longer exposure of the blots revealed that the knockdown of HIF-1α using 
siRNA was able to reduce protein levels below this normoxic control (Fig. 4.3 C)  
 
Following specific depletion of each HIF-α protein, we assessed the functional effects 
of the knockdowns on levels of ADAMTS5, MMP13 and TIMP3 mRNA levels after 
normalising the data using the housekeeping gene RPLP0.  ADAMTS5 and MMP13 were 
significantly downregulated by hypoxia compared with siLuc in 20% oxygen (1.63 and1.49 
fold downregulated respectively) (Fig. 4.4 A and B).  The hypoxic downregulation of MMP13 
was significantly reversed by HIF-1α depletion, resulting in MMP13 mRNA levels greater 
than those present under normoxic conditions (Fig. 4.4 A).  Most interestingly, this suggests 
that even under normoxic conditions the low level of HIF-1α protein may be functional in 
HACs and this has an anti-catabolic effect suppressing MMP13 expression.   Longer 
exposure revealed detectable levels of HIF-1α protein (and faintly detectable levels of HIF-2α 
protein) even under normoxic conditions.  The depletion of HIF-2α had no significant effect 
on the hypoxic downregulation of MMP13 and the depletion of HIF-1α + HIF-2α 
significantly reverses MMP13 downregulation in a manner similar to HIF-1α depletion alone.   
 
Curiously, unlike MMP13, the hypoxic suppression of ADAMTS5 mRNA levels could 
not be reserved using either HIF-1α or HIF-2α depletion suggesting a different, HIF-
independent mechanism of regulation (Fig. 4.4 B). 
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FIGURE 4.3. Knockdown of HIF-1α and HIF-2α in passaged HACs.  All data in the figure 
were obtained from passaged (P1-P3) HACs after 3 days in culture at either 20% or 1% oxygen.  
Cells were transfected 10nM siRNA against HIF-1α (siHIF-1α), HIF-2α (siHIF-2α) or both at the 
same time (siH1 + siH2).  siRNA against luciferase was used as a control (siLuc).  TaqMan Real-
time PCR data showing relative mRNA levels of HIF-1α (A), HIF-2α (B) versus hypoxic control 
(siLuc 1%).  Western blot confirming knockdown of HIF-1α and HIF-2α in HACs (C). 
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FIGURE 4.4. Role of HIF-1α, but not HIF-2α in hypoxic downregulation of MMP13.  All 
data in the figure were obtained from passaged (P1-P3) HACs after 3 days in culture at either 20% 
or 1% oxygen.  Cells were transfected 10nM siRNA against HIF-1α (siHIF-1α), HIF-2α (siHIF-
2α) or both at the same time (siH1 + siH2).  siRNA against luciferase was used as a control 
(siLuc).  TaqMan Real-time PCR data showing the effect of HIF-1α and HIF-2α depletion on 
relative mRNA levels of MMP13 (A) and ADAMTS5 (B) under hypoxic conditions.  Hypoxia 
induced downregulation of MMP13 is HIF-1α and not HIF-2α dependent, while ADAMTS5 
downregulation was unaffected by depletion of either HIF isoform.  Note: *P < 0.05; ***P < 
0.001. 
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  FIGURE 4.5.  Hypoxic induction of TIMP3 is HIF-1α, but not HIF-2α dependent.  All data in 
the figure were obtained from passaged (P1-P3) HACs after 3 days in culture at either 20% or 1% 
oxygen.  Cells were transfected 10nM siRNA against HIF-1α (siHIF-1α), HIF-2α (siHIF-2α) or 
both at the same time (siH1 + siH2).  siRNA against luciferase was used as a control (siLuc).  
TaqMan real-time PCR data showing the effect of HIF-1α and HIF-2α depletion under hypoxic 
conditions on mRNA levels of TIMP3 (A) compared with normoxic control (siLuc 20%).  
Hypoxic upregulation of TIMP3 is HIF-1α, and not HIF-2α dependent.  Western blotting of 
secreted TIMP3 confirmed mRNA data at the protein level (B). 
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TIMP3 mRNA expression was significantly increased in response to hypoxia (Fig. 4.5  A).  
This hypoxic induction was confirmed at the mRNA (Fig. 4.5 A) and protein level (Fig. 4.5 
B).  The hypoxic mRNA induction was not significantly affected by HIF-2α depletion but 
abolished by HIF-1α depletion (Fig. 4.5 A).  This data was supported by western blot analysis 
and confirmed at the protein level from culture media of passaged HACs demonstrating that 
these anti-catabolic effects of hypoxia are HIF-1α, and not HIF-2α dependent (Fig. 4.5  B).  
Detection of TIMP3 following HIF-α isoforms depletion was challenging and often TIMP3 
did not produce a clean band.  However when considered with mRNA data this hints at a 
HIF-1α dependence.  
 
In summary, MMP13 mRNA was downregulated and TIMP3 upregulated by hypoxia 
in a HIF-1α (not HIF-2α) dependent manner. In fact, HIF-1α depletion reversed the hypoxic 
downregulation of MMP13 mRNA to levels exceeding normoxia suggesting functional HIF-
1α activity even in normoxic conditions.   Surprisingly, ADAMTS5 mRNA downregulation in 
response to hypoxia was independent of the HIF-α isoforms.   
 
4.5  Regulation of catabolic mediators in human articular 
chondrocytes by hypoxia  
 
In order to further investigate a possible anti-catabolic role of the HIF-signalling 
pathway, passaged HACs were transfected with siRNA against PHD2 or luciferase as a non-
targeting control.  Following transfection, passaged HACs were cultured for 3 days under 
normoxic (20% oxygen) or hypoxic (1% oxygen) conditions.  The mRNA levels of catabolic 
enzymes ADAMTS4, ADAMTS5, MMP1, MMP3, MMP13 as well as anti-catabolic enzymes 
TIMP1, TIMP2 and TIMP3 and a marker of chondrocyte hypertrophy COL10A1 were 
analysed after normalising the data using the housekeeping gene RPLP0 (Fig. 4.6.  Fig. 4.7.  
Fig. 4.8).  Consistent with our work in human cartilage explants we observed an anti-
catabolic effect of hypoxia in isolated HACs.  Hypoxia downregulated aggrecanase 
ADAMTS5 expression (2 fold reduction) and collagenase MMP13 expression (1.56 fold 
reduction) (Fig. 4.6 B.  Fig. 4.7 C).  Unlike in explants, MMP3 was not found to be regulated 
by hypoxia (Fig. 4.7  B). 
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Depletion of PHD2 using siRNA enhanced the downregulation of ADAMTS5 and 
MMP13 mRNA expression.  This pattern of hypoxic downregulation correlated with the 
pattern of HIF-α isoform stability.  The knockdown of PHD2 under 20% oxygen 
downregulates ADAMTS5 by 2.5 fold and MMP13 by 2 fold (compared with control levels in 
normoxia).  The knockdown of PHD2 in 1% oxygen tension enhances downregulation 
beyond hypoxic levels alone for ADAMTS5 expression (downregulated 3.22 fold) and 
MMP13 (3.22 fold) compared with control levels in normoxia (Fig. 4.6  B.  Fig. 4.7 C).  
Depletion of PHD2 in 20% and 1% oxygen tension had no significant effect on MMP3 
mRNA expression (Fig. 4.7 B). 
 
Consistent with our work in human cartilage explants catabolic regulators TIMP1 and 
TIMP2 were found not to be regulated by hypoxia (Fig. 4.8 A and B).  This lack of a hypoxic 
induction of TIMP1 was confirmed at the protein level by western blotting the culture 
medium (following acetone precipitation) (Fig. 4.8 A).  TIMP3, a key regulator of matrix 
metalloproteinases was upregulated 2.5 fold at the mRNA level in response to hypoxia (Fig. 
4.8 C).  TIMP3 was not detectable in HAC culture medium following acetone precipitation 
and western blotting.  However, following treatment of HAC cultures with 200µg/ml heparin, 
hypoxic upregulation of TIMP3 was confirmed at the protien level.  Depletion of PHD2 in 
HACs upregulated TIMP3 at the mRNA level, however this tread was found to be not 
statistically significant.  Messenger RNA levels of a key marker of chondrocyte hypertrophy, 
COL10A1 were not regulated by hypoxia and depletion of PHD2 did not have a significant 
effect on COL10A1 mRNA levels (Fig. 4.8 D). 
 
In summary, our work in HACs reinforces our findings in human cartilage explants, 
that is hypoxia has an anticatabolic effect, downregulating expression of key catabolic 
enzymes (ADAMTS5 and MMP13) and upregulating essential catabolic inhibitor TIMP3 
which inhibits a broad spectrum of MMPs in addition to the aggrecanases ADAMTS4 and 
ADAMTS5.  The hypoxic upregulation of TIMP3 was confirmed at both mRNA and protein 
level. The marker of chondrocyte hypertrophy COL10A1 was found to be not regulated by 
hypoxia. The hypoxia-induced downregulation of key catabolic enzymes can be further 
enhanced by PHD2 enzyme depletion representing a further benefit of PHD2-specific 
inhibition with regard to cartilage maintenance and potentially repair. 
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FIGURE 4.6.  PHD2 depletion in HACs enhances hypoxic downregulation of aggrecanase 
ADAMTS5 at the mRNA level.  All data in the figure were obtained from passaged HACs after 
3 days in culture at either 20% or 1% oxygen. Cells were transfected with 10nM siRNA against 
PHD2 (siPHD2), or, as a control against luciferase (siLuc).  TaqMan real-time PCR data showing 
mRNA expression of key aggrecanase enzymes ADAMTS4 (A) and ADAMTS5 (B).  ADAMTS5 
mRNA is downregulated in response to hypoxia and this hypoxic downregulation is further 
enhanced by PHD2 depletion.  Note: ns – not significant; **P < 0.01; ***P < 0.001. 
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FIGURE 4.7. PHD2 depletion in HACs enhances hypoxic downregulation of key catabolic 
enzyme MMP13 at the mRNA level.  All data in the figure were obtained from passaged 
HACs after 3 days in culture at either 20% or 1% oxygen. Cells were transfected with 10nM 
siRNA against PHD2 (siPHD2), or, as a control against luciferase (siLuc).  TaqMan real-time 
PCR data showing mRNA expression of matrix metalloproteinase enzymes MMP1, MMP3 and 
MMP13 (A, B and C, respectively).  MMP13 mRNA levels are downregulated in response to 
hypoxia and this hypoxic downregulation is further enhanced by PHD2 depletion.  Note: ns – 
not significant; *P < 0.05; **P <0.01; ***P < 0.001. 
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FIGURE 4.8. Hypoxia upregulates catabolic regulator TIMP3 and does not regulate 
hypertrophy marker COL10A1 at the mRNA level.  All data in the figure were obtained from 
passaged HACs after 3 days in culture at either 20% or 1% oxygen. Cells were transfected with 
10nM siRNA against PHD2 (siPHD2), or, as a control against luciferase (siLuc).  TaqMan real-
time PCR data showing relative mRNA levels of catabolic regulators TIMP1, TIMP2, TIMP3 (A, 
B and C, respectively) and marker of chondrocyte hypertrophy COL10A1 (D).  Hypoxia 
significantly increases mRNA levels of TIMP3, although PHD2 depletion did not have an effect. 
Note: ns – not significant; ***P < 0.001. 
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FIGURE 4.9. Hypoxia enhances TIMP3 secretion in HACs.  Data are from 
passaged (P1-P3) HACs after culture for 3 days at 20% oxygen or 1% oxygen.  
Secreted TIMP1 (A) and TIMP3 (B) was detected following acetone precipitation of 
culture media.  Cell culture medium was supplemented with 200µg/ml heparin in 
order to detect TIMP3.  Data were normalised based on Bradford measurements of 
protein content of cell layers.     
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4.6  IL-1α stimulation stabilises HIF-1α but not HIF-2α in human 
articular chondrocytes  
 
Passaged human articular chondrocytes from a range of patients were treated with 
10ng/ml IL-1α or vehicle (serum free media) and cultured under normoxic (20% oxygen) or 
hypoxic (1% oxygen) conditions for 24 hours.  In HACs cultured under normoxic conditions 
IL-1α stimulation resulted in HIF-1α protein stabilisation.  There was some variability 
between patients, but generally, levels of HIF-1α protein were greater than or roughly equal 
with unstimulated hypoxic levels (1% oxygen).  HACs cultured at 1% oxygen and stimulated 
with IL-1α could achieve levels of HIF-1α above those in hypoxic alone (Fig. 4.10).  This 
suggests IL-1α stimulation may be able to stabilise HIF-1α isoforms using a mechanism 
independent of inhibiting HIF-α-prolyl hydroxylation.  In stark contrast, IL-1α stimulation of 
HACs cultured under normoxia did not result in HIF-2α stabilisation and IL-1α stimulation 
under hypoxia actually decreased HIF-2α protein levels compared to hypoxia alone (Fig 
4.11). 
 
In a series of timecourse experiments HACs were cultured under normoxia for 2 days 
before being exposed to 10ng/ml IL-1α and lysed at 0-, 1-, 3-, 6-, 12- and 24- hours.  The rate 
of HIF-1α stabilisation varied between patients to some extent but in all cases IL-1α 
stimulation resulted in a transient HIF-1α stabilisation peaking between 6 to 12 hours and 
significantly reduced at 24 hours (the final timepoint of the experiment) (Fig 4.12. A.  Fig. 
4.13. A). In contrast, IL-1α stimulation in HACs cultured under normoxia did not result in 
HIF-2α stabilisation (Fig. 4.12. B.  Fig. 4.13. B).  The mRNA levels of HIF-1α and HIF-2α 
were also analysed after normalising the data using the housekeeping gene RPLP0.  We 
observed that IL-1α stimulation resulted in increased levels of HIF-1α mRNA, although the 
time-course was different  to the HIF-1α protein response, since mRNA levels continued to 
rise throughout the experimental period. Again the HIF-2α response was very different to 
HIF-1α since HIF-2α mRNA levels were completely unaffected by IL-1α stimulation (Fig. 
4.14 + Fig. 4.15). 
  
Chapter 4                          Hypoxia is an Anti-catabolic Regulator of Human Articular Cartilage 
 
 
 
134 
 
 
  
FIGURE 4.10. IL-1α stimulation stabilises HIF-1α in human articular chondrocytes.  
Passaged (P1-P2) HACs from 5 different donors were stimulated with either IL-1α 
[10ng/ml] or vehicle (serum free media) and incubated at either 20% or 1% oxygen tension 
for 24 hours.  IL-1α stabilises HIF-1α protein even under normoxic conditions to levels 
greater than or roughly equal with unstimulated hypoxic control (1% oxygen).  HACs 
cultured at 1% oxygen and stimulated with IL-1α has higher levels of HIF- than hypoxia 
alone. 
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FIGURE 4.11. IL-1α stimulation does not stabilise HIF-2α in human articular 
chondrocytes under normoxic conditions and may decrease protein levels in hypoxia.  
Passaged (P2-P3) HACs from 2 different donors were stimulated with either IL-1α 
[10ng/ml] or vehicle (serum free media) and incubated at either 20% or 1% oxygen 
tension for 24 hours.  IL-1α stimulation of HACs cultured under normoxia did not result 
in HIF-2α stabilisation and IL-1α treatment under hypoxia appeared to result in reduced 
HIF-2α levels. 
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FIGURE 4.12.  IL-1α stimulation stabilises HIF-1α in human articular chondrocytes 
peaking at between 6 and 12 hours but does not affect HIF-2α levels.  In a timecourse 
experiment passaged (P1-P2) HACs were cultured under normoxia for 2 days before being 
exposed to 10ng/ml IL-1α and lysed at 0, 1, 3, 6, 12 and 24 hours thereafter.  The timepoint 
of peak HIF-1α levels varied between donors but in all cases IL-1α stimulation resulted in 
HIF-1α stabilisation peaking between 6-12 hours (A).  In contrast IL-1α stimulation in 
HACs cultured under normoxia did not result in any detectable HIF-2α stabilisation (B). 
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FIGURE 4.13. IL-1α treatment (in normoxia) stabilises HIF-1α, but not  HIF-2α in 
human articular chondrocytes.  In a timecourse experiment passaged HACs were 
cultured under normoxia for 2 days before being exposed to 10ng/ml IL-1α and lysed at 0, 
1, 3, 6, 12 and 24 hours thereafter.  A 24 hour hypoxia control was added to this 
experiment.  Consistent with previous experiments IL-1α stimulation resulted in HIF-1α 
stabilisation peaking at 6 hours.  This peak in HIF-1α levels was higher than that achieved 
after 24 hours in hypoxia (last lane) (A).   In contrast, unlike hypoxia treatment, IL-1α 
stimulation in HACs cultured under normoxia did not result in HIF-2α stabilisation (B). 
 
Chapter 4                          Hypoxia is an Anti-catabolic Regulator of Human Articular Cartilage 
 
 
 
138 
 
 
 
 
 
  
FIGURE 4.14. IL-1α stimulation increases HIF-1α mRNA levels in human articular 
chondrocytes.  In a timecourse experiment passaged (P2-P3) HACs were cultured under 
normoxia for 2 days before being exposed to 10ng/ml IL-1α and lysed at 0, 1, 3, 6, 12 and 
24 hours thereafter.  TaqMan PCR data showing relative levels of mRNA for HIF-1α over 
the timecourse.  All values were normalised using housekeeping gene RPLP0 and represent 
mean and SEM results of 3 independent experiments (i.e., cells from 3 different donors).    
IL-1α stimulation in HACs increased HIF-1α steady state mRNA levels over the 24 hour 
period. Note: ns – not significant; **P <0.01; ***P < 0.001. 
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FIGURE 4.15. IL-1α treatment has no effect on HIF-2α mRNA steady state levels in 
human articular chondrocytes.  In a timecourse experiment passaged (P2-P3) HACs 
were cultured under normoxia for 2 days before being exposed to 10ng/ml IL-1α and 
lysed at 0, 1, 3, 6, 12 and 24 hours thereafter.  TaqMan PCR data showing relative levels 
of mRNA for HIF-2α over the timecourse.  All values were normalised using those 
obtained from the RPLP0 housekeeping gene and represent mean and SEM results of 3 
independent experiments (i.e., cells from 3 different donors). Note: ns, not significant.    
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In order to further probe how HIF-1α might be regulated by IL-1α we monitored 
levels of HIF-targeting PHD2 protein (Fig. 4.16), which we previously identified as the 
dominant regulator of HIF-α isoforms in HACs.  IL-1α stimulation of HACs had no effect on 
the levels of PHD2 protein and although we haven’t directly assessed PHD activity it seems 
likely that an alternative mechanism of HIF-1α stablisiation independent of the PHDs is 
responsible for the IL-1α response. Since there was a difference in the steady state mRNA 
levels of HIF-1α in response to IL-1α there may be transcriptional or  mRNA stability 
regulation of HIF-1α by IL-1α.  
 
It has been previously demonstrated in mouse macrophages that the p38 MAP kinase 
pathway regulates mRNA stability via both the expression and post-translational modification 
of Tristetraporolin (TTP) (Mahtani et al., 2001).  TTP is a well known regulator of 
adenosine/uridine-rich element (ARE) containing mRNAs and controls target gene stability 
by binding to the 3’-untranslated region (3’-UTR) containing ARE motifs and recruiting 
factors that mediate decapping, deadenylations and mRNA destruction.  Importantly, TTP is 
in an active dephosporylated state in unstimulated HAC.  However, in response to IL-1α 
stimulation TTP is phosphorylated and inactivated (serines 52 and 178) through the p38 
pathway and MAPK-activated protein kinase 2 (MK2) allowing the accumulation of ARE-
containing mRNAs. 
  
In order to further investigate these findings HACs from a range of patients were pre-
incubated with either p38 MAP kinase inhibitor SB202190 or vehicle (DMSO) 1 hour before 
being exposed to 10ng/ml IL-1α and lysed after 6 hours.  IL-1α stimulation upregulates HIF-
1α mRNA 2.41 fold (Fig. 4.17 A), this value is consistent with levels from earlier timepoint 
experiments (Fig. 4.15) and HIF-1α stabilisation is detectable at the protein level.  Treatment 
with 2µM SB202190 inhibits IL-1α induced increase in HIF-1α gene expression and reduces 
HIF-1α stabilisation at the protein level (although does not totally abolish it) (Fig. 4.17 A and 
B).  This data suggests that the activation of the p38 pathway is necessary for the stabilisation 
of HIF-1α, however because we did not check the stability of HIF-1α mRNA we cannot 
confirm that this effect is mediated by TTP inactivation and promoting HIF-1α mRNA 
stability and not p38 MAP kinase directly/indirectly increasing HIF-1α transcription.  
 
This implications of these findings will be further discussed in the subsequent section. 
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FIGURE 4.16. IL-1α stimulation does not alter protein levels of PHD2, the 
dominant HIF-α regulator in human articular cartilage.  In a timecourse 
experiment passaged (P1-P2) HACs from 2 donors were cultured in 20% oxygen 
for 2 days before being exposed to 10ng/ml IL-1α and lysed at 0, 1, 3, 6, 12 and 24 
hours thereafter.  Western blotting was performed to study PHD2 protein levels 
and there appears to be no significant affect on PHD2 levels in response to IL-1α. 
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FIGURE 4.17. IL-1α induced increase in HIF-1α mRNA and protein levels are 
partially p38 MAP kinase dependent.  Passaged (P2) HACs from 4 different donors 
were pre-incubated with either 2µM p38 MAP kinase inhibitor SB202190 or vehicle (0.1% 
DMSO) 1 hour before being exposed to 10ng/ml IL-1α and lysed after 6 hours.  TaqMan 
PCR data showing relative levels of mRNA for HIF-1α 6 hours after IL-1α treatment (A).  
Preincubation with 2µM SB202190 partially  inhibits the IL-1α induced increase in HIF-
1α expression.  This was confirmed at the protein level by western blotting (B). Note: ***P 
< 0.001. 
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4.7  Discussion 
 
We have identified PHD2 as the key hydroxylase in HACs responsible for regulating 
HIF-1α and HIF-2α.  We have shown that specific inhibition of PHD2 promotes the 
differentiated phenotype and enhances cartilage matrix production by HACs both in 
normoxia and hypoxia.   
 
Here we report the benefit of hypoxia, namely the stabilisation of HIF-α isoforms 
inhibits IL-1α induced aggrecan cleavage in human cartilage explants.  Furthermore, hypoxia 
suppresses the endogenous release of aggrecan fragments in unstimulated cartilage 
suggesting that hypoxia has an anti-catabolic effect in cartilage is able to reduce matrix 
degradation.  In order to investigate the anticatabolic effect we monitored expression of a 
number of genes and found that the stabilisation of HIF-α isoforms in human articular 
cartilage explants has an anti-catabolic effect downregulating mRNA expression of several 
catabolic proteases associated with cartilage matrix degradation and upregulating anti-
catabolic inhibitor tissue inhibitor of metalloproteinases 3 (TIMP3).  This result in human 
tissue (cartilage explants) was replicated in HACs (monlayer cultures) and using an RNAi 
approach we provide clear evidence that hypoxia and specifically the stabilisation HIF-1α 
(not HIF-2α) has an anti-catabolic effect in human articular cartilage.  Furthermore, we show 
that depletion of PHD2 enhances this anti-catabolic effect in both normoxia and hypoxia.  
Finally, stimulation with IL-1α stabilises HIF-1α but decreases HIF-2α in HACs.  Data 
suggests that this may be partly mediated at the transcriptional level and would seem to 
represent a different mechanism than hypoxia of HIF regulation. 
4.7.1  Hypoxia has an anti-catabolic effect and this is enhanced by PHD2 
depletion  
 
 Proinflammatory cytokine interleukin 1 (IL-1) has been shown to upregulate catabolic 
enzymes (MMPs and ADAMTSs), increase inducible nitric oxide synthase (iNOS) 
expression and suppress the synthesis of aggrecan and type II collagen in chondrocytes 
(Bocquet et al., 1986; Kobayashi et al., 2005; Pasternak et al., 1986).  The stimulation of 
cartilage explants with IL-1 induces the rapid depletion of proteoglycans in cartilage explant 
cultures and is chondrocyte dependent (Flannery et al., 1999; Gebauer et al., 2005; 
Saklatvala, 1987; Vincenti and Brinckerhoff, 2002).  Here we report that although there was 
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some variability between patients, human cartilage explants exposed to hypoxia are more 
resistant to IL-1α induced aggrecan cleavage than normoxic controls providing evidence of 
the anti-catabolic and chondroprotective effect of hypoxia.  The anti-catabolic effect of 
hypoxia in response to IL-1α stimulus is striking, however, IL-1 is mainly produced by 
macrophages and although it has been reported that chondrocytes have the capacity to 
synthesis IL-1 it remains controversial whether it can be produced in amounts necessary for 
pathogenesis (Gruber et al., 2004).   
 
The addition of IL-1α is a harsh inflammatory stimulus used to trigger aggrecan 
release and whilst a useful experimental tool it may not be an accurate representation of the 
physiological environment in cartilage.  Therefore unstimulated cartilage was also cultured 
overnight in either 20% oxygen or 1% oxygen in order to provide data that could more easily 
by extended to healthy human articular cartilage.  Assuming that chondrocytes experience 
physiological oxygen tensions ~6-1% oxygen, 1% oxygen would be representative of the 
microenvironment at the core of the of the tissue.  Here we report that hypoxia suppresses the 
release of endogenous aggrecan fragments in unstimulated cartilage suggesting that hypoxia 
has an anti-catabolic effect in cartilage is able to reduce matrix degradation even in normal 
(unstimulated) tissue.  It is also possible to suggest that supra-physiological, (20% oxygen), 
conditions has a catabolic effect on cartilage explants increasing the rate of cartilage 
degradation.  Unlike bone, which undergoes perpetual remodelling, articular cartilage is 
believed to have a very low rate of matrix turnover.  Our work is consistent with this finding 
as there are very low levels of aggrecan ARGSV neoepitope release in unstimulated 1% 
oxygen (physiological levels). 
 
We suggest that this anti-catabolic hypoxic effect on human cartilage may be 
mediated by the downregulation of key catabolic enzymes responsible for matrix turnover 
(ADAMTS5 and MMP13) and the upregulation of the metalloproteinase inhibitor TIMP3.  
As we have previously demonstrated in our previous chapter (Chapter 3), the beneficial 
effects of HIF-α stabilisation in chondrocytes can be enhanced above physiological maximum 
levels (1% oxygen).  This will be further discussed below. 
 
The ADAMTS’s (A Disintegrin And Metalloproteinase with Thrombospondin 
Motifs) are a family of 19 metalloproteinases with sequence homology to ADAM protease 
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but which lack the transmembrane domain, having at least one thrombospondin type 1 
sequence motif (TSR) familiar with extracellular matrix proteins.  MMP and ADAMTS 
generated neoepitope aggrecan fragments have been identified in culture media of cartilage 
explants in vitro as well as human osteoarthritic synovial fluid suggesting elevated 
aggrecanase/MMP levels or activity in vivo (Fosang et al., 1996; Lark et al., 1997; Little et 
al., 2002; Lohmander et al., 1993; Sandy et al., 1992; Sandy and Verscharen, 2001).  Little 
and colleagues generated a line of aggrecan knockin mice with a mutation between the G1 
and G2 globular domains, this mutation rendered aggrecan resistant to aggrecanase activity.  
It was reported that knockin mutation significantly inhibited proteoglycan loss, diminished 
cartilage degradation and promoted cartilage repair (Little et al., 2007).  Adamts5 knockout 
mice are significantly resistant to IL-1α + retinoic acid induced aggrecan cleavage as well as 
surgically induced cartilage destruction, compared with wild-type mice (Glasson et al., 2005).  
Adamts5 knockout mice are significantly resistant to IL-1α + retinoic acid induced aggrecan 
cleavage as well as surgically induced cartilage destruction, compared with wild-type mice 
(Glasson et al., 2005).  Resistance to the progression of osteoarthritis was not reported in 
Adamts4 knockout mice after surgical induction of joint instability and therefore Adamts5 is 
believed to be the main aggrecanase in mouse (Glasson et al., 2004).  However Song and 
colleagues demonstrated that the depletion of either ADAMTS5 or ADAMTS4 using siRNA 
in human cartilage explants inhibits proteoglycan release when explants were stimulated with 
tumour necrosis factor α (TNF-α) and oncostatin M (OSM).  This suggests that despite the 
dominant role of Adamts5 in mouse both ADAMTS4 and ADAMTS5 may contribute 
towards cartilage destruction in human osteoarthritis (Song et al., 2007).  
 
MMP13 is a matrix metalloproteinase thought to play a critical role in cartilage 
destruction.  MMP13 is more active against type II collagen than other collagenases and 
chondrocytes’ expression of MMP13 mRNA is increased in late-stage human osteoarthritis 
(OA) cartilage in association with cartilage erosion (Aigner et al., 2001; Minond et al., 2006).  
It has been previously suggested that one of the earliest events associated with OA is the loss 
of aggrecan core protein from the cartilage extracellular matrix and this is a prerequisite for 
the subsequent proteolysis of collagen fibres.  Because chondrocytes continuously 
resynthesise aggrecan, this first step is potentially reversible.  The second step is considered 
permanent because, despite repair attempts, the original fibrous collagen network cannot be 
restored (Mankin and Lippiello, 1970; Mort and Billington, 2001).  Neuhold and colleagues 
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used a tetacyclin-induced cartilage specific promoter to constitutively overexpress active 
human MMP13 in hyaline cartilage of transgenic mice.  Overexpression resulted in focal OA 
cartilage pathology at load bearing sites similar to human OA including proteoglycan and 
type II collagen degradation (Neuhold et al., 2001).  Little and colleagues demonstrated that 
the cartilage of Mmp13-/- mice is protected from structural cartilage damage in a surgically 
induced model of OA, however there was no significant reduction in aggrecanolysis, 
osteophyte development or chondrocyte hypertrophy (Little et al., 2009).  MMP13-/- mice 
were able to inhibit cartilage degradation in the presence of aggrecan loss, this may suggest 
that aggrecan depletion on its own does not drive cartilage degradation.   
 
In summary, ADAMTS5 and MMP13 are catabolic enzymes clearly associated with 
cartilage destruction and potentially key to the chronic disease of osteoarthritis in humans.  
 
Four TIMPs have been identified (TIMP1, 2, 3, 4), they are synthesised by 
chondrocytes and are endogenous inhibitors of MMP and to a lesser extent ADAMTS 
activity.  TIMP1, 2, 3 and 4 all broadly inhibit all MMPs, with different effectiveness (Baker 
et al., 2002).  TIMP3 has been reported to inhibit all MMPs, in addition to ADAM-17, 
ADAMTS4 and ADAMTS5.  The Ki of TIMP3 for ADAMTS4 and ADAMTS5 is in the 
subnanomolar range (Hashimoto et al., 2001; Kashiwagi et al., 2001).  In addition TIMP3 is 
able to bind to polyanionic matrix components allowing for localisation in the cartilage 
extracellular matrix.  It has been reported that TIMP3 inhibits aggrecanse activity in vitro 
when added exogenously to IL-1α or retinoic acid stimulated bovine and porcine cartilage 
explants suppressing aggrecan neoepitope release (Gendron et al., 2003).  Finally, Timp3-/- 
mice have increased proteinase activity and spontaneously development cartilage degradation 
illustrating the important role of TIMP3 in regulating extracellular matrix homeostatis 
(Sahebjam et al., 2007).  
 
In the present study we reported that hypoxia inhibits aggrecan cleavage in IL-1α 
stimulated and unstimulated human cartilage explants.  In order to further investigate this 
mechanism we analysed the gene expression of a number of catabolic and anti-catabolic 
genes.  Hypoxia was found to significantly downregulate key catabolic genes ADAMTS5 and 
MMP13 at the mRNA level in cartilage explants and isolated HACs.  
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This downregulation could be further enhanced by PHD2 depletion in HACs, which 
stabilises both HIF-1α and HIF-2α above hypoxic levels.  The knockdown of PHD2 at 20% 
and 1% oxygen tension in HACs decreased ADAMTS5 expression 2.5 fold and 3.22 fold 
respectively and MMP13 2.0 fold and 3.22 fold respectively (compared to control levels in 
normoxia) and this pattern of downregulation corresponded with the pattern HIF-α isoforms 
stabilisation.  Crucially, here we demonstrate that similar to the anabolic effect reported in 
Chapter 3, PHD2 displays significant activity even at 1% oxygen and the depletion of PHD2 
under hypoxic conditions decreases levels of key proteases ADAMTS5 and MMP13 
compared with hypoxic controls.  Assuming 1% oxygen mimics the physiological 
microenvironment chondrocytes experience at the core of healthy human articular cartilage, 
the inhibition of PHD2 is able to enhance anti-catabolic effects beyond endogenous levels.  
This offers exciting opportunities of manipulating the endogenous oxygen sensing pathways 
and inhibiting cartilage matrix degradation. 
 
TIMP3 mRNA was upregulated in response to hypoxia and this hypoxic induction 
was confirmed at the protein level.  PHD2 knockdown at 20% and 1% in HACs upregulated 
TIMP3 1.5 fold and 2.7 fold respectively (compared to control levels in normoxia) however 
these upward trends were found to be not statistically significant.   
 
We did not confirm the downregulation of ADAMTS5 and MMP13 at the protein level 
because we did not have access to suitable antibodies.  It is possible to suggest that 
ADAMTS5 and MMP13 mRNA levels do not necessarily correspond with secreted protein 
levels, however results of the aggrecan neoepitope assay suggest a downregulation of these 
key catabolic enzymes in response to hypoxia.  In summary, hypoxia downregulates catabolic 
genes ADAMTS5 and MMP13 and increases expression of catabolic regulator TIMP3, this 
may suggest that the HIF-pathway is anti-catabolic in human cartilage and HACs.  This 
hypoxic downregulation of key catabolic gene MMP13 can be further enhanced at the mRNA 
level by PHD2 enzyme depletion representing a further benefit of PHD2-specific inhibition 
with regard to the repair of cartilage matrix. 
 
Interestingly, HIF-1α depletion under hypoxic conditions reverses MMP13 mRNA 
downregulation to levels exceeding normoxia.  This would suggest that even under normoxic 
conditions there are low levels of HIF-1α protein present in HACs, and indeed HIF-1α was 
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detectable in 20% oxygen, albeit at much lower levels than hypoxia (Fig 4.3).  Our results 
suggest that these low levels of stabilised HIF-1α have an anti-catabolic effect 
downregulating MMP13 mRNA.  This is interesting and unexpected finding, since HIF-α 
isoforms are thought to be completed degraded under normoxic conditions.  In has been 
previously demonstrated  in vitro using recombinant PHD that PHD1/2/3 have essentially 
identical Km values for oxygen, approximately 25% O2, suggesting that the PHD enzymes are 
fully active in 20% oxygen (Hirsila et al., 2003).  Perhaps the PHD enzymes are not 100% 
efficient at hydroxylating HIF-1α in 20% oxygen or maybe there are other factors present 
helping to stabilise HIF-1α in cartilage.  In order to confirm this we intend to carry out further 
work depleting HIF-1α and HIF-2α in HACs under normoxic conditions and measuring 
MMP13 mRNA using real-time PCR.  MMP13 mRNA hypoxic downregulation was found to 
be HIF-1α, and not HIF-2α dependent.   
 
In contrast to MMP13, ADAMTS5 mRNA hypoxic downregulation could not be 
reversed by HIF-1α or HIF-2α depletion suggesting a hypoxia-dependent but HIF1/2α-
independent mechanism.  This is very interesting in the context of our PHD2 depletion data 
and suggests that PHD2 is able to regulate ADAMTS5 through an indirect and unknown 
mechanism.  One possible explanation is that PHD2 hydroxylates or interacts with a non-HIF 
target responsible for the regulation of ADAMTS5 mRNA expression.  PHD2 ability to 
interact with non-HIF targets has been previously hypothesised as Phd2-/- mice have severe 
heart defects without the accumulation of either HIF-1α and HIF-2α isoforms in heart tissue. 
 
TIMP3, a main regulator of a broad spectrum of MMPs as well as ADAM-17, 
ADAMTS4 and ADAMTS5 was upregulated at the mRNA and protein level in response to 
hypoxia and this was also found to HIF-1α dependent, but not HIF-2α dependent. 
 
Two recent publications in Nature Medicine have suggested that HIF-2α is a 
transactivator of many catabolic enzymes and have implicated it in a mouse model of 
osteoarthritis (Saito et al., 2010; Yang et al., 2010).   
 
Saito and colleagues initially performed a screen of transcription factors that regulate 
the expression of type X collagen in chondrocytes (COL10A).  COL10A1 is a marker of 
chondrocyte hypertrophy.  HIF-2α was reported to be a strong transactivator of the COL10A1 
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promoter, and later identified to regulate expression of vascular endothelial growth factor 
(VEGFA) and matrix metalloproteinase-13 (MMP-13) in a mouse chondrogenic cell line 
(ATDC5) and human nonchondrogenic (HeLa) cells.  A HRE was identified in the COL10A1 
promoter via consensus sequence and HIF-2α was shown to bind to the region via 
electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP).  
Catabolic factors MMP3, MMP9 as well as markers for endochondral ossification associated 
runt-related transcription factor-2 (RUNX2), Indian hedgehog (IHH) and parathyroid 
hormone 1 receptor (PTH1R) were also identified as possible transcriptional targets of HIF-
2α.  This work was supported by in vivo evidence as genetic deletion of one HIF-2α allele 
(Epas1+/-) resulted in mice which were more resistant to cartilage degradation and osteophyte 
formation than their wildtype littermates following surgical induction of osteoarthritis.  
Consistent with work in cell lines, expression of Col10a1, Vegf and Mmp13 was noticeably 
suppressed in Epas1+/- mice compared to wildtype littermates.  HIF-2α protein levels were 
reported to be higher in human osteoarthritic cartilage versus non-diseased cartilage and a 
functional single nucleotide polymorphism (rs17039192) in human HIF-2α gene was 
associated with knee osteoarthritis in a Japanese population. 
 
Complimentary to Saito et al. Yang and colleagues found that the overexpression of 
HIF-2α (using Epas1 overexpression adenovirus) enhanced expression of catabolic factors  
Mmp1, Mmp3, Mmp9, Mmp12, Mmp13, Adamts4, Nos2 and Ptgs2 in mouse articular 
chondrocytes and these levels were suppressed when HIF-2α was depleted using siRNA.  
Both Epas1-transgenic mice (under promoter and enhancer regions of Col2a1 gene) and the 
overexpression of HIF-2α in wildtype mouse knee joints via intra-articular injection of Ad-
Epas1 resulted in joint tissue destruction.  Consistent with Saito and colleagues genetic 
deletion of one HIF-2α allele (Epas1+/-) conferred more resistance to cartilage destruction 
than wildtype littermates following surgical induction of osteoarthritis or collagenase 
injection into knee joints.  Similar to Saito and colleagues, HIF-2α protein levels were 
reported higher in human osteoarthritic damaged cartilage regions versus non-damaged 
regions.   
 
 Both publications use the DMM (destabilised medial meniscus) osteoarthritis mouse 
model which has a strong inflammatory component.  Furthermore, intra-articular injection of 
Ad-Epas1 in wildtype mouse knee joints causes complete joint destruction and clear 
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synovitis.  Episodically inflammation of the synovial membrane has been reported in 
osteoarthritis in humans however it is debatable whether levels of inflammation this intense 
can be considered true osteoarthritis. 
 
Saito and colleagues reported that a functional single nucleotide polymorphism (SNP) 
(rs17039192) in human HIF-2α gene (EPAS1) was associated with knee osteoarthritis in a 
Japanese population.  However, a recent large genetic study using ~7000 subjects from four 
independent populations (Japanese, Chinese, European and Australian) further investigated 
the associating between the HIF-2α SNP and knee osteoarthritis.  Replication of the work 
using a larger sample size found no statistical significant association between mutations in 
the HIF-2α (EPAS1 gene) and human knee osteoarthritis (Nakajima et al., 2011). 
 
Gelse and colleagues carried out a study injecting the joints of BALB/C mice with 2-
Methoxestradiol (2ME2).  2ME2 has been shown to decrease levels of HIF-α isoforms in 
chondrocytes through an unknown mechanism of inhibition.  Injection of 2ME2 led to 
osteophyte formation and progressive joint destruction compared to controls, without an 
accompanying inflammatory response. Immunohistochemistry revealed a decrease in 
intracellular HIF-1α levels (and presumably HIF-2α levels) resulting in increased apoptosis 
of articular chondrocytes (Gelse et al., 2008).  This suggests that HIF-α isoforms in mouse 
articular cartilage are essential for maintaining cartilage function, at least through prevention 
of cell death. 
 
Here we demonstrate that in contrast to two recent publications in Nature Medicine 
the stabilisation of HIF-1α and HIF-2α (using hypoxia) in human explants and HACs does 
not increase the expression of catabolic genes:  mRNA expression of MMP1, ADAMTS4 and 
COL10A1 (a marker of chondrocyte hypertrophy and endochondroal ossification) are 
unaffected by HIF-α isoform stabilisation.  Infact HIF-α isoform stabilisation using either 
hypoxia or PHD2 knockdown downregulated the expression of ADAMTS5 and MMP13 at the 
mRNA level in human cartilage explants and HACs.  Furthermore the stabilisation of HIF-α 
isoforms upregulates metalloproteinase inhibitor TIMP3. 
 
Consistent with work carried out by Yang et al., we report that HIF-α isoform 
stabilisation in human articular chondrocytes increases mRNA expression of MMP3 at the 
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mRNA level.  MMP3 mRNA was increased 4.5 fold in human cartilage explants in response 
to hypoxia.  Similarly MMP3 mRNA was upregulated 1.67 fold by hypoxia in HACs 
although this was not found to be significant.  Matrix metalloproteinase-3 (MMP-3) or 
Stromelysin-1 is a key member of the MMP family and has a broad substrate specificity 
including proteoglycans, gelatine, laminin, vitronectin, fibronectin and type IV collagen.  
MMP3 mRNA levels are reported to be strongly upregulated in early degenerated human 
articular cartilage relative to healthy articular cartilage but then decreased in late stage OA 
(Aigner et al., 2003; Bau et al., 2002).  Furthermore, it is believed to control the activation of 
proMMP zymogens, for example:  MMP3 activates proMMP1 and proMMP13 (Knauper et 
al., 2002; Visse and Nagase, 2003).  It is associated with growth plate dissolution in rats with 
collagen-induced arthritis (Takahi et al., 2002).  ~250 fold upregulation of MMP-3 mRNA 
and ~40 upregulation of ADAMTS5 mRNA was reported in bovine cartilage explants after 
application of a single injurious compression (Jeffrey et al., 1997).  It is difficult to explain 
why hypoxia may have two simultaneous opposing catabolic (upregulating MMP3) and anti-
catabolic (downregulation ADAMTS5/MMP13, upregulating TIMP3) effects.  However, 
aggrecan neoepitope experiments reveal that overall treatment with hypoxia in porcine 
cartilage has an anti-catabolic effect with regard to endogenous matrix degradation (Fig. 4.1). 
 
 A recent publication by Ströbel and colleagues observed that in HACs the expression 
of MMP1 and MMP13 was reduced at the mRNA and protein level in response to low 
oxygen tension (5%) (Strobel et al., 2010).  This hypoxia induced downregulation of MMP13 
is consistent with the findings of the present study.  MMP2 protein levels were also slightly 
reduced by hypoxia but this was not significant.  MMP3 levels were not investigated.  Further 
investigations using immunohistochemistry and scanning electronmicroscopy revealed that 
hypoxia significantly reduced the amount type II collagen C-telopeptide fragments released, 
increased collagen fibril length and reduced collagen fibrillation.  When cadmium chloride (a 
HIF-α inhibitor) was added to HACs under hypoxic conditions the hypoxia induced 
downregulation was abrogated confirming the involvement of the HIF-pathway in this anti-
catabolic effect (Strobel et al., 2010).  Norman and colleagues report similar findings but in 
human renal fibroblasts.  Fibroblasts cultured under hypoxic conditions downregulate MMP1 
mRNA levels and upregulate TIMP1 and TIMP3 leading to decreased extracellular matrix 
turnover (Norman et al., 2000). 
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In order to explain the species differences between human and mouse it is necessary 
to consider if HIF-2α is detectable in normal undamaged human and mouse articular 
cartilage.  Both publications in Nature Medicine report elevated levels of HIF-2α protein 
levels in human osteoarthritic cartilage versus non-diseased cartilage.  Neither paper 
considers HIF-1α stabilisation.  Immunohistochemisry of human articular cartilage confirms 
the presence of HIF-1α and HIF-2α protein (Bohensky et al., 2009; Coimbra et al., 2004; 
Yudoh et al., 2005).  Levels of HIF-1α stabilisation correspond with logical pattern of oxygen 
gradient, increasing in intensity away from the surface of the tissue (Brucker et al., 2005).  
Yudoh and colleagues investigated human articular cartilage of osteoarthritis (OA) patients 
and reported high expression of HIF-1α in degenerated regions compared with 
macroscopically intact regions.  Inflammatory signals (IL-1β, TNF-α) in human chondrocytes 
and mechanical stress (overloading) in bovine cartilage discs have been shown to stabilise 
HIF-1α (Coimbra et al., 2004; Pufe et al., 2001; Yudoh et al., 2005).  It has been suggested 
that HIF-1α is anti-apoptotic and protects articular chondrocytes from cell death induced by 
catabolic stress (Yudoh et al., 2005).  Conversely, Bonhensky and colleagues reported that 
osteoarthritis decreases levels of detectable HIF-2α in human articular cartilage.  The 
decrease in HIF-2α was linked with increased cell death in chondrocytes and it was proposed 
that HIF-2α modules is a modulator of autophagy and protects cells from apopotsis 
(Bohensky et al., 2009).  However, as previously demonstrated in the previous Chapter HIF-α 
isoforms have a very short half life under normoxic conditions (20% oxygen) and therefore it 
is challenging to process and fix tissue samples as small differences in processing time can 
influence HIF-α isoforms stabilisation.    
 
We have previously shown that in HACs hypoxia upregulates key extracellular matrix 
genes via SOX9 and this is dependent upon HIF-2α suggesting an anabolic and not catabolic 
role of HIF-2α in human articular cartilage (Lafont et al., 2007).  This again is in contrast to 
recent work by Saito et al., and Yang et al., who reported elevated levels of HIF-2α in 
cartilage of experimentally induced osteoarthritis in mice and osteoarthritic cartilage in 
humans.   
 
Yang and colleagues report that an absence of detectable HIF-2α protein in 
undamaged articular cartilage of CBA/CaCrl and C57BL/6 mice.  Saito et al., report very 
faintly detectable levels of HIF-2α protein in undamaged articular cartilage of C56BL/6 mice.  
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Human cartilage in the major joints is several millimetres thick (2.26mm) whilst mouse 
cartilage is only a few cell layers thick (0.058mm) (1971, Stockwell).  It is logical to assume 
that human articular cartilage has a much lower oxygen tension and chondrocytes within the 
tissue are exposed to more sever chronic hypoxia than in mouse.  The absence of a persistent 
hypoxic signal in mouse cartilage and the absence of permanent HIF-1α and HIF-2α isoform 
stabilisation may be the cause of species differences.  Perhaps humans adapted this 
permanent HIF-2α and HIF-1α stabilisation as a signal to promote the chondrocyte 
phenotype, enhance matrix deposition and suppress matrix turnover whereas mouse has 
adapted HIF-2α as a catabolic factor which may actually be responsible for promoting 
osteoarthritis. 
 
In summary, there are two mechanisms of chondroprotection: upregulation of 
anabolism and suppression of catabolism.  Having previously discussed the anabolic benefits 
of hypoxia here we report that hypoxia and namely the stabilisation of HIF-α isoforms 
inhibits aggrecan degradation in IL-1α stimulated and unstimulated human cartilage explants 
suggesting that hypoxia has an anti-catabolic effect in human cartilage explants is able to 
repress matrix degradation.  We believe that the use of unstimulated healthy human cartilage 
explants may give our data high clinical relevance and means that it can be easily 
extrapolated to endogenous human articular cartilage.  Further investigation in human tissue 
(cartilage explants) and HACs suggested that the observed anti-catabolic effects may be 
mediated by the downregulation of key proteases responsible for matrix turnover 
(ADAMTS5 and MMP13) and the upregulation of the metalloproteinase inhibitor TIMP3.  
Moreover, we provide clear evidence that hypoxia and specifically the stabilisation HIF-1α 
(not HIF-2α) has an anti-catabolic effect in human articular cartilage.  It is interesting that the 
two mechanisms of hypoxia-induced chondroprotection are each mediated by a different 
HIF-α isoform: anabolism, by HIF-2α and anti-catabolism, by HIF-1α. 
 
Finally, using an RNAi approach we show that depletion of PHD2 enhances this anti-
catabolic effect in both normoxia and hypoxia.  Assuming 1% oxygen mimics the 
physiological microenvironment chondrocytes experience at the core of healthy human 
articular cartilage, the inhibition of PHD2 is able to significantly enhance anti-catabolic 
effects above endogenous levels.  This offers exciting opportunities of manipulating the 
chondrocyte oxygen sensing pathways and inhibiting cartilage matrix degradation above 
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endogenous: Fully turning on the HIF-pathway and doing better than nature.  The therapeutic 
applications of manipulating oxygen sensing pathways to enhance cartilage matrix synthesis, 
reduce activity of catabolic proteases and enhance chondrocytes phenotype will be further 
discussed in Chapter 6. 
4.7.2  IL-1α stimulation stabilises HIF-1α and decreases HIF-2α in human 
articular chondrocytes  
 
Proinflammatory cytokine interleukin 1 (IL-1) has two forms, α and β, both have 
similar effects on cartilage.  The stimulation of cartilage explants with IL-1 upregulates 
catabolic enzymes (MMPs and ADAMTSs) and induces the rapid depletion of proteoglycans 
in explants cultures (Flannery et al., 1999; Gebauer et al., 2005; Saklatvala, 1987; Vincenti 
and Brinckerhoff, 2002).  Yang and colleagues recently reported that the stimulation of 
primary mouse chondrocytes with IL-1β enhanced HIF-2α mRNA levels and increased 
protein stabilisation.  This IL-1β induced stabilisation was found to be NF-κB and c-Jun N-
terminal kinase (Jnk) dependent (Yang et al., 2010).  Unfortunately, the effect of IL-1β on 
HIF-1α levels was not investigated by the authors.   
 
We report that IL-1α stimulation of HACs results in an increase in HIF-1α at the 
mRNA level and HIF-1α protein stabilisation even under normoxic conditions.  Levels and 
rate of HIF-1α stabilisation varied between patients, over a timecourse HIF-1α protein levels 
peaked between 6 – 12 hours however the mRNA levels continued to increase over a 24 hour 
period of IL-1α treatment.  Here we report that 24 hours after IL-1α stimulation in normoxia 
HIF-1α levels are approximately greater than or equal with unstimulated hypoxic controls (in 
1% oxygen).  HACs cultured at 1% oxygen and stimulated with IL-1α increased levels of 
HIF-1α protein above those seen in hypoxia alone.  In contrast to Yang and colleagues (who 
used murine chondrocytes), IL-1α stimulation in HACs suppressed HIF-2α levels rather than 
increased them.    
 
Surprisingly we report that the transient burst of HIF-1α levels in response to IL-1α 
stimulation had no effect on PHD2 levels.  Electrophoretic mobility-shift assays have 
demonstrated the binding of HIF-1α to HREs upstream of PHD2 and HREs have been 
identified (using bioinformatics) 40kb upstream of PHD3 (Metzen et al., 2003; Pescador et 
al., 2005).  It is logical to assume that an increase in HIF-1α levels would also increase PHD2 
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(and PHD3) levels.  Perhaps the transient burst of HIF-1α was not sufficient to significantly 
upregulate PHD2 protein levels (PHD3 levels were not monitored). 
 
The mechanism of HIF-1α stabilisation by IL-1α remains unclear.  HACs cultured at 
1% oxygen and stimulated with IL-1α increased levels of HIF-1α protein above those seen in 
hypoxia alone suggesting an additive effect (a mechanism of stabilisation independent of 
inhibition HIF-α-proline hydroxylation).  If the stabilisation of HIF-1α by IL-1α was 
mediated by PHD-inhibition we would expect to see a decrease in PHD enzyme activity or 
abundance.  IL-1α stimulation did not affect PHD2 abundance levels (the dominant regulator 
of HIF-1α in HACs).  Moreover, IL-1α stimulation stabilises HIF-1α levels, but decreases 
HIF-2α under hypoxic conditions.  If PHD2 activity was inhibited by IL-1α stimulation we 
would expect to see both HIF-α isoforms stabilised (no HIF-1α specificity) and no a decrease 
of HIF-2α under hypoxic conditions.   
 
Perhaps IL-1α stimulation inhibited PHD1 or PHD3 activity.  However, when 
investigated using RNAi specific depletion PHD1 did not result in HIF-1α specific 
stabilisation and PHD3 did not have a detectable effect on levels of either HIF-α isoform in 
normoxia (Chapter 3).  This suggesting that PHD enzyme abundance /activity are not 
decreased by IL-1α stimulation and perhaps the mechanism of HIF-1α stabilisation is 
mediated by an HIF-1α mRNA stability / transcriptional effect. 
 
In an effort to further probe the mechanism of HIF-1α stabilisation further we carried 
out experiments using the MAPK p38 inhibitor SB202190.   These experiments suggested 
that the IL-1α induced HIF-1α stabilisation may be p38 MAP kinase dependent.  Pre-
incubation with SB202190 abolished IL-1α induced HIF-1α mRNA upregulation and 
decreased HIF-1α protein stabilisation in HACs.  The suppression of HIF-1α protein 
stabilisation in HACs was not complete and may suggest that the mechanism of HIF-1α 
stabilisation by IL-1α may not be completely p38 MAP kinase dependent.  This work would 
be consistent with previous observations, Yudoh and colleagues report IL-1β stimulation of 
HACs results in HIF-1α stimulation and this stimulation was phosphatidylinositol 3-kinase 
and p38 MAP kinase dependent (Yudoth et al., 2004).  Similarly the stimulation of healthy 
and osteoarthritic chondrocytes under normoxic conditions with [10ng/ml] TNF-α has been 
reported to stabilise HIF-1α protein (Coimbra et al., 2004).  This TNF-α induced stabilisation 
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was partially abrogated by 1 hour pre-incubation of healthy and osteoarthritic chondrocytes 
with p38 MAP kinase inhibitor (SB203580) or NF-κB inhibitor pyrrolidine dithiocarbamate 
(PDTC) and it was concluded that TNF-α induced HIF-1α stabilisation was partially 
dependent on the p38 MAP kinase and NF-κB signalling pathways (Coimbra et al., 2004). 
 
Adenosine/uridine-rich elements (ARE’s) are common RNA stability determinants 
found in the 3’- untranslated region (3’- UTR) of mRNAs characterised by rapid, transient 
gene expression for example, cytokines, growth factors and proto-oncogenes (Lai et al., 1999; 
Sawaoka et al., 2003).  Tristetraporolin (TTP) is a well known regulator of ARE-containing 
mRNAs and controls target gene stability by binding to the 3’-UTR-containing ARE motifs 
and recruiting factors that mediate decapping, deadenylations and mRNA destruction.  It has 
been previously demonstrated in mouse macrophages that the p38 pathway regulates both the 
expression and post-translational modification of TTP (Mahtani et al., 2001).  Kim and 
colleagues recently identified 8 putative TTP-binding motifs in HIF-1α 3’-UTR, 
demonstrated that TTP binds directly to HIF-1α 3’-UTR mRNA and that the overexpression 
of TTP, reduced not just HIF-1α steady state levels, but also reduced HIF-1α protein 
stabilisation in 1% oxygen (Kim et al., 2010).  It may be that IL-1α acts through the p38 
pathway, phosphorylating TTP by MAPK-activated protein kinase 2 (MK2), inhibiting its 
activity and preventing the mRNA-destabilising function of TTP leading to accumulation of 
ARE containing mRNAs.  This would increase HIF-1α mRNA stability and potentially lead 
to greater HIF-1α protein stabilisation.  Addition of the SB202190 inhibitor would prevent 
TTP phosphorylation and lead to HIF-1α mRNA destruction.   
 
In chapter 3 we previously reported that hypoxia significantly downregulated the 
mRNA levels of HIF2α and in particular, HIF1α at the mRNA level.  Depletion of PHD2 
significantly decreases HIF1α mRNA levels even under normoxic (20% oxygen) conditions 
(Fig. 3.10 A).  Kim and colleagues reported the hypoxic induction of TTP in several cell lines 
(HEK293T, Hep3B, PLC/PRF/5 and HCT116) (Kim et al., 2010).  This seems to be 
consistent with our results.  Inhibition of PHD enzymes (either limiting molecular oxygen or 
PHD2 depletion) increases levels of TTP and therefore accelerates the rate of HIF-1α mRNA 
destruction.  In our further work we intend to confirm the hypoxic induction of TTP and its 
regulation of HIF-1α mRNA in HACs. 
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However, stabilised HIF-1α protein was detectable 3 hours after stimulation with IL-
1α, this correlated with an approximately 2.5 – 3 fold increase in mRNA levels.  If IL-1α’s 
HIF-1α stabilising ability was mediated through either increasing the rate of HIF-1α gene 
transcription or an increase in HIF-1α mRNA stability it is difficult to explain how such a 
modest increase in mRNA level is able to overcome the endogenous cellular turnover of HIF-
α isoforms in the cytoplasm under normoxic conditions.  Perhaps there is a “lag time” before 
the PHD enzymes are able to adjust to the new levels of HIF-1α protein.  It would be 
interesting to see if this “lag time” was more prolonged under hypoxic conditions. 
 
In summary, the addition of IL-1α stabilises HIF-1α even under normoxic conditions 
(albeit in a transient fashion) and IL-1α decreases HIF-2α protein levels under hypoxic 
conditions in HACs.  This is in contrast to recent work in mouse chondrocytes which reported 
that the addition of IL-1β stabilises HIF-2α (Yang et al., 2010).  The IL-1α induced 
stabilisation of HIF-1α in the present study was partially suppressed by SB202190, an 
inhibitor p38 MAP kinase and therefore believed to be partially p38 MAP kinase dependent 
and suggests a transcriptional effect.  However, the exact mechanism of stabilisation remains 
unknown.  Our data suggests that the stabilisation of HIF-1α is, at least partially p38 
dependent, however further work is needed to uncover the mechanistic details. 
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5.1  Introduction 
 
We previously identified PHD2 as the key hydroxylase in human articular 
chondrocytes (HACs) responsible for regulating HIF-1α and HIF-2α.  We have shown that 
both hypoxia and the specific inhibition of PHD2 promote the differentiated phenotype by 
upregulating SOX9, enhancing cartilage matrix production by HACs and decreasing the rate 
of matrix degradation.   
 
HIF-1α has previously been described as a critical factor for murine chondrocyte 
development and survival (Schipani et al., 2001).  Furthermore, it has been reported that 
hypoxia (specifically the stabilisation of HIF-1α) increases cartilage extracellular matrix 
synthesis in murine chondrocytes and upregulates Sox9 in mouse mesenchymal cells 
(Amarilio et al., 2007; Pfander et al., 2003).  Recently work by Zhang and colleagues 
reported that the induction of ischemic osteonecrosis in porcine femoral heads stabilised HIF-
1α, upregulated Sox9 and increased cartilage matrix deposition in epiphyseal cartilage 
(Zhang et al., 2011).  Given our previous human data we investigated whether the effect of 
PHD enzyme inhibition would have similar effects in murine and porcine cartilage. 
 
Here we report that similarly to our work with human explants, hypoxia has a pro- 
anabolic and an anti-catabolic effect in porcine cartilage.  Hypoxia inhibited aggrecan 
cleavage in unstimulated porcine cartilage explants and even suppresses aggrecan cleavage 
when explants are stimulated with proinflammatory cytokine interleukin 1α (IL-1α).  It is 
believed that this anti-catabolic effect is mediated by the hypoxic downregulation of Adamts5 
at the mRNA level and increasing secreted Timp3 levels.  In addition, we demonstrate that 
hypoxia Sox9 and Col2a1 mRNA in porcine cartilage explants suggesting that hypoxia 
promotes the chondrocyte phenotype and increases extracellular matrix deposition.  However, 
mouse articular cartilage data suggests there are key species differences in the way articular 
chondrocytes respond to hypoxia between man and mouse.  Sox9 and cartilage matrix 
expression (Col2a1 and Col11a2) are not regulated by hypoxia in murine articular cartilage 
and chondrocytes. 
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5.2  Hypoxia inhibits IL-1α induced articular aggrecan degradation in 
porcine cartilage explants 
 
In order to study the effect of hypoxia on aggrecan degradation, we stimulated porcine 
articular cartilage explants with proinflammatory cytokine interleukin 1α (IL-1α).  
Stimulation with IL-1α causes the cleavage of the aggrecan core protein by aggrecanases 
within the first interglobular domain (between G1 and G2) (Flannery et al., 1999; Gebauer et 
al., 2005; Saklatvala, 1987; Vincenti and Brinckerhoff, 2002).  Proteolysis occurs at the 
Glu373 – Ala374 bond resulting in the C-terminal neoepitope NITEGE (bound to the 
hyaluronan backbone) and the N-terminal neoepitope ARGSV.  This C-terminal aggrecan 
fragment can be detected by western blotting cartilage explant culture medium with 
antibodies which recognize the ARGSV neoepitope.  In contrast to previous work human 
articular cartilage explants (Chapter 4) in porcine explants anti-ARGSV neoepitope 
antibodies recognise a dominant >250 kDa band and a fainter 150 kDa fragment.  Release of 
ARGSV neoepitope was detected 24 hours after stimulation with IL-1α and even present in 
unstimulated cartilage. 
 
Porcine articular cartilage was taken from the 2nd-3rd metacarpophalangeal (MCP) 
joints of 3 to 6 month old (male and female) pigs.  Cartilage explants from 4 joints were cut 
into cubes (3 mm3), pre-incubated in normoxic or hypoxic conditions for 48 hours stimulated 
with either IL-1α or vehicle (serum free media) and returned to original oxygen tensions.  We 
found that similar to human cartilage explants hypoxia inhibited the release of ARGSV 
neoepitope when explants were stimulated with IL-1α (Fig 5.1).  Consistent with previous 
work in human cartilage explants the ARGSV neoepitope release was IL-1α dose dependent 
and long exposure of X-ray film revealed that hypoxia also inhibited ARGSV neoeptitope 
release in unstimulated cartilage explants (Fig. 5.1). 
 
In summary, treatment of cartilage explants with hypoxia inhibits IL-1α induced 
aggrecan cleavage in both human and porcine human cartilage explants. 
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FIGURE 5.1. Hypoxia inhibits aggrecan degradation in porcine articular cartilage explants.  
Porcine articular cartilage was taken from the 2nd-3rd metacarpophalangeal (MCP) joints of 3 to 6 
month old (male and female) pigs.  Cartilage explants from 4 joints were cut into cubes (3 mm3), 
pre-incubated in normoxic or hypoxic conditions for 48 hours before treatment with either IL-1α 
(10ng/ml or 1ng/ml) or vehicle (serum free media) and returned to original oxygen tensions.  
Aggrecan fragments containing ARGSV neoepitope were released into the medium, precipitated 
using acetone precipitation and detected via Western blotting using anti-ARGSV neoepitope 
antibodies.   
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5.3  Up-regulation of anabolic and anti-catabolic factors in porcine 
cartilage explants under hypoxic conditions  
 
Porcine articular cartilage was taken from the 2nd-3rd metacarpophalangeal (MCP) 
joints of 3 to 6 month old (male and female) pigs obtained from a local slaughterhouse within 
16 hours of slaughter.  After skinning the trotter, the MCP joint was opened in a biological 
safety cabinet.  Cartilage explants from 1 joint were dissected using aspetic technique from 
the articular surface directly into DMEM and cut into cubes (3 mm3).   
 
20 Porcine cartilage explants (~60mg wet weight) per dish were incubated for 3 days 
under normoxic (20% oxygen) or hypoxic (1% oxygen) conditions.  The messenger RNA 
(mRNA) levels of master regulator transcription factor Sox9 as well as key cartilage matrix 
proteins (Col2a1, Aggrecan), catabolic enzymes (Adamts5, Mmp13) and key proteinase 
inhibitor (Timp3) were analysed after normalising the data using the housekeeping gene 
RPLP0.     
 
Similarly to human explants, hypoxia upregulates Sox9 (1.9 fold) and Col2a1 (3.1 
fold) at the mRNA level (Fig. 5.2 A, B, C).  Aggrecan mRNA levels are increased by hypoxia 
1.53 fold but this trend was not statistically significant (Fig. 5.2 C).   
 
Adamts5 expression was downregulated (1.6 fold) in response to 1% oxygen tension 
(Fig. 5.2 D).  In contrast to human cartilage explants hypoxia increased the average mRNA 
levels of Mmp13 by 2.93 fold, however this difference was not significant (Fig.  5.2 E).  
Finally Timp3 mRNA was not significantly affected by hypoxia although clearly increased 
levels of Timp3 protein were detected in the culture medium by western blot (Fig.  5.2 F, G). 
 
In summary, consistent with human data the treatment of porcine cartilage explants 
with hypoxia increases Sox9 expression, upregulates key cartilage gene Col2a1, decreases 
aggrecanase Adamts5 and upregulates Timp3 at the protein level. 
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FIGURE 5.2.  Hypoxia upregulates cartilage specific transcription factor Sox9, main cartilage 
matrix protein type II collagen, key catabolic regulator Timp3 and downregulates aggrecanase 
Adamts5 in porcine articular cartilage explants.  TaqMan PCR data showing relative levels of 
mRNA for Sox9, Col2a1, Aggrecan, Adamts5, Mmp13 and Timp3 (A – F, respectively) after 20 porcine 
explants were cultured for 3 days in 20% or 1% oxygen.  All values were normalised using the RPLP0 
housekeeping gene and represent mean and SEM results of 3 independent experiments (i.e., explants 
from 3 different porcine trotters).  Note: ns - not significant; *P < 0.05; ***P < 0.001 (versus 20% 
oxygen).  Secreted TIMP3 (G) was detected in 1% oxygen treated explant cultures following acetone 
precipitation of culture media.  Cell culture medium was supplemented with 200µg/ml heparin in order 
to detect TIMP3. 
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5.4  No hypoxic regulation of cartilage specific transcription factor 
Sox9 in murine hip cartilage explants and isolated chondrocytes 
 
Mouse hip explants were prepared from the hips of 6-week-old male C57Bl/6 mice.  
The skin and soft tissue was removed from the hind legs.  The hip joints were dislocated and 
the proximal femoral heads isolated using aspetic technique under an anatomical microscope.  
5 femoral heads were cultured in two different oxygen tensions (20%, 1% oxygen) or treated 
with 2mM of 2-oxoglutarate analogue DMOG for 3 days.  In contrast to our previous findings 
in human and porcine cartilage explants, hypoxia did not induce Sox9 at the protein level and 
even DMOG treatment has no significant effect on Sox9 levels in murine cartilage explants 
(Fig. 5.3. A and B).  This experiment was repeated in passaged murine chondrocytes and 
consistent with femoral head data the inhibition of HIF-hydroxylases using either hypoxia or 
DMOG did not induce Sox9 expression over control conditions (20% oxygen) (Fig. 5.3. C 
and D).  These experiments suggest that in contrast to human (and porcine) cartilage Sox9 is 
not regulated by the HIF-pathway in murine articular cartilage. 
 
In order to further investigate this we isolated murine chondrocytes from the femoral 
heads of 6-week-old male C57Bl/6 mice.  Passaged murine chondrocytes were cultured under 
normoxia, hypoxia or in the presence of 2mM DMOG for 3 days.  The mRNA levels of 
master regulator transcription factor Sox9 and key cartilage matrix proteins (Col2a1, 
Col11a2), as well as known hypoxia responsive genes Phd2 and Glut1 were analysed after 
normalising the data using the housekeeping gene Rplp0 (Fig. 5.4. A to E).  In contrast to 
HACs we did not observe an induction of genes associated with the chondrocyte phenotype 
in response to hydroxylase inhibition.  Col2a1 was not upregulated in response to hypoxia 
(Fig 5.4. C).  Sox9 mRNA levels were not affected by 1% oxygen tension, this lack of SOX9 
hypoxic induction is consistent with previous work at the protein level in both mouse 
chondrocytes and mouse hip cartilage explants (Fig. 5.3).   
 
Due to the limited number of murine chondrocytes we were unable to assess 
stabilisation of HIF-α isoforms at the protein level in response to PHD enzyme inhibition.  
However, the upregulation of known hypoxia responsive gene Phd2 in response to hypoxia 
and DMOG treatment suggests a functional HIF response to hypoxia in these cells (Fig. 5.4 
A).   
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FIGURE 5.3.  No  hypoxic regulation of Sox9 protein levels in murine hip explants and 
isolated chondrocytes in response to hypoxia.  Data are based on mouse femoral hip explants 
from 6-week-old male C57Bl/6 mice after culture for 3 days at 20% oxygen, 1% oxygen or 
treated with 2-oxoglutarate analogue DMOG (5 hip explants per data point).  A and B, western 
blot showing no changes in SOX9 levels in response to either treatment.  Mouse articular 
chondrocytes (passage 2) were cultured for 3 days at 20% oxygen, 1% oxygen or treated with 
2-oxoglutarate analogue DMOG.  C and D, western blot showing change in SOX9 levels in 
response to either treatment. 
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FIGURE 5.4.  Hypoxia does not regulate cartilage specific transcription factor SOX9 or key 
cartilage matrix collagens at the mRNA level.  Mouse chondrocytes (passage 2) were cultured for 3 
days at 20% oxygen, 1% oxygen or treated with 2-oxoglutarate analogue DMOG.  TaqMan PCR data 
showing relative levels of mRNA of Phd2 (A), Glut1 (E) and key chondrocyte markers Sox9, Col2a1, 
Col11a2, (B – D, respectively) were analysed after normalising the data using Rplp0.  Key 
chondrocyte marker levels were unchanged in response to hypoxia or DMOG treatment. Note: ns - 
not significant; **P < 0.01 (versus 20% oxygen). 
Chapter 5                                                  Effects of hypoxia on Porcine and Murine Cartilage and Chondrocytes 
 
167 
 
We considered that mouse hip explants were not pure populations and may contain a 
mixture of articular, growth plate and hypertrophic chondrocytes.  Using RT-PCR we 
confirmed that the passaged chondrocytes expressed high levels of key chondrocyte markers 
Sox9, Col2a; while the marker of chondrocyte hypertrophy Col10a1 was only detectable at 
very low levels (data not shown). 
 
In summary, studies of mouse femoral hip cartilage and isolated mouse chondrocytes 
suggest that Sox9 is not regulated by the HIF-pathway at the protein or mRNA level.  This 
work is different to the data found in humans (and pigs) and possible reasons for the species 
difference will be examined in the discussion.  
 
5.5 Phd2 depletion in mouse chondrocytes does not appear to 
regulate Sox9 at the protein level  
 
In order to further investigate the role of HIF-pathway on the main markers of the 
chondrocyte phenotype, we transfected passaged mouse chondrocytes with small interfering 
RNA (siRNA) against either Phd2 (the main regulator of HIF-1α and HIF-2α in HACs) or 
Luciferase (as a non-targeting control).  Following transfection, passaged mouse 
chondrocytes were cultured for 3 days at either 20% or 1% oxygen and lysed.  Real-time 
PCR was used to confirm Phd2 knockdown, Phd2 mRNA was depleted 81% on average 
compared with luciferase control (Fig. 5.5. A).  There appeared to be no regulation of Sox9 in 
mouse chondrocytes at the protein level in response to Phd2 knockdown (Fig. 5.6).  Due to a 
limited number of cells were unable to draw any conclusions of the effect of Phd2 
knockdown on mRNA level of Sox9 and Col2a1.  Preliminary results suggest that Phd2 
depletion may increase expression known hypoxia (Fig. 5.5. B, C, D). 
 
In summary, consistent with our previous work in mouse femoral hip cartilage and 
passaged mouse chondrocytes, the specific depletion of HIF-targeting hydroxylase PHD2 has 
appears to no significant effect on Sox9 levels.  This provides further evidence that the HIF-
pathway does not regulate the chondrocyte phenotype in murine cartilage.  Possible reasons 
for these species difference will be examined in the discussion.    
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FIGURE 5.5.  Phd2 depletion in passaged mouse chondrocytes.  All data in the figure were 
obtained from passaged mouse chondrocytes (P2-P3) after 3 days in culture at either 20% or 1% 
oxygen.  Cells were transfected with 10nM against PHD2 (siPHD2), or, as a control against 
luciferase (siLuc).  TaqMan PCR data showing relative levels of mRNA for Phd2, Sox9, Col2a1, 
Glut1 (A – D, respectively) were analysed after normalising the data using the housekeeping gene 
Rplp0.  PHD2 depletion increased expression of hypoxia response gene Glut1 but did not alter 
mRNA levels of Sox9 or Col2a1. 
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FIGURE 5.6.  Sox9 protein is not regulated by Phd2 enzyme depletion in passaged 
mouse chondrocytes under 20% or 1% oxygen tension.  All data in the figure were 
obtained from passaged mouse chondrocytes (P4) after 3 days in culture at either 20% or 1% 
oxygen.  Cells were transfected with 10nM against PHD2 (siPHD2), or, as a control against 
luciferase (siLuc).  A and B, western blots showing no change in SOX9 protein levels in 
response to PHD2 enzyme depletion. 
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5.6  Discussion: 
 
We previously identified PHD2 as the key HIF-targeting hydroxylase in human 
articular chondrocytes (HACs) responsible for regulating HIF-1α and HIF-2α.  We have 
shown that hypoxia in HACs promotes the differentiated phenotype, enhances cartilage 
matrix production and decrease the rate of endogenous matrix degradation.  These effects can 
be further enhanced by specific inhibition of PHD2 in hypoxia which we demonstrated to be 
the main regulator of HIF-1α and HIF-2α in HACs.    
 
Investigating the effect of hypoxia and HIF-targeting hydroxylase inhibition in murine 
and porcine cartilage we have identified interesting species differences.  Here we report that 
hypoxia has an anabolic and an anti-catabolic effect in porcine cartilage.  The stabilisation of 
HIF-α isoforms inhibits IL-1α induced aggrecan cleavage in porcine cartilage explants.  
Furthermore, hypoxia suppresses the endogenous release of aggrecan fragments in 
unstimulated cartilage suggesting that hypoxia has an anti-catabolic effect in cartilage and is 
able to reduced matrix degradation.  In order to further investigate the similarities with 
human cartilage we monitored expression of a number of genes and found that the 
stabilisation of HIF-α isoforms in porcine cartilage explants has anabolic and anti-catabolic 
effect.  Hypoxia upregulated anabolic genes (Sox9 and Col2a1), downregulated key 
aggrecanase (Adamts5) and upregulated anti-catabolic enzyme tissue inhibitor of 
metalloproteinases 3 (Timp3).  This is similar to our previous work in human cartilage 
explants and HACs; hypoxia enhances cartilage matrix synthesis and reduces activity of 
catabolic proteases.     
 
However, murine cartilage and chondrocytes showed strikingly different results, with 
Sox9 and subsequent matrix gene expression being unaffected by hypoxia and PHD 
inhibition.  This may explain some of the previously reported discrepancies between mouse 
and human (larger animal studies) with respect to HIF regulation of cartilage function.  
5.6.1  Hypoxia in cartilage has an anabolic and anti-catabolic effect in 
porcine cartilage explants 
 
 Here we report that, similar to our work in human cartilage, hypoxia has an anti-
catabolic effect in porcine cartilage explants.  Porcine cartilage explants exposed to hypoxia 
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are more resistant to IL-1α induced aggrecan cleavage than normoxic controls providing 
evidence of the anti-catabolic and chondroprotective effect of hypoxia. 
 
Similarly to our previous work with healthy human articular cartilage (Chapter 4), 
porcine cartilage was also cultured overnight in either 20% oxygen or 1% oxygen without IL-
1α stimulation in order to more accurately mimic physiological conditions in vivo.  Assuming 
that chondrocytes experience physiological oxygen tensions of ~1-6% oxygen, 1% oxygen 
would be representative of the microenvironment at the core of the of the tissue.  Here we 
report that hypoxia suppresses the release of endogenous aggrecan fragments in unstimulated 
cartilage suggesting that hypoxia has an anti-catabolic effect in cartilage is able to reduce 
matrix degradation even in healthy unstimulated tissue.  It is also possible to suggest that 
supra-physiological, (20% oxygen), conditions have a catabolic effect on cartilage explants 
increasing the rate of cartilage degradation. 
 
In order to further investigate the similarities between human and porcine cartilage 
porcine cartilage explants were cultured for 3 days under normoxic (20% oxygen) and 
hypoxic (1% oxygen) conditions.  Hypoxia had an anabolic effect in porcine cartilage 
explants upregulating Sox9 and Col2a1 at the mRNA level.  We have previously 
demonstrated that this hypoxic upregulation in HACs was HIF-2α dependent and it would be 
interesting to determine if this hypoxic regulation was HIF-1α or HIF-2α dependent.  We also 
observed an anti-catabolic effect as hypoxia downregulated key aggrecanase Adamts5 
(responsible for aggrecan core protein cleavage) and upregulated anti-catabolic enzyme tissue 
inhibitor of metalloproteinases 3 (Timp3) (although this was not confirmed at the mRNA 
level).  This anabolic/anti-catabolic effect of hypoxia is consistent with our findings in human 
cartilage (Chapter 3 and Chapter 4).  We suggest that this anti-catabolic hypoxic effect on 
porcine cartilage may be mediated by the downregulation of key aggrecanase Adamts5 and 
the upregulation of the metalloproteinase inhibitor Timp3. 
 
However there were some differences between porcine and human cartilage explants.  
Although we observed, on average, an increase in Aggrecan mRNA levels in hypoxia (~1.5 
fold) this trend was not statistically significant.  In addition we observed greater hypoxic 
induction of Sox9 and extracellular matrix genes in human cartilage compared with porcine 
cartilage, for example:  hypoxia upregulates Sox9 (5.8 fold) and Col2a1 (29.9 fold) in human 
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cartilage vs.  Sox9 (1.9 fold) and Col2a1 (3.1 fold) in porcine cartilage.  Possible reasons for 
this species difference will be explained below (Chapter 5.5.2).  Finally, in contrast to human 
explants Mmp13 expression was increased ~2.93 fold in response to hypoxia however this 
was found to be not statistically significant.  MMP13 is a key catabolic enzyme with high 
activity against type II collagen and thought to play a critical role in cartilage destruction.  
However aggrecan-derived neoepitope assays reveal that, like for human explants, treatment 
with hypoxia in porcine cartilage has an anti-catabolic effect with regard to endogenous 
matrix turnover (Chapter 4). 
 
Recent work by Zhang and colleagues in the porcine model supports our work.  
Ischemic osteonecrosis was surgically induced in Yorkshire immature pigs aged 5 to 6 weeks 
old by applying a ligature around the femoral neck.  Gross and histological assessment of 
femoral heads revealed significantly thicker cartilage layer in pigs after two weeks of 
surgically induced ischaemia compared with control group (1200µm versus 1800µm) (Kim et 
al., 2009a; Zhang et al., 2011).  Messenger RNA was isolated from cartilage 24 hours after 
ischemic induction and consistent with our work hypoxia was found to significantly 
upregulate Sox9 (~2.3 fold), Col2a1 (~2.5 fold) and Aggrecan (~1.5 fold) at the mRNA level.  
Significant increases in HIF-1α and Sox9 levels were confirmed at the protein level in 
ischemic femoral heads via immunostaining of epiphyseal cartilage 2 weeks after the surgical 
induction of ischemia.  Zhang and colleagues concluded that HIF-1α stabilisation in porcine 
epiphyseal cartilage upregulates Sox9 levels and enhances cartilage matrix deposition; 
however they failed to investigate HIF-2α.   
 
 In summary, consistent with our previous work in human cartilage explants we report 
that hypoxia has two mechanisms of chondroprotection in porcine cartilage explants: 
anabolic / anti-catabolic effects.  Stabilisation of HIF-α isoforms increased expression of key 
cartilage master regulator transcription factor Sox9 and key cartilage matrix gene Col2a1 at 
the mRNA level.  In addition, stabilisation of HIF-α isoforms inhibits aggrecan degradation 
in IL-1α stimulated and unstimulated porcine cartilage explants suggesting that hypoxia has 
an anti-catabolic effect in porcine cartilage explants in both normal and inflammatory 
settings.  The use of unstimulated porcine cartilage explants gives our data high clinical 
relevance and gives a more accurate representation of what may be expect in vivo.  Finally, 
analysis of gene expression revealed that Aggrecanase Adamts5 was downregulated in 
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response to hypoxia and catabolic-regulator Timp3 was upregulated suggesting a possible 
mechanism by which hypoxia inhibits aggrecan degradation in porcine articular. 
5.6.2  Hypoxia and the mouse chondrocyte phenotype 
 
Here we report that inhibition of mouse HIF-targeting hydroxylase enzymes using 
hypoxia and dimethyloxaloylglycine (DMOG) did not significantly affect Sox9 expression in 
either mouse cartilage explants or isolated chondrocytes.  Key extracellular matrix protein 
Col2a1 was found to be largely unaffected by hypoxia.  DMOG induced upregulation of 
Phd2 mRNA (a hypoxia inducible gene) and this was used as a positive control of HIF-α 
isoform stabilisation.  Specific depletion of Phd2 in passaged mouse chondrocytes using 
siRNA did not appear to regulate Sox9 protein levels further supporting the lack of hypoxic 
regulation of the chondrocyte phenotype. 
 
Hif-1α-/- mice die in utero as early as E8.5 exhibiting multiple morphological defects 
demonstrating that HIF-1α is essential for embryonic development (Compernolle et al., 2003; 
Iyer et al., 1998; Ryan et al., 1998).  Similarly, HIF-β-/- mice die in utero between 9.5 and 
10.5 days gestation from primarily from defects in placenta angiogenesis (Kozak et al., 1997; 
Maltepe et al., 1997).  Schipani and colleagues demonstrated that the mouse developmental 
growth plate is hypoxic and that HIF-1α is essential for proliferation and survival of murine 
growth plate chondrocytes in vivo.  Cartilage-specific HIF-1α depletion led to cell death 
within articular and growth plate chondrocytes resulting in long bone, rib and vertebral body 
defects coupled with decreased expression of the CDK inhibitor p57 (Schipani et al., 2001).  
It was concluded that HIF-1α is essential for growth plate development and chondrocyte 
survival in response to hypoxic conditions. 
 
Scortegagna and colleagues demonstrated that  Hif-2α -/- mice survive but have 
substantially shorter lifespan, lower body weight, overt cardiac hypertrophy, mitochondrial 
dysfunction, skeletal myopathy and hepatosteatosis compared with Hif-2α +/+ providing 
evidence that while HIF-2α is not embryonic lethal, it plays an important functional role and 
is not redundant (Scortegagna et al., 2003).  Similarly, homozygous knockout of HIF-2α in 
the limb bud mesenchyme caused a modest delay in endochondral bone development at 
E17.5 (Araldi et al., 2011).   Others have shown that homozygous deficient Hif-2α-/- mice die 
at the early embryonic stage (Tian et al., 1998).  A recent publication in Nature Medicine 
Chapter 5                                                  Effects of hypoxia on Porcine and Murine Cartilage and Chondrocytes 
 
174 
 
reported that heterozygous deficient Hif-2α+/- mice grew without abnormalities of major 
organs but showed mild dwarfism compared to wild-type littermates (Saito et al., 2010).  
Heterozygous deficient Hif-2α +/- mice have a reduced limb length (8-16% shorter), increased 
hypertrophic and proliferation zones suggesting a role of Hif-2α in endochondroal 
ossification and bone growth in mouse (Saito et al., 2010). 
 
Hypoxia has been shown to increase cartilage matrix deposition in murine epiphyseal 
chondrocytes.  The deletion of the pVHL (which would stabilise both HIF-1α and HIF-2α) 
results in significantly reduced chondrocyte proliferation rate, ~1.4 fold increase in Col2a1 
mRNA expression and the presence of atypical large cells within the resting zone (Pfander et 
al., 2004b).  Pfander and colleagues also isolated and cultured epiphyseal chondrocytes from 
wild-type and Hif-1α-/- mice.  They reported that the exposure of wild-type cells to 0.5% 
oxygen increased Col2a1 protein levels ~2 fold and this hypoxic induction was lost in Hif-
1α--/- cells (Pfander et al., 2003).  Aggrecan mRNA and protein levels were unchanged upon 
exposure to hypoxia (Pfander et al., 2003). 
 
Ren and colleagues isolated mouse chondrocytes from the hips and knees of 3- or 4- 
day old C56BL/6 mice.  All mice possessed homologous loxP sites flanking the HIF-1α 
locus.  Mouse chondrocytes were exposed to hypoxic conditions and the upregulation of 
Col2a1 (~1.5 fold) and Aggrecan (~1.4 fold) observed via real-time PCR (Ren et al., 2008).  
When the chondrocytes were infected with an adenovirus containing Cre recombinase 
(creating Hif-1α-/-cells) this hypoxia induced extracellular matrix synthesis was lost.  Ren and 
colleagues concluded that the hypoxia induced cartilage matrix synthesis was HIF-1α 
dependent (Ren et al., 2008)(Ren et al., 2008). 
 
Work by Amarilio and colleagues examined the expression of tissue specific 
transcription factor Sox9 under hypoxic conditions in mouse mesenchymal cells derived from 
E11.5 Hif1α floxed mouse embryos infected with AdCre or AdGfp.  Low oxygen tensions 
increased Sox9 expression (~2 fold) in control cells and this hypoxic induction of Sox9 was 
lost in Hif-1α depleted cells.  This hypoxic induction of Sox9 was not confirmed at the 
protein level.  Conversely, the overexpression of Hif-1α induced an increase in Sox9 
expression (Amarilio et al., 2007).  Chromatin immunoprecipitation provided evidence for 
direct recruitment of HIF-1α to the Sox9 promoter (Amarilio et al., 2007).  Hypoxia 
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upregulated Col2a1 (~1.7 fold) and Aggrecan (~2.3 fold) at the mRNA level in mouse 
mesenchymal cells and this hypoxic induction is lost in Hif-1α depleted cells (Amarilio et al., 
2007). 
 
Saito and colleagues recently overexpressed HIF-2α in a mouse chondrogenic cell line 
(ATDC5 cells) treated with normoxia and found overexpression of HIF-2α significantly 
increased mRNA levels of Col2a1 (~2 fold) and Aggrecan (~2 fold).  ATDC5 cells 
transfected with siRNA against Hif-2α did not show a significance decrease in Col2a1 or 
Aggrecan mRNA levels compared to control (Saito et al., 2010).  However this is expected as 
experiments were performed under normoxic conditions HIF-2α would not be stabilised at 
20% oxygen due to hydroxylation of its proline residues by the PHD enzymes. 
 
 Although hypoxia has been shown to increase cartilage matrix deposition in murine 
chondrocytes this reported hypoxic induction is far weaker than we have reported in HACs.  
Isolated and cultured mouse chondrocytes exposed to hypoxia typically upregulate Col2a1 
mRNA 1.5 – 2 fold and these values are consistent with our murine data (~1.5 fold) 
(Amarilio et al., 2007; Pfander et al., 2003; Pfander et al., 2004b; Ren et al., 2008; Saito et 
al., 2010).  Aggrecan mRNA levels have been reported unchanged upon exposure to hypoxia 
or upregulated between 1.4 – 2.3 fold at the mRNA level (Amarilio et al., 2007; Pfander et 
al., 2003; Pfander et al., 2004b; Ren et al., 2008; Saito et al., 2010).  In contrast HACs treated 
with hypoxia upregulate Col2a1 4 - 12 fold and Aggrecan 2 – 5 fold at the mRNA level 
(Lafont et al., 2007; Murphy and Polak, 2004; Thoms and Murphy, 2010). 
 
The reasons for these differences between human and porcine cartilage on the one 
hand and mouse cartilage on the other may be due to the age of the tissue studied 
(development vs. adult) and also anatomical differences.   
 
Addressing the first point initially, many studies focus on mouse development, 
mesenchymal stem cell differentiation and limb bud formation.  As embryos grow, cells 
quickly move beyond the diffusion distance of oxygen; limb bud formation and endochondral 
ossification occur in an avascular and therefore hypoxic environment.  HIF-α isoforms are 
clearly necessary for embryonic development and Schipani and colleagues demonstrated that 
HIF-1α is essential for normal growth plate development and chondrocyte survival 
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(Compernolle et al., 2003; Iyer et al., 1998; Ryan et al., 1998).  However, is mouse adult 
cartilage hypoxic and can mouse developmental data be extrapolated to adult human articular 
cartilage? 
 
All species’ articular cartilage is avascular, however, despite this similarity there are 
key differences in joint loading, cell density and cartilage thickness.  Differences in body 
weight (72kg human, 90kg porcine and 0.025kg mouse) and stance (biped versus quadruped) 
play a significant role in joint mechanics and loading (Adams, 2006).  Murine cartilage has 
~23 fold greater cell density than human cartilage.  Finally human and porcine cartilage in the 
major joints is several millimetres thick (~2.26mm human, ~1.2mm porcine) whilst mouse 
cartilage is only a few cell layers thick (~0.058mm) (Brighton and Heppenstall, 1971; Lund-
Olesen, 1970; Stockwell, 1971; Zhang et al., 2011).   
 
One reason for species differences between cartilage in larger animals (human and 
porcine) and mouse may be cartilage thickness.  It is logical to assume that articular cartilage 
from larger animals has a much lower oxygen tension and chondrocytes within the tissue are 
exposed to more severe and chronic hypoxia than in smaller animals.  Presumably this is why 
hypoxic induction of cartilage matrix genes in human, porcine and bovine chondrocytes is 
much stronger than in mouse chondrocytes (Domm et al., 2002; Lafont et al., 2007; Murphy 
and Polak, 2004; Murphy and Sambanis, 2001; Thoms and Murphy, 2010). 
 
Immunohistochemisry of healthy human articular cartilage reports detectable levels of 
HIF-1α and HIF-2α protein (Coimbra et al., 2004; Yudoh et al., 2005).  
Immunohistochemical detection of HIF-α isoforms in human osteoarthritic cartilage suggests 
a decrease in HIF-2α and an increase in HIF-1α (Bohensky et al., 2009; Coimbra et al., 2004; 
Yudoh et al., 2005).  In contrast, Yang and colleagues report that an absence of detectable 
HIF-2α protein in undamaged articular cartilage of CBA/CaCrl and C57BL/6 mice.  Saito 
and co-workers report very faintly detectable levels of HIF-2α protein in undamaged articular 
cartilage of C56BL/6 mice.  HIF-1α detection was also reported in the undamaged articular 
cartilage of 12-week old BALB/C mice (Gelse et al., 2008). 
 
The absence of a severe chronic hypoxic signal in mouse cartilage would explain the 
lack of permanent HIF-2α isoform stabilisation.  Differences between species may be due to 
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scale.  Perhaps larger animals adapted this permanent HIF-2α isoform stabilisation as a signal 
to promote the chondrocyte phenotype and enhance matrix deposition whereas mouse did not   
 
In summary, whilst mouse articular cartilage has some similarities to human articular 
cartilage, there are key species differences in the way chondrocytes respond to hypoxia.  
Sox9 and key cartilage matrix gene Col2a1 are not regulated by hypoxia in mouse articular 
chondrocytes.  These species differences between human, porcine and mouse may be due to 
how larger animals have adapted to take advantage of the chronic hypoxic stimulus present in 
their thicker articular cartilage.  Our data suggests that the inhibition of PHD enzymes to 
promote the chondrocyte phenotype and enhance matrix deposition is of limited use in mouse 
models and future pre-clinical work should focus on larger animals (e.g., pigs, cows, sheep). 
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6.1  Summary  
 
We report that PHD2 is the dominant PHD enzyme in human articular chondrocytes 
(HACs) responsible for regulating both HIF-1α and HIF-2α.  Consistent with what we have 
previously reported in HACs (Lafont et al., 2007), hypoxia promotes an anabolic response in 
freshly isolated chondrocytes and human cartilage explants.  We also here demonstrate that 
specific depletion of HIF targeting hydroxylase PHD2 in freshly isolated and passaged HACs 
significantly upregulates the cartilage master regulator, transcription factor (SOX9) and key 
matrix genes (COL2A1, COL9A1, COL11A2, and AGGRECAN).   
 
The use of non-specific hydroxylase inhibitor dimethyloxalylglycine (DMOG) 
upregulates SOX9 expression in HACs but inhibits collagen proyl-4-hydroxylase function 
leading to suppression of type II collagen secretion.  This illustrates the importance of HIF-
specific hydroxylase inhibition and demonstrates the adverse effects of non-specific 
hydroxylase inhibition on collagen processing.  Crucially, it is particularly relevant to 
cartilage as it is a highly collagen rich tissue.  Interestingly, we observed that PHD2 
inhibition upregulates key pro-Lysyl hydroxylases involved in collagen formation implying 
that PHD2 inhibition offers a novel means to enhance cartilage repair not just by upregulating 
SOX9 and key cartilage matrix proteins but through upregulation of enzymes involved in 
pro-collagen fibril formation. 
 
Here we demonstrate that hypoxia (predominantly through the stabilisation of HIF-α 
isoforms) inhibits aggrecan degradation in IL-1α stimulated and unstimulated human 
cartilage explants suggesting that hypoxia also an anti-catabolic effect in human cartilage 
explants.  Further investigation in human tissue (cartilage explants) and HACs suggested that 
the observed anti-catabolic effects may be mediated by the downregulation of key proteases 
responsible for matrix turnover (ADAMTS5 and MMP13) and the upregulation of the 
metalloproteinase inhibitor TIMP3.  Moreover, we provide clear evidence that hypoxia and 
specifically the stabilisation HIF-1α (rather than HIF-2α) has an anti-catabolic effect in 
human articular cartilage.  Therefore hypoxia has dual, complimentary mechanisms of 
chondroprotection in human articular cartilage:  a anabolic effect (mediated predominantly by 
HIF-2α) and an anti-catabolic effect (predominantly mediated by HIF-1α).  Using an RNAi 
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approach we show that depletion of PHD2 enhances this anti-catabolic effect in both 
normoxia and hypoxia. 
 
Crucially, we report that PHD2 displays significant activity even in 1% oxygen, since 
depletion of PHD2 under such conditions resulted in greatly increased levels of both HIF-α 
isoforms and further enhanced anabolic/anti-catabolic gene expression.  1% oxygen tension 
represents the lower end of the range of oxygen tensions in cartilage.  By inhibiting PHD2 we 
are able to upregulate HIF-1α/HIF-2α (and subsequently increase the anabolic/anti-catabolic 
effect) to levels in excess of those achieved by such physiological hypoxic conditions.  This 
opens novel, exciting possibilities of manipulating the endogenous oxygen sensing pathways 
in order to promote articular chondrocyte function, inhibit matrix destruction, enhance 
cartilage synthesis and to stimulate repair.  Phrased concisely:  Inhibiting PHD2 allows us to 
enhance HIF-signalling pathway in cartilage above physiological levels allowing us to do 
better than nature.   
 
We also observed that IL-1α stabilises HIF-1α even under normoxic conditions and 
IL-1α decreases HIF-2α protein levels under hypoxic conditions in HACs.  The IL-1α 
induced stabilisation of HIF-1α in the present study was partially suppressed by SB202190, 
an inhibitor p38 MAP kinase and therefore believed to be partially p38 MAPK dependent.  
However, the exact mechanism of stabilisation remains unknown. 
 
Consistent with our findings in human cartilage explants we report that hypoxia has 
two mechanisms of chondroprotection in porcine cartilage explants: anabolic and anti-
catabolic.  Hypoxia-induced stabilisation of HIF-α isoforms increased expression of key 
cartilage master regulator transcription factor Sox9 and key cartilage matrix gene Col2a1 at 
the mRNA level.  In addition, stabilisation of HIF-α isoforms inhibits aggrecan degradation 
in IL-1α stimulated and unstimulated porcine cartilage explants suggesting that hypoxia has 
an anti-catabolic effect in porcine cartilage explants.  Finally, analysis of gene expression 
revealed that Aggrecanase Adamts5 was downregulated in response to hypoxia while the 
endogenous protease inhibitor Timp3 was upregulated suggesting a possible mechanism by 
which hypoxia inhibits aggrecan degradation in porcine cartilage. 
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Whilst mouse articular cartilage has obvious similarities to human articular cartilage 
there are key species differences in the way the resident chondrocytes respond to hypoxia.  
Sox9 protein and Col2a1 mRNA levels were not found to be regulated by hypoxia.  These 
species differences between human and porcine on the one hand, and mouse on the other, 
perhaps illustrate how larger animals have adapted to take advantage of chronic the hypoxic 
stimulus present in their cartilage.  These species differences reported in this thesis should 
inform our approach to future clinically orientated studies. 
 
6.2  Future work 
6.2.1  Quantitative data from western blotting  
 
Western blotting is typically used for qualitative purposes.  Furthermore, it can be 
difficult to deduce changes at the protein level when either there is high variability in α-
tubulin loading control or there is no loading control at all (ARGSV neoepitope release).  In 
order to confirm our results we intend to provide quantitative data that can be statistically 
tested.  Western blotting films will either be scanned or PVDF blots analysed using a 
chemiluminescence camera.  Quantitative values of protein levels will be determined by 
dividing the densitometry value of the desired protein by the α-tubulin loading control.  This 
will provide quantitative data which can be statistically analysed to determine if changes in 
protein amounts are significant.  This method assumes that the bands analysed are within the 
linear range of each immunosignal (not underexposed or oversaturated).  This will enable us 
to more accurately confirm changes at the protein level. 
6.2.2  Use of more physiological oxygen tensions 
 
Here we defined hypoxia as the level of molecular oxygen at which HIF-α isoforms 
become stabilised (≤ 5% O2) and defined normoxia as level of oxygen under normal 
atmospheric conditions (20% O2).  As previously mentioned (see Chapter 1) we acknowledge 
that these are not levels of oxygen normally experienced in vivo as the levels of molecular 
oxygen in vascularised tissues may vary between 10-14% O2.  This raises interesting 
questions about the therapeutic applications of our results as normoxic data may be 
considered artificially high or supra-physiological.  We intend to repeat PHD2 knockdown at 
a range of oxygen tensions 20%, 10%, 5% in order to examine if PHD2 enzyme inhibition 
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enhances chondrocyte function at these oxygen levels.  We may also be interesting to 
examine the effect of anoxia (0% O2) on chondrocyte function.     
6.2.3  Examining the effect of PHD inhibition in osteoarthritic cartilage 
 
Here we report the beneficial effect of PHD2 inhibition in healthy human articular 
cartilage and HACs.  In order to confirm the therapeutic application of PHD inhibition we 
intend to repeat our experiments in osteoarthritic cartilage explants and osteoarthritic 
chondrocytes.  In this thesis our donors ranged in age from 8-55 years, in future work it 
would be particularly interesting to focus on more elderly, osteoarthritic donors (>60 years) 
as this would more accurately represent our target population. 
6.2.4  Use of clinically relevant animal models   
 
We reported in Chapter 5, whilst there are some similarities, mouse articular 
chondrocytes do not respond the same way to hypoxia as human articular chondrocytes.  
Specifically, hypoxia does not promote the differentiated chondrocyte phenotype or enhance 
matrix deposition in mouse articular chondrocytes.  Sheep are often used in cartilage repair 
studies, while cow and pig cartilage shows a similar hypoxia responsiveness to human 
(Domm et al., 2002; Kim et al., 2009a; Lafont et al., 2007; Thoms and Murphy, 2010; Zhang 
et al., 2011).  Therefore, more suitable animal models to investigate the effectiveness of 
PHD-specific inhibitors in a preclinical setting would be these larger animals - porcine, 
bovine or ovine models.  
6.2.5  Regulation of collagen prolyl-4-hydroxylases by hypoxia 
 
Collagen proyl-4-hydroxylases (C-P4Hs) are tetramers (consisting of 2 α subunits and 
2 β units) responsible for catalysing the formation of 4-hydroxyproline by hydroxylation of –
X-Pro-Gly- triplicates within the pro-α collagen chains.  Like HIF-targeting hydroxylases 
collagen proyl-4-hydroxylases use 2-oxoglutarate and oxygen as substrates (iron and 
ascorbate as cofactors) to hydroxylate proline residues and this hydroxylation is essential for 
the formation of intramolecular hydrogen bonds and subsequent stable triple-helical 
formation within the endoplasmic reticulum (Jimenez et al., 1973; Kukkola et al., 2003; 
Myllyharju, 2003; Van Den Diepstraten et al., 2003). 
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It has been demonstrated that hypoxia increases expression of collagen proyl-4-
hydroxylases α and β subunits in primary human articular chondrocytes and this upregulation 
was abolished by treatment with 2-Methoxestradiol (2ME2) (Grimmer et al., 2006; Hofbauer 
et al., 2003).  It will be of interest to investigate the hypoxic induction of C-P4Hα1, C-P4Hα2 
and C-P4Hβ in primary and passaged HACs.  In addition, we intend to determine if this 
hypoxic upregulation is HIF-1α or HIF2α dependent and investigate if levels of C-P4Hα1, C-
P4Hα2 and C-P4Hβ can be further enhanced by PHD2 depletion.  This would provide further 
evidence for the beneficial effects of PHD2 inhibition; enhancing both COL2A1 mRNA and 
the cellular machinery necessary for collagen post-translational processing.   
6.2.6  Regulation of HIF-α activity by FIH-1 
 
The asparaginyl hydroxylase Factor Inhibiting HIF (FIH-1) regulates the 
transcriptional activity of HIF-α.  FIH-1 hydroxylates a specific asparginyl residue within the 
c-terminal transactivation domain of the α-subunit.  This hydroxylation disrupts the binding 
of the CBP/p300 coactivator and inhibits HIF transcriptional activity.  We have previously 
demonstrated we can deplete FIH-1 expression using RNAi in passaged HACs achieving a 
97% knockdown compared with luciferase control.  In order to investigate the effects in 
chondrocytes we intend to knockdown the expression of FIH-1 under normoxic (20% 
oxygen) and hypoxic (1% oxygen) conditions in primary and passaged human articular 
chondrocytes and monitor the expression of HIF-target genes (e.g., SOX9, MIG6, VEGF, 
GLUT1), in addition to binding of HIFs to isolated HREs. 
6.2.7  Regulation of key matrix metalloproteinase ADAMTS5 by PHD2 
 
In the present study we found that hypoxia significantly downregulates key catabolic 
genes ADAMTS5 and MMP13 at the mRNA level in cartilage explants and isolated HACs.  
This downregulation could be further enhanced by PHD2 depletion in HACs.  Interestingly, 
ADAMTS5 hypoxic downregulation was found not to be HIF-1α or HIF-2α dependent. 
 
We previously mentioned that PHD2’s ability to interact with non-HIF targets has 
been hypothesised.  Phd2-/- mice have severe heart defects without the accumulation of either 
HIF-1α or HIF-2α isoforms in heart tissue.  We intend to investigate this direct or indirect 
interaction between PHD2 and ADAMTS5. 
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6.2.8  Mechanism of HIF-1α stabilisation by IL-1α stimulation 
 
Here we report that treatment of HACs with proinflammatory IL-1α stabilises HIF-1α 
protein even under normoxic conditions.  The IL-1α induced stabilisation of HIF-1α was 
partially suppressed by SB202190, an inhibitor p38 MAPK. 
 
Kim and colleagues demonstrated that tristetraprolin (TTP), a regulator of mRNA 
stability is hypoxia inducible and binds to the 3’-UTR of HIF-1α via AU-rich elements and 
downregulates the transcript’s stability.  It will be of interest to ascertain if the IL-1α induced 
stabilisation of HIF-1α in HACs is due to mRNA stability changes and to elucidate the 
possible role of TTP in this process. 
 
6.3  Final Discussion and Therapeutic applications 
 
Loss of articular cartilage due to age or focal cartilage defects resulting form sports 
related trauma are difficult to repair, as once damaged cartilage has a limited intrinsic matrix 
remodelling and repair capacity.  In addition to sports injuries another major cause of 
cartilage loss is the age-related disease osteoarthritis.  Although the mechanisms of initiation 
are unclear (and probably diverse) osteoarthritis is a chronic disease believed to be caused by 
an imbalance between net anabolic (matrix synthesis) and net catabolic (matrix degradation) 
activity.  This leads to the progressive loss of articular cartilage over time and finally results 
in joint pain, loss of function and reduced quality of life.  
6.3.1  Current limitations of clinical interventions 
 
 Focal cartilage lesions can be managed using a number of procedures including 
lavage, microfracture (generating fibrocartilage scar tissue plug) and nonbiological implants 
(metallic or cell-free polymer plugs) (Stroh et al., 2011).  However these tissue plugs do not 
have the same biomechanical propteries as normal aticular cartilage and may degrade over 
time. 
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There is no current effective disease modifying pharmacological therapy for 
osteoarthritis.  Conventional treatments are aimed at treating the symptoms and include 
physical therapy, suppression of inflammation, analgesia and in advance stages of OA, 
surgical intervention (joint replacement with a prosthesis) (Conaghan et al., 2008). 
 
 Catabolic aggrecanases ADAMTS-4 and ADAMTS-5, and collagenases such as 
MMP-13 have previously been identified as responsible for joint destruction and identified as 
promising targets to curtail OA disease pathology.  Unfortunately trials of small molecule 
inhibitors targeting these catabolic factors have produced disappointing results and stress the 
importance of minimising inhibitor toxicity, limiting side effects of the inhibitor and the need 
for specificity in targeting individual metalloproteinases responsible for joint destruction. 
(Burrage and Brinckerhoff, 2007; Chuma et al., 2004; Flannery, 2010; Fosang and Little, 
2008; Little et al., 2007; Nagase et al., 2006; Troeberg et al., 2008). 
 
Osteoarthritis is a disease of irreversible articular cartilage degradation and leads to 
chronic disability.  Conventional therapeutics do not inhibit the underlying pathologic tissue 
catabolism or encourage tissue repair.  Indeed, even if effective, aggrecanase and collagenase 
inhibitors might only solve half the problem.  They may have a strong anti-catabolic effect, 
preventing further cartilage degradation, however, patients often present physical symptoms 
late in the disease after there has already been significant cartilage destruction.  Existing 
catabolic inhibitors are unable to reverse previous matrix loss and do not have a strong 
anabolic effect.   
6.3.2  Novel dual anabolic and anti-catabolic therapeutic approach 
 
We propose a novel therapeutic approach manipulating the endogenous oxygen 
sensing pathways in chondrocytes.  We aim to inhibit PHD2 and stabilise both HIF-1α and 
HIF-2α.  We have demonstrated that hypoxia stabilises HIF-1α and HIF-2α in chondrocytes 
and that each isoform has distinct targets providing two complementary mechanisms of 
chondroprotection: upregulation of anabolism (predominantly via HIF-2α) and suppression of 
catabolism (predominantly via HIF-1α).  Theoretically, inhibition of HIF-targeting PHD2 
provides a novel mechanism to promote chondrocyte function in vivo by suppressing MMP 
and ADAMTS mediated matrix degradation and reversing matrix destruction by increasing 
expression of cartilage extracellular matrix proteins and repairing articular cartilage. 
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Crucially, through this work we demonstrate that PHD2 displays significant activity 
even at the low end of the physiological oxygen tension range in human articular cartilage 
(1% oxygen), since depletion of PHD2 under these conditions resulted in greatly increased 
levels of both HIF-α isoforms.  Thus inhibiting PHD2 can fully activate, in a controlled 
manner, the HIF-signalling pathway in cartilage allowing us to enhance its effects above 
physiological conditions.  Furthermore, our work was carried out in healthy human cartilage 
explants and healthy freshly isolated and passaged human articular chondrocytes.  Healthy 
human cartilage is a rare and clinically invaluable tissue.  Unfortunately, human osteoarthritic 
cartilage samples are often unusable due to the advanced, end-stage degradative changes.  In 
addition, we believe our primary human cell/tissue data are more applicable to the clinical 
setting than, for example, murine cartilage or chondrocyte cell line studies. 
6.3.3  PHD enzyme-specific inhibition 
  
Experiments with the general hydroxylase inhibitor dimethyloxalylglycine (DMOG) 
highlight the importance of development of HIF-specific hydroxylase inhibitors with regard 
to the collagen rich tissue cartilage.  Gelse and colleagues carried out a study injecting the 
joints of STR/ORT mice with the non-specific hydroxylase inhibitor dimethyloxalylglycine 
(DMOG).  STR/ORT mice spontaneously develop osteoarthritis and injection of DMOG was 
unable to prevent the formation of severe arthritis.  Although Sox9 was up-regulated in 
response to DMOG injection, immunohistochemistry and immunofluorecence revealed 
incomplete post-translational processing and intracellular accumulation of type II collagen in 
chondrocytes.  Similary, our work demonstrates that whilst DMOG upregulates SOX9 in 
HACs it inhibits type II collagen secretion (Thoms and Murphy, 2010).  It was concluded that 
this impaired secretion of collagen was due to inhibition of collagen proyl-4-hydroxylases by 
the non-specific hydroxylase inhibitor DMOG (Berg et al., 1983; Gelse et al., 2008).  
Presumably, addition of DMOG leads to misfolded, unhydroxylated procollagens that are 
retained within the cell.  This stresses the importance of developing specific PHD inhibitors 
(or at least HIF-specific prolyl-4 hydroxylases) which do not inhibit key collagen proyl-4-
hydroxylases which are essential for correct collagen posttranslational modification. 
 
Lionard and colleagues recently investigated the role of specific PHD enzyme 
inhibition in vivo in order to stabilise HIF-α isoforms and promote post-ischaemic 
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neovascularisation.  The right femoral artery was ligated in mice in order to create an 
ischaemic event and the mice injected with plasmids encoding for short hairpin RNA directed 
against PHD1, PHD2, PHD3 or a control.  Transfection was associated with a specific, 
transient decrease in targeted PHD enzyme mRNA, an increase in HIF-1α levels and 
proangiogenic factors (VEGF, eNOS) (Loinard et al., 2009).  Microangiography revealed that 
14 days after transfection, PHD2 and PHD3 depletion increased capillary density by 1.8- and 
2.1-fold, and foot perfusion by 1.2- and 1.4-fold, respectively, compared with controls.  HIF-
2α levels were not investigated; however this work suggests exciting possibilities for 
therapeutic use of specific-PHD enzyme inhibition (Loinard et al., 2009). 
 
 The use of shRNA in vivo to promote cartilage repair is appealing as it would provide 
a PHD specific depletion without inhibiting key collagen proyl-4-hydroxylases.  Song and 
colleagues have previously demonstrated that ADAMTS4 and ADAMTS5 mRNA expression 
could be depleted in human cartilage explants in vitro using siRNA (Song et al., 2007).  
However, the extensive cartilage extracellular matrix  make the tissue resistant to transfection 
requiring large amounts of siRNA (100nM) and results in inefficient knockdowns (Song and 
colleagues could only achieve a 60-75% depletion at the mRNA level).  This level of PHD 
enzyme depletion may not be sufficient to stabilise HIF-α in vivo, the depletion would only 
be transient and the high amount of siRNA could have adverse side effects. 
 
Therefore a PHD inhibitor would preferably be a small molecule inhibitor which is; 
PHD-enzyme (and preferable PHD2) specific and does not suppress collagen proyl-4-
hydroxylase function.  In order to investigate the therapeutic applications of PHD2 inhibition 
the following issues would need to be considered: 
6.3.4 Small molecule inhibitors of PHDs   
 
Hydroxylase enzyme small molecule inhibitors are already being developed by 
several biotech and pharmaceutical companies and offer an exciting therapeutic approach for 
the treatment of: anaemia, wound healing, thalassemia and inflammatory disorders (Fraisl et 
al., 2009; Yan et al., 2010).  Iron chelator desferoxamine, a non-specific inhibitor of the PHD 
enzymes has historically been used as a treatment for anaemia.  Similarly, HIF-α regulation 
of vascular endothelial growth factor (VEGF), hypoxia tolerance and ischaemic 
preconditioning makes PHD enzyme inhibition an attractive target for therapeutic 
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angiogenesis.  It has been suggested that PHD enzyme inhibition could be used in the event 
of blood vessel occlusion (e.g., stroke and myocardial infarction) to promote the formation of 
new blood vessel formation (angiogenesis) and reperfusion of the ischaemic tissue or 
promote hypoxia tolerance and cell survival in cells downstream of the occlusion in order to 
protect against acute ischaemic damage (Fraisl et al., 2009). 
 
In a recent review of patent applications it was reported that many companies 
including GlaxoSmithKline, FibroGen, Bayer and Merck & Co have submitted patent 
applications for PHD inhibitors as HIF-stabilisers (reviewed by (Yan et al., 2010)).  FG-2216 
and FG-4592 are two examples of oral PHD inhibitors which have completed Phase II 
clinical trials.   Both inhibitors are designed by FibroGen for the treatment of anaemia and 
reports indicate that inhibitors significantly increase levels in haemoglobin and erythropoietin 
levels in patients with chronic kidney disease (Urquilla et al., 2004).  Other examples of 
small molecule inhibitors include:  ASP-1517 (Astellas), GSK1278863A (GlaxoSmithKline) 
and AKB-6548 (Akebia Therapeutics) which are all currently in Phase I clinical trials (Yan et 
al., 2010). 
 
 Cartilage is a collagen rich tissue, therefore it is essential that PHD inhibition be 
achieved without inhibiting 2-oxoglutarate dependent collagen proyl-4-hydroxylases (C-
P4Hα1, C-P4Hα2 and C-P4Hβ).  Amgen claim to have developed several quinolone and 
azaquinolone based compounds which selectively inhibit PHD2, without significantly 
affecting collagen proyl-4-hydroxylase function.  Compound 42 is an example of one of these 
compounds and is reported in a review by Yan and colleagues to have the following selective 
properties IC50:  PHD2 = 0.003µM; C-P4Hα1 > 40µM; C-P4Hα2 = 34.3µM (Yan et al., 
2010).  No experimental data could be found regarding this compound. 
6.3.5 Side effects and complications of PHD inhibition 
 
Concerns of the unwanted side effects of PHD inhibitors can be linked to either the 
long term stabilisation of HIF-α isoforms outside of articular cartilage or the activation of 
undesirable genes by HIF-α isoforms in chondrocytes.  Addressing the first point initially, 
aberrant PHD enzyme inhibition and HIF-α isoforms stabilisation in other tissues has been 
associated with polycythemia, cancer and hypoxic pulmonary hypertension (Yan et al., 
2010).  
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Heterozygous mutation in the PHD2 gene (H374R) is associated with heritable 
polycythemia (due to elevated EPO expression) and recurrent paraganglioma (rare 
neuroendocrine neoplasm) (Ladroue et al., 2008).  Patients have very high haemoglobin 
levels (~23 g/dl vs. 13 g/dl WT) and are at an increased risk of serious thromboembolic 
events including myocardial infarction and stroke (Unger et al., 2010). 
 
 During periods of rapid cell division (eg: solid tumours) cells may outgrow their 
vascular supply.  Cells are located sufficiently far from the blood vessel that they are beyond 
the diffusion distance of oxygen (~100-300µm) and as a result solid tumours often experience 
hypoxia.  Stabilisation of HIF-α switches cells’ to an anaerobic metabolism, stimulates new 
blood vessel formation and promotes cell survival.  Hypoxia is a sign of advanced disease 
and associated with poor clinical outcome (Kim et al., 2009b; Ruan et al., 2009).  Mutations 
in pVHL are linked with a heritable cancer syndrome predisposes patients to multiple 
vascularized tumours (Ivan et al., 2001).  However, it is unclear whether HIF-α stabilisation 
itself is responsible for tumourigenesis or HIF-α stabilisation is due to the hypoxia 
microenvironment of solid tumours). 
 
 Recent work in mice and humans suggests that HIF-α stabilisation plays an important 
role in pulmonary hypertension (tissue remodelling of the vascular lumen leading to right 
ventricular hypterophy) (Yildiz, 2009).  HIF-1α+/- and HIF-2α+/- mice are resistant to vascular 
remodelling, pulmonary hypertension, right ventricular failure (Brusselmans et al., 2003; Yu 
et al., 1999).  Consistent with work in mice, inhibition of PHD enzymes with DFO treatment 
in humans activates HIF and mildly elevates pulmonary hypertension (Balanos et al., 2002).   
   
 These negative side effects are intuiative if HIF-α isoforms are stabilised in 
vascularised tissues as this is a non-physiological stress.  However we would not expect these 
effects in articular cartilage as hypoxia is a chronic state and inhibiting PHD2 would enhance 
HIF-α isoforms above current, physiological levels.  Therefore, out of concern for the many 
possible effects described above for other tissues it is important to attempt to restrict HIF-α 
manipulation to the chondrocytes within the articular cartilage.   
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 Addressing the second concern, HIF-α isoforms are known to regulate more than 100 
genes via hypoxia response elements and have a diverse range of transcriptional targets 
ranging from energy metabolism, to apoptosis and angiogenic signalling (Schofield et al., 
2004).  The stabilisation of HIF-α isoforms in HACs will promote the chondrocyte phenotype 
however, it will also upregulate all other HIF-target genes and may have undesirable 
consequences.  It is important to highlight that hypoxia also upregulates many beneficial 
proteins including chondromodulin-1 (Chm-1) which stabilises the chondrocyte phenotype 
and has an anti-angiogenic effect in cartilage (Klinger et al., 2011; Lafont et al., 2008; 
Murphy, 2011). 
6.3.6  Administration of PHD inhibitors  
 
 Due to possible side effects of systemic HIF stabilisation it is important to stabilise 
HIF-α isoforms only within articular cartilage.  In order to achieve this we would suggest that 
the compound be administered via an intra-articular injection rather than oral (and systemic 
HIF-α stabilisation). 
 
 However, it is important to consider that an intra-articular injection of the compound 
would not necessarily be articular cartilage-specific.  Logically PHD2 would also be inhibited 
in meniscal cartilage, synovial fibroblasts and possibly the fat pad and subchondral bone.  
Adesida and colleagues reported that hypoxia upregulates the expression cartilage matrix 
genes in human meniscus cells (Adesida et al., 2006).  However, hypoxia has been shown to 
upregulate vascular endothelial growth factor (VEGF) and pro-apoptotic BCL2/adenovirus 
E1B 19 kDa protein-interacting protein 3 (BNIP3) in osteoarthritic synovial fibroblasts 
(Barbara Muz, Data not published). 
 
Osteoarthritis may be characterised by symptoms (pain, stiffness, crepitus, decreased 
mobility and deformity) or radiographic criteria (e.g., joint space narrowing) or both.  
Because cartilage is aneural symptoms do not often present until late-stage disease and 
confusingly structural changes such as joint space narrowing can often occur without painful 
symptoms.   
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This raises an interesting question, when should a PHD2 inhibitor be administered, 
and how frequently?  Should it be given to healthy non-symptomatic patients to maintain 
cartilage structural integrity throughout life or only administered immediately after injury?  
Joint pain is a symptom of end stage disease, by which point has there already been too much 
articular cartilage destruction to initiate HIF-α mediated repair?   
 
Studies in large animal modles are initially needed to help better inform these 
important issues.  Injections of an intra-articular PHD-inhibitor in humans would rely upon 
early detection using advanced imaging in order to identify early structural changes in a 
patient’s cartilage. 
6.3.7  Tissue Engineering 
 
 One exciting area of possible focal cartilage defect treatment is cell-based therapies; 
e.g., repair by autologous chondrocyte implantation.  These therapies rely on the culture of 
human chondrocytes in vitro before they are seeded onto a scaffold and implanted.  However, 
the chondrocyte phenotype is unstable in vitro and is lost in standard cell culture conditions 
(Benya et al., 1978; von der Mark et al., 1977).   Chondrocytes cultured as a monolayer de-
differentiate with passage.  They lose their round shape and appear more fibroblastic like.  
Chondrocyte markers SOX9, type II collagen and aggrecan are downregulated and type I 
collagen is upregulated (Glowacki et al., 1983).  Type I collagen has inferior mechanical 
properties and is found in fibrocartilage, rather than articular.  The differentiated chondrocyte 
phenotype can be maintained by culturing chondrocytes in type II collagen matrices, 3-
dimentionsal alginate scaffolds (alginate beads) or culturing cells under hypoxic conditions 
(Murphy and Sambanis, 2001; Shakibaei and De Souza, 1997; Stewart et al., 2007).   
 
A small molecule PHD2 inhibitor would offer a novel way to restore the healthy 
phenotype of osteoarthritic chondrocytes in vivo or restoring the differentiated phenotype to 
passaged human chondrocytes in vitro (in for example, within a cartilage bioreactor).  
Alternatively, passaged human chondrocytes could be transfected with a construct expressing 
shRNA against PHD2 under a regulatable promoter (e.g., tamoxifen-inducible) before being 
implanted into lesions.  This would enable regulation of shPHD2 expression and limit HIF-α 
manipulation to the cartilage lesion. 
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6.4  Conclusions  
  
            This thesis documents our efforts to investigate the regulation of HIF-α isoforms in 
human articular chondrocytes by proyl hydroxylases domain enzymes (PHD1, PHD2, PHD3) 
with the aim of development of a novel therapeutic approach to promote chondrocyte 
function in cartilage.   
  
Using RNAi we were able to identify PHD2 as the dominant PHD in HACs 
responsible for regulating both HIF-1α and HIF-2α.  Knockdown of PHD2 alone was 
sufficient to stabilise both HIF1-α and HIF-2α in normoxic conditions, and the levels of HIF-
1α and HIF-2α in hypoxia could also be further enhanced with PHD2 depletion. 
 
 We report that depletion of PHD2 provides two mechanisms of chondroprotection in 
HACs.  Stabilisation of HIF-2α promotes the chondrocytes phenotype (via SOX9) and 
cartilage extracellular matrix synthesis (COL2A1, COL9A1, COL11A2 and AGGRECAN).  
Complimentary to this anabolic effect, stabilisation of HIF-1α has an anti-catabolic effect 
downregulating key matrix metalloproteinases (ADAMTS5 and MMP13), upregulating 
metalloproteinase inhibitor (TIMP3) and is able to suppress aggrecan degradation in human 
cartilage explants.  These results offer an exciting novel therapy to maintain and repair 
articular cartilage. 
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Inhibition of Hypoxia-inducible Factor-targeting Prolyl
Hydroxylase Domain-containing Protein 2 (PHD2) Enhances
Matrix Synthesis by Human Chondrocytes*
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Human articular cartilage is an avascular tissue, and there-
fore it functions in a hypoxic environment. Cartilage cells, the
chondrocytes, have adapted to this and actually use hypoxia to
drive tissue-specific functions. We have previously shown that
human chondrocytes enhance cartilage matrix synthesis in
response to hypoxia specifically through hypoxia-inducible fac-
tor 2 (HIF-2)-mediated up-regulation of master regulator
transcription factor SOX9, which in turn drives expression of
the main cartilage-specific extracellular matrix genes. HIF-
isoforms are themselves regulated by specific prolyl hydroxylase
domain-containing proteins, which target them for proteoso-
mal degradation. In fact, prolyl hydroxylase domains are the
direct oxygen sensors because they require molecular oxygen as
a co-substrate. Here, we have identified PHD2 as the dominant
isoenzyme regulating HIF-2 stability in human chondrocytes.
Moreover, specific inhibition of PHD2 using RNA interference-
mediated depletion caused an up-regulation of SOX9 and
enhanced extracellular matrix protein production. Depletion of
PHD2 resulted in greater HIF-2 levels and therefore enhanced
SOX9-induced cartilage matrix production compared with the
levels normally found in hypoxia (1% oxygen) implying that
PHD2 inhibition offers a novel means to enhance cartilage
repair in vivo. The need for HIF-specific hydroxylase inhibition
was highlighted because treatment with the 2-oxoglutarate ana-
logue dimethyloxalylglycine (which also inhibits the collagen
prolyl 4-hydroxylases) prevented secretion of type II collagen, a
critical cartilage matrix component.
Articular cartilage consists of a single cell type, the chon-
drocyte, which is solely responsible for the synthesis and
maintenance of the extracellular matrix (1). The rigid nature
of type II collagen fibrils present in the matrix confers tensile
strength to the tissue, and the swelling pressure caused by
water-saturated aggrecan molecules creates a compressive gel-
like stiffness allowing the tissue to resist deformation and giving
cartilage its ability to absorb shocks (1, 2). Due to its shock-
absorbing and articulating functions, articular cartilage cannot
afford a blood or nerve supply. The tissue is therefore depen-
dent on diffusion of oxygen from the synovial fluid on one side
and the vascularized underlying bone on the other. As a result,
articular cartilage (at least in larger animals and man) is main-
tained in a low oxygen environment (1–5% oxygen tension)
throughout life (3–5). There is now significant evidence that
hypoxia is a critical parameter in promoting the chondrocyte
phenotype. It has been shown that hypoxia up-regulates key
cartilage transcription factor SOX9 and increases expression of
themain extracellularmatrix genes in bovine and human chon-
drocytes (6–10).
The response of cells to hypoxia is mediated by hypoxia-
inducible factors (HIFs),2 heterodimeric transcription factors
consisting of an  and  subunit (11). Both subunits are consti-
tutively expressed at themRNA level; however, the  subunit is
regulated post-translationally by oxygen levels. In well oxygen-
ated cells, the  subunit is hydroxylated on specific, conserved
proline residues by HIF-targeting prolyl hydroxylase domain-
containing proteins (PHD1, PHD2, and PHD3) (12–14). The
PHD isoenzymes are a subfamily of dioxygenases that use
molecular oxygen and 2-oxoglutarate as co-substrates to add
hydroxyl groups to specific proline residues on the HIF- sub-
unit (15–17). The hydroxylated proline residues on HIF- are
recognized by von Hippel-Lindau protein of the E3 ubiquitin
ligase complex, ubiquitinated and subsequently degraded by
the 26 S proteasome (18). As intracellular oxygen concentra-
tions are reduced, the activity of the PHDs is suppressed, and
HIF- isoforms are not hydroxylated and therefore escape pro-
teosomal degradation and so heterodimerize with HIF-1,
translocate to the nucleus, and bind to cis-regulatory hypoxia-
response elements in target genes. Previous work in our labo-
ratory has demonstrated that hypoxic induction of the key car-
tilage matrix genes in human chondrocytes is mediated
specifically by the HIF-2 isoform that up-regulates SOX9,
leading to enhanced expression of the cartilage matrix genes
(9).
Suppression of PHD enzymes leads to stabilization of HIFs
and offers a potential treatment option for many ischemic dis-
orders, such as peripheral artery occlusive disease, myocardial
infarction, and stroke (19). We hypothesized that antagonizing
specific PHDs could be a novel way of promoting cartilage
matrix deposition fromchondrocytes by increasingHIF-2 sta-
bility and up-regulating key transcription factor SOX9. We
investigated the role of each PHD isoenzyme in isolated healthy
* This work was supported by Arthritis Research United Kingdom.
1 To whom correspondence should be addressed. Tel.: 44-2083834470; Fax:
44-2083834499; E-mail: c.murphy@imperial.ac.uk.
2 The abbreviations used are: HIF, hypoxia-inducible factor; PHD, prolyl
hydroxylase domain; RNAi, RNA interference; HAC, human articular chon-
drocyte; DMOG, dimethyloxaloylglycine; DFO, desferrioxamine; siRNA,
small interfering RNA; FIH, factor inhibiting HIF.
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human articular chondrocytes adopting an RNAi-mediated
approach. We provide strong evidence that specific inhibition
of PHD2 enhances cartilage matrix production by chondro-
cytes, and these results thus identify PHD2-specific inhibition
as a novel means to stimulate chondrocyte anabolism and
therefore cartilage repair.
EXPERIMENTAL PROCEDURES
Cell Culture—Healthy human articular cartilage was ob-
tained from patients after they provided informed consent and
following local ethics committee guidelines. Samples of carti-
lage were obtained from patients following above knee ampu-
tations due to soft tissue sarcomas and osteosarcomas not
involving the joint. Tissue was obtained from 21 patients (17
male, 4 female; aged 8–55 years,mean age 26.6 years). Cartilage
was digested as described previously (9). Briefly, the cartilage
was diced into small pieces and digested in collagenase over-
night. Freshly isolated cells were initially seeded at a density of
8 103 cells/cm2 in Dulbecco’s modified Eagle’s medium with
10% fetal calf serum.Chondrocyteswere passaged at the time of
confluency (7 days) and re-seeded at 5 103 cells/cm2.
Small Interfering RNA Transfection—Primary (P0) or pas-
saged (P1–P3) human articular chondrocytes (HACs) were
seeded at 5 103 cells/cm2 in 6-cm dishes. Cultures were incu-
bated at 37 °C, 20% oxygen, 5% CO2 until 50% confluent (typi-
cally after 1 day). Lipofectamine 2000 (Invitrogen) was used to
transfect cells with small interfering RNA (siRNA) at a final
concentration of 10 nM in serum-free Opti-MEM I. PHD1,
PHD2, and PHD3 targeting siRNAs, which were used, are listed
in Table 1. As a control, siRNAs against luciferase (Dharmacon,
Lafayette, CO) were transfected in parallel. Four hours after
transfection, the Opti-MEM was removed and replaced with
Dulbecco’s modified Eagle’s medium containing 10% fetal calf
serum pre-equilibrated at the appropriate oxygen tension (20
or 1%). Cells were subsequently incubated in each oxygen ten-
sion for 3 days.
RNA Isolation, Reverse Transcription, and Real Time PCR—
RNA was extracted and prepared using the RNeasy mini kit
(Qiagen, Crawley, UK) following themanufacturer’s guidelines.
cDNA was generated using a reverse transcription kit (Pro-
mega, Southampton, UK) and random primers from 0.5 g of
total RNA. Newly synthesized cDNA was diluted 5-fold in
DNase-free water. Four percent of this cDNAwas then used for
real time PCR assays using TaqMan technology and a PCRCor-
bett Research thermocycler (Corbett Research, Australia). The
 threshold cycle (Ct) method of relative quantitation was
used to calculate relative mRNA levels for each transcript
examined. The ribosomal protein gene (RPLP0) was used to
normalize the data as it was not regulated by hypoxia in our
system. Pre-developed primer/probe sets for the following
genes were purchased from Applied Biosystems (Foster City,
CA):PHD1,PHD2,PHD3, FIH1,COL2A1,COL9A1,COL11A2,
AGGRECAN, SOX9, VEGF, and RPLP0.
Protein Extraction and Western Blotting—To detect HIF-
isoforms, cells were lysed immediately after termination of the
experiment in urea lysis buffer (8 M urea, 10% glycerol, 1% SDS,
5mM dithiothreitol, 10mMTris-HCl); otherwise, the cells were
lysed in radioimmunoprecipitation assay buffer (100 mM
Trizma base, pH 7.4, 300 mM NaCl, 20 mM NaF, 2 mM EDTA,
0.2 mM -glycerophosphate, 2%(w/v) sodium vanadate, 2%
deoxycholate, 0.5% SDS, and 1% Nonidet P-40). A protease
inhibitor mixture (Sigma) was added just prior to cell lysis. Cell
lysates were sonicated for 5 s and spun at 12,000 rpm for 10min
at 4 °C to remove any cell debris. 20 g of protein was resolved
by SDS-PAGE, transferred onto polyvinylidene difluoride
membranes for Western blotting, and visualized using the
enhanced chemiluminescence method. To detect PHD3 and
HIF-2, 40 g of protein was used. Primary antibodies used
were rabbit anti-SOX9 (Chemicon AB5535, 1:1000), rabbit
anti-PHD2 (Abcam AB4561, 1:1000), mouse anti-PHD3 (clone
188e, a kind gift from Professor Chris Pugh, Oxford, UK),
mouse anti-HIF-1 (BD Transduction Laboratories, clone 54,
1:250), mouse anti-HIF-2 (Santa Cruz Biotechnology Sc-
13596, 1:250), and mouse anti--tubulin monoclonal antibody
(Sigma, 1:4000).
For detection of secreted type II collagen, HACswere serum-
starved for 2 days, 24 h following transfection. Approximately 1
ml of conditioned medium was precipitated with trichloroace-
tic acid, loaded on a 6% polyacrylamide gel, and blotted with
anti-COL2A1 antibody (Chemicon MAB8887, 1:1000). The
exact volume of media used was adjusted after standardization
according to total protein content in the cell layer, measured
using the Bradford assay.
Statistical Analysis—Data were compared using a one-way
analysis of variance with Bonferroni post test. The software
GraphPad Prism 4 (GraphPad Software, SanDiego) was used to
perform statistical analysis. Results are expressed as a mean
S.E. Probability values less than 0.05 were considered
significant.
RESULTS
PHD2 Is theMost Abundant PHD Isoenzyme, and PHD2 and
-3 areHypoxia-inducible inHACs—ThemRNA levels ofPHD1,
PHD2, and PHD3 under normoxic (20% oxygen) and hypoxic
(1% oxygen) conditions were analyzed after normalizing the
data using the housekeeping gene RPLP0. The relative abun-
dance of each genewas calculated after assigning the expression
level of PHD3 at 20% oxygen to a value of 1. This method of
calculating the relative abundance of the three PHD isoen-
zymes at the mRNA level makes the assumption that the effi-
ciency of amplification between the different PCR primers is
equal (in practice, all amplification efficiencies were similar,
being over 90%). PHD2was themost abundant transcript of the
three isoenzymes in both 20 and 1% oxygen (Fig. 1A). Interest-
ingly, althoughPHD3had themost pronounced hypoxic induc-
tion (average 19.2-fold induction), it was the least abundant
PHD enzyme at themRNA level in both 20 and 1% oxygen (Fig.
1A). This is consistent with data at the protein level. PHD2 and
PHD3 proteins were found to be induced by hypoxia (Fig. 1, B
and C). In addition, 20 g of PHD2 was visualized using
enhanced chemiluminescence after 3 min of exposure to x-ray
film, whereas 40 g of PHD3 required 45 min of exposure to
detect any protein (note, the top band in all PHD2 blots is
nonspecific).
Depletion of PHDs in HACs—PHD1, PHD2, and PHD3 were
specifically depleted inHACs using siRNA (Fig. 2,A–C, respec-
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tively). Two different oligonucleotides were used for each gene
(for sequences see Table 1). siRNA against luciferase (siLuc)
was used as a control. Messenger RNA analysis by real time
PCR revealed that PHD1was depleted 72% (siPHD1 number 1)
and 95% (siPHD1 number 2) on average compared with siLuc
levels. PHD2 was depleted 82% (siPHD number 1) and 86%
(siPHD2 number 2) on average, and PHD3was depleted by 87%
(siPHD3 number 1) and 84% (siPHD3 number 2) on average.
Western blot confirmed the depletion of PHD2 (Fig. 2D) and
PHD3 (Fig. 2E) at the protein level. Knockdown of PHD3 was
performed in the presence of the iron chelator desferrioxamine
(DFO) as PHD levels were easily detectable in DFO, but they
were relatively low in hypoxia and were undetectable in nor-
moxia. The oligonucleotides that produced the greatest knock-
down at the mRNA level were used in further experiments.
Depletion of PHD2 in Normoxia Stabilizes HIF-2 and Up-
regulates Master Chondrocyte Transcription Factor SOX9—In
normoxia, HIF- isoforms are rapidly degraded in the cell as
there is sufficient oxygen for the HIF-targeting prolyl hydroxy-
lases to target them for vonHippel-Lindau-mediated proteoso-
mal degradation. However, the knockdown of PHD2 in HACs
greatly stabilized both HIF-1 and HIF-2 in normoxia (20%
oxygen) suggesting that PHD2 significantly contributes to
HIF- regulation (Fig. 3A). The knockdown of PHD1 also con-
tributed to the stabilization of HIF-1 in normoxia but to a
much lesser extent than PHD2 depletion, and it had no detect-
able effect on HIF-2 levels. PHD3 suppression had no detect-
able effect on levels of either HIF- isoform in normoxia.
Because depletion of PHD2 alone had such a pronounced effect
on HIF-2 stabilization, and we have previously shown that
HIF-2 specifically mediates hypoxic induction of the differen-
tiated chondrocyte phenotype through up-regulation ofmaster
tissue-specific transcription factor SOX9 (9), we further
explored PHD2 regulation of HIF-2 isoform stability through
reoxygenation experiments. PHD2-depleted HACs were cul-
tured in hypoxia for 3 days before being exposed to 20% oxygen
for 0, 5, 10, 20, 40, and 60 min prior to lysing. Small interfering
FIGURE 1. PHD2 is the most abundant PHD isoenzyme in HACs, whereas
PHD2 and PHD3 are both hypoxia-inducible.Data are from passaged (P1–
P3)HACs after culture for 3 days at 20%oxygen, 1%oxygenor treatedwith 10
nM of the hypoxia mimetic DFO. A, TaqMan-based data showing the relative
mRNA abundance in cultured HACs of the PHD enzymes at themRNA level in
normoxic or hypoxic conditions (PHD3 mRNA levels in 20% oxygen was
assigned a value of 1). Values are the means  S.E. of seven independent
experiments (i.e. HACs from seven different donors); ns  not significant; *,
p 0.05; ***, p 0.001. B, Western blot showing increased PHD2 levels (lower
band) in hypoxia (1% oxygen), and after treatment with DFO. C, PHD3 levels,
like PHD2 were increased by hypoxia and DFO.
FIGURE 2. RNAi-mediated depletion of PHD1/2/3 in HACs. TaqMan real time PCR data showing mRNA depletion of PHD1 (A), PHD2 (B), and PHD3 (C) in
passaged HACs after 3 days in culture. Cells were transfected with 10 nM siRNA directed against each PHD, and an siRNA targeting luciferase (siLuc) was used
as a control. Values represent themean S.E. from three to five independent experiments (i.e.HACs from three to five different donors). ns, not significant; *,
p 0.05; ***, p 0.001 versus 20% oxygen siLuc. D, Western blot showing RNAi-mediated depletion of PHD2 protein (lower band) in HACs (in 20% oxygen).
E, RNAi-mediated PHD3 protein depletion is shown in the presence of the hypoxia mimetic DFO, as PHD3 levels in normoxia were undetectable. In all cases,
HACs were cultured for 3 days before termination of experiment.
PHD2Depletion PromotesMatrix Production by Chondrocytes
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RNA against luciferase (siLuc) was used as a control to provide
accurate comparison with PHD depletion. Upon exposure to
normoxia, HIF- subunits have a very short half-life (5 min).
However, the knockdown of PHD2 greatly slowed the rate of
degradation of both HIF-1 and HIF-2 (Fig. 3, B and C,
respectively), thus confirming the importance of PHD2 in reg-
ulation of HIF-2 stability.
We next investigated the levels of HIF-2-inducible carti-
lage-specific transcription factor SOX9 in PHD1/2/3 knock-
downs in HACs in 20% oxygen. Strikingly, only depletion of
PHD2 resulted in enhanced SOX9 protein levels compared
with luciferase controls (Fig. 3D). This is critical because SOX9
drives expression of the cartilage-specific extracellular matrix
genes that are essential for the formation of a suitable load-
bearing tissue, the primary function of articular cartilage.
PHD2Depletion Promotes the Differentiated HAC Phenotype
in Both Normoxia and Hypoxia—We next investigated the
effect of PHD2 depletion in hypoxic as well as normoxic condi-
tions in primary and passaged HACs (Fig. 4A). There was no
detectable difference in HIF-1 levels between PHD2-depleted
cultures in 20 and 1% oxygen, both being greater than that
achieved by hypoxia alone (siLuc in 1% oxygen) (Fig. 4B). In
contrast, the knockdown of PHD2 at 20% oxygen stabilizes
HIF-2 to levels approximately equal to that in hypoxia alone
(Fig. 4C). However, depletion of PHD2 in 1% oxygen further
enhanced HIF-2 levels suggesting that PHD2 is not the only
factor regulating HIF-2 levels in hypoxia. The finding that
PHD2 depletion in hypoxia resulted in greater stabilization of
both HIF- isoforms compared with control hypoxic condi-
tions indicates that there is still significant PHDenzyme activity
in 1% oxygen, which is in the physiological range for human
articular cartilage.
Levels of SOX9 were analyzed in PHD2-depleted HAC cul-
tures from a range of patients. SOX9 protein was enhanced by
PHD2 depletion in a manner very similar to that of HIF-2, i.e.
with greatest levels achieved in 1% oxygen (Fig. 4D). We next
investigated type II collagen (COL2A1) as it is regulated by
SOX9, and critically it provides the required tensile strength
needed for cartilage to perform its load-bearing and articulat-
ing functions. Secreted levels of this matrix protein were also
significantly enhanced by PHD2 depletion, with highest levels
occurring when PHD2 was depleted in hypoxia (Fig. 4E).
Following PHD2 depletion in HACs (Fig. 5A), SOX9mRNA
was significantly up-regulated (Fig. 5B) in a manner similar to
the response observed at the protein level. In fact, the key car-
tilage extracellularmatrix genes (which are regulated bymaster
chondrocyte transcription factor SOX9) were up-regulated in
response to PHD2 inhibition. The knockdown of PHD2 in 1%
oxygen tension increased COL2A1 expression 38.5-fold,
COL9A1 34.5-fold, COL11A2 58.9-
fold, and AGGRECAN 6.5-fold
(compared with control levels in
normoxia) (Fig. 5, C–F, respec-
tively). Expression of a nonhypoxia-
regulated gene, factor inhibiting HIF
(FIH), was unaltered in response to
PHD2 depletion (Fig. 5G).
General 2-Oxoglutarate-depen-
dent Hydroxylase Inhibition Up-
regulates SOX9 but Inhibits Se-
cretion of the Cartilage Collagen
COL2A1—The 2-oxoglutarate ana-
logue DMOG inhibits all members
of the 2-oxoglutarate-dependent
hydroxylase family, which includes
not only theHIF-targeting hydroxy-
lases, but also the collagen prolyl
4-hydroxylases. DMOG treatment
increased expression of SOX9 at the
gene (Fig. 6A) and protein level (Fig.
6B). VEGF, a classic HIF target gene
was also up-regulated by DMOG
(Fig. 6C). However, DMOG-in-
duced up-regulation of SOX9 did
not result in induction of the carti-
lage-specific collagens COL9A2,
COL11A2, and COL2A1 (Fig. 6,
FIGURE 3. PHD2 depletion in normoxia stabilizes HIFs and up-regulates master chondrocyte transcrip-
tion factor SOX9. A, unlike PHD1 or PHD3, depletion of PHD2 resulted in significant stabilization of both
HIF-1 andHIF-2protein inHACs following3daysof culture in 20%oxygen. Control (siLuc) shows that neither
HIF isoform is normally detectable in the presence of 20% oxygen. Depletion of PHD2 significantly slows the
rateofHIF-1 (B) andHIF-2 (C) degradationupon reoxygenation, i.e. switching the cells from1 to20%oxygen.
Following siRNA transfection, HACswere incubated 3 days in 1%oxygenbefore being exposed to 20%oxygen
for the indicated time (inminutes) prior to lysing. Control siRNA (siLuc) transfectionswere carriedout inparallel.
Note, for simplicity -tubulin loading controls from representative experiments are shown. D, depletion of
PHD2, but not PHD1or PHD3, resulted in increased SOX9protein inHACs after 3 days in culture in 20%oxygen.
TABLE 1
Oligonucleotide sequence of PHD targeting siRNAs
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D–F, respectively).Western blot analysis demonstrates that the
addition of DMOG completely inhibits secretion of type II col-
lagen protein into the culture medium (Fig. 6G). Therefore,
DMOG, like hypoxia and PHD2 depletion, up-regulates SOX9.
However, crucially, unlike hypoxia or PHD2 depletion, this
does not lead to enhanced cartilage
matrix gene expression, and in the
case of COL2A1, it completely
inhibited its secretion thus prevent-
ing elaboration of a functional carti-
lage matrix.
DISCUSSION
We have previously shown that
HIF-2 (not HIF-1) is essential
for hypoxic induction of cartilage
matrix gene expression inHACs (9).
Furthermore, it achieves this pre-
dominantly through up-regulation
of tissue-specific transcription
factor SOX9, which drives carti-
lage matrix gene expression (20).
Because HIFs themselves are regu-
lated by specific prolyl hydroxylases
(PHDs), we investigated which of
these enzymes targets HIF-2 and
whether their specific inhibition
could promote matrix production.
Using an RNAi approach, we identi-
fied PHD2 as the key hydroxylase in
HACs responsible for regulating
HIF-2. Crucially, we provide clear
evidence that such specific inhibi-
tion of PHD2 promotes the differ-
entiated phenotype and enhances
cartilage matrix production by
HACs both in normoxia and
hypoxia. The latter finding, i.e.
enhanced HIF-2 stabilization (and
subsequent SOX9 induction of the
matrix genes) by PHD2 inhibition
even in hypoxia, which is the normal
condition of cartilage (3–5), sug-
gests that PHD2 still shows signifi-
cant activity in vivo. This opens up
the exciting possibility of PHD2-
specific inhibition as a means to
enhance cartilage matrix synthesis
in vivo, a factwith obvious relevance
to development of novel cartilage
repair therapies.
PHD1,- 2, and -3 were all detect-
able in normal HACs, with PHD2
being the most abundant. These
hydroxylases have previously been
reported in human cartilage at the
mRNA and protein level (21). In
addition, mRNA studies in rats
reported that in all organs examined (heart, liver, kidney, brain,
testis and lung) PHD2 was found to be the most commonly
expressed (22, 23). Similarly to previous reports in other cell
types (24, 25), our results showed that PHD2 and PHD3 are
up-regulated in response to hypoxia in HACs. It has been
FIGURE 4. PHD2 depletion in HACs up-regulates SOX9 and secreted COL2A1 protein levels both in nor-
moxiaand inhypoxia.A, PHD2wasdepleted inHACs inboth20 and1%oxygen cultures.B, HIF-1 levelswere
enhanced inPHD2-depletedHACs, althoughnodifferencewasdetectablebetweenPHD2-depleted cultures in
1 or 20% oxygen. C, HIF-2 levels were enhanced following PHD2 depletion in both normoxia and in hypoxia.
D, SOX9 protein levels, like HIF-2, were up-regulated by PHD2 depletion, with greatest levels occurring in
hypoxia. E, secretedCOL2A1was detected following trichloroacetic acid precipitation of culturemedium.Data
were normalized to total protein content in the cell layer (as described under “Experimental Procedures”).
Secreted COL2A1 protein levels followed a similar pattern to HIF-2 and SOX9, being highest in PHD2-de-
pleted HACs cultured in hypoxia. Note, all data in the figure was obtained from primary and passaged HACs
after 3 days in culture. Cells were transfected with 10 nM siRNA against PHD2 (siPHD2) or as a control against
luciferase (siLuc). For simplicity, only -tubulin loading controls from representative experiments are shown.
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hypothesized that this occurs in a negative feedback mecha-
nism ensuring the rapid degradation of HIF- isoforms and
down-regulation of hypoxia-responsive genes once the cells
encounter increased oxygen levels (26). Although we observed
PHD3 to be the most highly hypoxia-inducible hydroxylase
(17.8-fold), it levels were relatively low, and it did not appear to
significantly contribute toward HIF- stabilization in HACs.
Koditz et al. (27) and colleagues recently demonstrated that
PHD3 interacts with activating transcription factor-4 (ATF-4)
suggesting it may play a role in regulating transcription factors
other than HIFs.
Work in a range of cell lines has suggested differential
function of the PHD enzymes in regulation of HIF- iso-
forms (28). In addition, Phd2 deletion in adult mice leads to
accumulation of HIF-1 but not HIF-2 in mouse liver and
kidney tissue (29). In contrast Phd1/Phd3 double knockouts
leads to preferential HIF-2 stabilization but not HIF-1 in
the liver (30). Aragones et al. (31) reported that Phd1/
mice had elevated levels of HIF-2 in their myofibers and
that HIF-1 levels were either low or undetectable. Although
these studies indicate that PHDs may show differential reg-
ulation of HIF- isoforms, at least some of the observed dif-
ferences are most likely due to the relative abundance of each
hydroxylase (which is dependent on cell and tissue type). In
fact, the Km values of all three PHD isoenzymes for recom-
binant HIF-1 and HIF-2 oxygen degradation domains are
quite similar, with PHD1 having the lowest Km value for both
recombinant HIF- oxygen degradation domains (32). All
three PHD isoenzymes also have virtually identicalKm values
for oxygen (21) implying that changes in oxygen tension will
not affect the relative contribution of the three enzymes to
HIF- stabilization. In our experiments with HACs, only
depletion of the most abundant hydroxylase (PHD2) signif-
icantly stabilized both HIF-1 and HIF-2 in 20% oxygen
FIGURE 5. PHD2 depletion in HACs enhances expression of the key differentiated chondrocyte markers. TaqMan real time pcr data showing relative
mRNA levels as follows: A, PHD2; B, SOX9; C, COL2A1; D, COL9A1; E, COL11A2; and F, AGGRECAN in control and PHD2-depleted HAC cultures. G, FIH, a known
nonhypoxia inducible gene, showed no change in response to PHD2 depletion. ns, not significant; *, p 0.05; **, p 0.01; ***, p 0.001.
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and slowed degradation of each HIF- isoform in reoxygen-
ation experiments.
Interestingly, however, there were differences between
HIF-1 and HIF-2 in regard to their stabilization by PHD2
depletion. No further increase in HIF-1 stabilization was
detectable in PHD2-depleted HACs when cultured in 1% oxy-
gen compared with that seen in 20% levels. In contrast, HIF-2
levels were further increased when PHD2-depleted cells were
cultured in hypoxia implying that other factors in addition to
PHD2may contribute toHIF-2 regulation in hypoxia. Neither
PHD1 nor PHD3 appear to be such factors because their deple-
tion had little impact on HIF-2 levels. Factor inhibiting HIF
(FIH) is an iron-dependent dioxygenase capable of repressing
HIF- activity (33, 34). However, depletion of FIH had no effect
on SOX9 expression even when performed in combination
with depletion of PHD2 (data not shown).
Despite the fact that Km values for oxygen are reported to be
between 10 and 25% oxygen, i.e. higher than that encountered
in vivo (21, 32), our results indicate that PHDs still display sig-
nificant activity in 1% oxygen because depletion of PHD2 in
hypoxia resulted in greatly increased levels of both HIF- iso-
forms. To be able to enhance HIF-2 levels above those typi-
cally found in hypoxia (the physiological condition of cartilage)
is potentially of great importance because we have previously
shown that HIF-2 up-regulates cartilage-specific matrix
expression through induction of SOX9 (9, 20). Here, we dem-
onstrate that specific depletion of HIF-2 targeting hydroxy-
lase PHD2 did indeed significantly up-regulate the cartilage
FIGURE 6. General 2-oxoglutarate-dependent hydroxylase inhibition up-regulates SOX9 but inhibits the cartilage collagens. Passaged HACs were
cultured for 3 days under normoxic (20%) or hypoxic (1%) conditions, in the presence/absence of 2-oxoglutarate analogue and hydroxylase inhibitor DMOG.
Addition of DMOG enhanced SOX9 mRNA (A) and protein levels (B). C, expression of classic HIF target gene VEGF was also significantly enhanced by DMOG;
however, expression of the cartilage-specific collagens COL9A1 (D), COL11A2 (E), and COL2A1 (F) was not induced by DMOG. G, DMOG treatment inhibited
secretion of COL2A1 protein in HACs. ns, not significant; *, p 0.05; **, p 0.01.
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master regulator, transcription factor SOX9, which subse-
quently up-regulated expression of key matrix genes COL2A1,
COL9A1, COL11A2, and AGGRECAN, crucially above the
levels normally detected in hypoxia (1% oxygen). In addition,
PHD2 depletion enhanced levels of secreted COL2A1 pro-
tein in HACs above those naturally occurring in hypoxia.
We have thus identified PHD2-specific inhibition as a novel
means to enhance cartilage matrix synthesis (pathway de-
tailed in Fig. 7).
Experiments with the general hydroxylase inhibitor DMOG
highlight the importance of development of HIF-specific
hydroxylase inhibitors with regard to chondrocyte metabo-
lism. Addition of DMOG enhanced SOX9 levels in HACs,
and we have previously shown that this is dependent (like
hypoxia) specifically on HIF-2 (35). However, unlike the
case of hypoxia or PHD2 depletion, DMOG did not result in
mRNA induction of the cartilage-specific collagen genes,
COL2A1, COL9A1, and COL11A2. Furthermore, secretion of
COL2A1 protein was blocked by DMOG. The latter is most
likely due to the fact that DMOG also inhibits the collagen
prolyl 4-hydroxylases, which are critical for post-translational
processing of collagen, in particular triple helical formation
(36). Similar results were reported by Gelse et al. (37) who car-
ried out a study injecting the joints of STR/ORT mice with
DMOG. These mice spontaneously develop osteoarthritis, and
injection of DMOG was unable to prevent the formation of
severe arthritis. However, the authors
reported intracellular accumulation
of type II collagen in chondrocytes
presumably due to incomplete post-
translational processing. Also simi-
larly to this study, they reported a
lack of Col2a1 mRNA induction by
DMOG in mouse chondrocytes,
despite enhanced Sox9 levels. They
suggested that the increased intra-
cellular accumulation of the collag-
ens caused by DMOG may operate
via a negative feedback mechanism
to down-regulate gene expression,
and counter any of the positive
effects of enhanced Sox9 levels.
Although this is a plausible explana-
tion, further work is needed to clar-
ify the issue. What these results do
clearly illustrate, however, is the
need for inhibitors that are specific
to the HIF-targeting PHDs.
This adverse effect of general
hydroxylase inhibition on collagen
processing is particularly relevant to
cartilage as it is a most highly colla-
gen-rich tissue. In fact, expression
of the collagen prolyl 4-hydroxy-
lases are actually up-regulated by
hypoxia (38). In addition, we have
previously shown that two further
enzymes involved in collagen proc-
essing LOXL3 and PLOD2 are also hypoxia-inducible (20).
Therefore, inhibition of PHD2 can up-regulate not only
COL2A1 transcription but also enzymes necessary for its post-
translational processing, thus representing a further benefit of
PHD2-specific inhibition with regard to elaboration of a func-
tional cartilagematrix byHACs. For this approach to be applied
to animal studies, and eventually clinical studies, inducible car-
tilage-specific PHD2 knock-out mice would be informative, in
addition to development of PHD isoform-specific (or at least
HIF-targeting hydroxylase-specific) small molecule inhibitors.
This is currently an area of active research.
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